## Patent Reference

- Title: ATM gene mutant and application thereof
- URL: https://patents.google.com/patent/CN106701709B/en

### Abstract

Abstract Translated from Chinese 本发明公开了ATM基因突变体及其应用，具体涉及分离的编码ATM基因突变体的核酸、分离的多肽、筛选易患共济失调毛细血管扩张症的生物样品的方法、筛选易患共济失调毛细血管扩张症的生物样品的系统以及用于筛选易患共济失调毛细血管扩张症的生物样品的试剂盒。其中，分离的编码ATM基因突变体的核酸，与SEQ ID NO：1相比，具有选自下列的至少一种突变：c.4777‑2A>T、c.3078G>T、c.7983_7985delTGT和c.477_481delATCTC。通过检测该突变体在生物样品中是否存在，可以有效地检测生物样品是否易患共济失调毛细血管扩张症。The invention discloses ATM gene mutants and applications thereof, in particular to an isolated nucleic acid encoding an ATM gene mutant, an isolated polypeptide, a method for screening biological samples susceptible to ataxia telangiectasia, and screening for ataxia susceptible A system of biological samples for telangiectasia and a kit for screening biological samples susceptible to ataxia telangiectasia. Wherein, the isolated nucleic acid encoding an ATM gene mutant, compared with SEQ ID NO: 1, has at least one mutation selected from the group consisting of: c.4777-2A>T, c.3078G>T, c.7983_7985delTGT and c. .477_481delATCTC. By detecting whether the mutant is present in a biological sample, whether the biological sample is susceptible to ataxia telangiectasia can be effectively detected.

### Description

Description Translated from Chinese ATM基因突变体及其应用ATM gene mutant and its application 技术领域technical field 本发明涉及技术领域。具体而言，本发明涉及ATM基因突变体及其应用。The present invention relates to the technical field. Specifically, the present invention relates to ATM gene mutants and uses thereof. 背景技术Background technique 共济失调毛细血管扩张症(ataxia-telangiectasia,AT)是一种罕见的常染色体隐性遗传(autosomal recessive inherited,AR)病，又叫Louis-Bar综合征，于1941年由Louis-Bar首先报道。AT发病率约1/4万～1/10万，多于儿童期起病，临床主要表现为进行性发展的小脑性共济失调，眼球结膜和面部皮肤的毛细血管扩张，反复发作的呼吸道感染；同时还具有对射线的杀伤作用异常敏感，染色体不稳定性，易患恶性肿瘤，免疫缺陷和抗射线的DNA复制合成等特征。Ataxia-telangiectasia (AT) is a rare autosomal recessive inherited (AR) disease, also known as Louis-Bar syndrome, first reported by Louis-Bar in 1941 . The incidence of AT is about 1/40,000 to 1/100,000, more than the onset in childhood. The main clinical manifestations are progressive cerebellar ataxia, telangiectasia of eye conjunctiva and facial skin, and recurrent respiratory tract infections. At the same time, it also has the characteristics of abnormal sensitivity to the killing effect of radiation, chromosomal instability, susceptibility to malignant tumors, immune deficiency and radiation-resistant DNA replication and synthesis. Savitsky和Uziel等率先克隆AT的疾病基因(ATM)，并将其定位于11q22.3。ATM是AT唯一的致病基因，全长约150kb，而编码序列只有12kb，共有66个外显子，编码一个有3056个氨基酸残基，分子质量为350000的蛋白质。ATM基因产物ATM编码蛋白作为直接感受DNA双链断裂(DSBs)损伤信号的上游分子，以其激酶活性，催化多种重要功能底物蛋白的磷酸化，使受损的DNA停止于细胞周期检测点并对其进行修复，对维持染色体的稳定性起重要作用。Savitsky and Uziel first cloned the AT disease gene (ATM) and located it at 11q22.3. ATM is the only pathogenic gene of AT, with a total length of about 150kb, while the coding sequence is only 12kb, with a total of 66 exons, encoding a protein with 3056 amino acid residues and a molecular mass of 350000. The ATM gene product ATM encodes the protein as an upstream molecule that directly senses DNA double-strand breaks (DSBs) damage signals. With its kinase activity, it catalyzes the phosphorylation of a variety of important functional substrate proteins and stops damaged DNA at the cell cycle checkpoint. And to repair it, it plays an important role in maintaining the stability of chromosomes. ATM基因的克隆为AT的基因诊断和症状前诊断奠定了基础，并且很大程度上解决了该病临床诊断困难的问题。ATM蛋白在胎儿和成人组织内均有广泛表达，其功能域包括磷酯酰肌醇3-激酶(phosphoinositide-3kinase,PI3K)、Rad3、亮氨酸拉链(leucine zipper,LZ)、局部的连接区域(focaladhesion target,FAT)、局部的连接区域C端(FATC)等。PI3K蛋白家族成员和具有Rad3结构域的蛋白家族成员参与了激活细胞周期关卡，控制端粒长度和应答DNA损伤等重要的生物学过程。The cloning of ATM gene lays the foundation for the genetic diagnosis and presymptomatic diagnosis of AT, and solves the problem of difficult clinical diagnosis of the disease to a large extent. ATM proteins are widely expressed in fetal and adult tissues, and their functional domains include phosphoinositide-3kinase (PI3K), Rad3, leucine zipper (LZ), and local junction domains. (focaladhesion target, FAT), local connection region C-terminal (FATC), etc. Members of the PI3K protein family and members of the protein family with the Rad3 domain are involved in important biological processes such as activating cell cycle checkpoints, controlling telomere length and responding to DNA damage. AT最显著的病理学表现是基因组的不稳定性，主要反应在高频率的染色体断裂，自发染色体末端融合和染色体内同源重组及染色体易位，以及体内、外染色体自发畸变率和辐射诱发染色体畸变率的异常增加。作为DNA损伤信号传导通路中最早的传感和中枢调控基因，ATM编码的ATM蛋白在电离辐射的诱导下被激活，并磷酸化其下游蛋白，通过调控细胞周期关卡、DNA损伤修复、细胞凋亡等维持基因组稳定性。AT细胞由于ATM基因突变，缺失了ATM蛋白，丧失了对下游基因的调控作用，使受损的DNA的合成受抑，阻碍DNA的修复过程，从而导致染色体的断裂和基因组不稳定。The most prominent pathological manifestations of AT are genomic instability, mainly reflected in high frequency of chromosome breakage, spontaneous chromosome end fusion and intrachromosomal homologous recombination and chromosomal translocation, as well as in vivo and extrachromosomal spontaneous aberration rates and radiation-induced chromosomes Abnormal increase in distortion rate. As the earliest sensor and central regulatory gene in the DNA damage signaling pathway, the ATM protein encoded by ATM is activated under the induction of ionizing radiation, and phosphorylates its downstream proteins to regulate cell cycle checkpoints, DNA damage repair, and apoptosis. to maintain genome stability. Due to the mutation of the ATM gene, AT cells lack the ATM protein and lose the regulation of downstream genes, inhibiting the synthesis of damaged DNA and hindering the DNA repair process, resulting in chromosome breakage and genome instability. ATM基因的突变具有极高的异质性，突变方式和突变检测都极为复杂。到目前为止，国外已经报道了400余种ATM基因突变，绝大多数AT患者为复合性杂合突变，突变形式有错义突变、无义突变、剪切位点突变、小片段插入突变、小片段缺失突变、大片段缺失和同义突变等，突变位点遍布基因全长，无突变热点。The mutation of ATM gene has extremely high heterogeneity, and the mutation mode and mutation detection are extremely complicated. So far, more than 400 ATM gene mutations have been reported abroad. Most AT patients are compound heterozygous mutations. The mutation forms include missense mutations, nonsense mutations, splice site mutations, small insertion mutations, small Fragment deletion mutations, large fragment deletions and synonymous mutations, etc., the mutation sites are all over the whole length of the gene, and there is no mutation hot spot. 因而，目前对共济失调毛细血管扩张症的致病基因ATM突变基因的研究仍有待深入。Therefore, the current research on the ATM mutation gene, the pathogenic gene of ataxia telangiectasia, still needs to be further studied. 发明内容SUMMARY OF THE INVENTION 本发明旨在至少在一定程度上解决上述技术问题之一。为此，本发明的一个目的在于提出一种能够有效筛选易患共济失调毛细血管扩张症的生物样品的方法。The present invention aims to solve one of the above-mentioned technical problems at least to a certain extent. To this end, an object of the present invention is to propose a method for effectively screening biological samples susceptible to ataxia telangiectasia. 本发明是基于发明人的下列工作完成的：发明人通过高通量外显子组测序联合候选基因突变验证的方法确定了共济失调毛细血管扩张症新的致病基因突变位点(ATM基因的c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del突变)。The present invention is based on the following work of the inventors: the inventors have determined a new pathogenic gene mutation site of ataxia telangiectasia (ATM gene) through the method of high-throughput exome sequencing combined with candidate gene mutation verification. c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del mutations). 根据本发明的第一方面，本发明提出了一种分离的编码ATM基因突变体的核酸。根据本发明的实施例，所述核酸与SEQ ID NO：1相比，具有选自下列的至少一种突变：c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)。即相对于野生型ATM基因，本发明的ATM基因具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)的至少一种。根据本发明的实施例，发明人确定了ATM基因的新突变体，该突变体与共济失调毛细血管扩张症的发病密切相关，从而通过检测该新突变体在生物样品中是否存在，可以有效地检测生物样品是否易患共济失调毛细血管扩张症。According to a first aspect of the present invention, the present invention provides an isolated nucleic acid encoding an ATM gene mutant. According to an embodiment of the present invention, the nucleic acid has at least one mutation selected from the group consisting of: c.5697C>A, c.4777-2A>T, c.3078G>T, c. .7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del). That is, compared to the wild-type ATM gene, the ATM gene of the present invention has c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del). at least one. According to the embodiments of the present invention, the inventors identified a new mutant of the ATM gene, which is closely related to the onset of ataxia telangiectasia, so that by detecting whether the new mutant exists in a biological sample, it can effectively to test biological samples for susceptibility to ataxia telangiectasia. 根据本发明的第二个方面，本发明提出了一种分离的多肽，该多肽与SEQ ID NO：2相比，具有选自下列的至少一种突变：p.Cys1899X、p.Glu2950fs、p.Trp1026Cys、p.Val2662del、p.Ile159fs和p.2951_2995del，通过检测生物样品中是否表达该多肽，可以有效地检测生物样品是否易患共济失调毛细血管扩张症。根据本发明的实施例，该多肽是由上述核酸编码的。According to a second aspect of the present invention, the present invention provides an isolated polypeptide having at least one mutation selected from the group consisting of p.Cys1899X, p.Glu2950fs, p. Trp1026Cys, p.Val2662del, p.Ile159fs and p.2951_2995del can effectively detect whether the biological sample is susceptible to ataxia telangiectasia by detecting whether the polypeptide is expressed in the biological sample. According to an embodiment of the present invention, the polypeptide is encoded by the above-mentioned nucleic acid. 根据本发明的地三个方面，本发明提出了一种筛选易患共济失调毛细血管扩张症的生物样品的方法，该方法包括以下步骤：从所述生物样品提取核酸样本；确定所述核酸样本的核酸序列；所述核酸样本的核酸序列与SEQ ID NO：1相比，具有选自c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)的至少一种突变是所述生物样品易患共济失调毛细血管扩张症的指示，任选地，所述生物样品为选自人体血液，任选地，所述核酸样本为全基因组DNA，任选地，所述共济失调毛细血管扩张症是常染色体隐性遗传疾病。通过根据本发明实施例的筛选易感共济失调毛细血管扩张症的生物样品的方法，可以有效地筛选易感共济失调毛细血管扩张症的生物样品。According to three aspects of the present invention, the present invention proposes a method for screening a biological sample susceptible to ataxia telangiectasia, the method comprising the steps of: extracting a nucleic acid sample from the biological sample; determining the nucleic acid The nucleic acid sequence of the sample; compared with SEQ ID NO: 1, the nucleic acid sequence of the nucleic acid sample is selected from the group consisting of c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c. At least one mutation of 477_481delATCTC and c.8851_8987del (exon 65del) is indicative of a susceptibility to ataxia telangiectasia in the biological sample, optionally the biological sample is selected from human blood, optionally the The nucleic acid sample is whole genome DNA, optionally, the ataxia telangiectasia is an autosomal recessive disorder. By the method for screening a biological sample susceptible to ataxia telangiectasia according to an embodiment of the present invention, a biological sample susceptible to ataxia telangiectasia can be effectively screened. 根据本发明的第四方面，本发明提出了一种筛选易患共济失调毛细血管扩张症的生物样品的系统，该系统包括：核酸提取装置，所述核酸提取装置用于从所述生物样品提取核酸样本；核酸序列确定装置，所述核酸序列确定装置与所述核酸提取装置相连，用于对所述核酸样本进行分析，以便确定所述核酸样本的核酸序列；判断装置，所述判断装置与所述核酸序列确定装置相连，以便基于所述核酸样本的核酸序列与SEQ ID NO：1相比，是否具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)的至少一种突变，判断所述生物样品是否易患共济失调毛细血管扩张症；任选地，所述共济失调毛细血管扩张症是常染色体隐性遗传疾病。利用该系统，能够有效地实施前述筛选易感共济失调毛细血管扩张症的生物样品的方法，从而可以有效地筛选易感共济失调毛细血管扩张症的生物样品。According to a fourth aspect of the present invention, the present invention proposes a system for screening a biological sample susceptible to ataxia telangiectasia, the system comprising: a nucleic acid extraction device for extracting from the biological sample Extracting a nucleic acid sample; a nucleic acid sequence determination device connected to the nucleic acid extraction device for analyzing the nucleic acid sample in order to determine the nucleic acid sequence of the nucleic acid sample; a judging device, the judging device Connected to the nucleic acid sequence determination device, so that based on the nucleic acid sequence of the nucleic acid sample compared with SEQ ID NO: 1, whether the nucleic acid sample has c.5697C>A, c.4777-2A>T, c.3078G>T, c at least one mutation of .7983_7985delTGT, c.477_481delATCTC, and c.8851_8987del (exon 65del) to determine whether the biological sample is susceptible to ataxia telangiectasia; optionally, the ataxia telangiectasia is Autosomal recessive disorders. Using this system, the aforementioned method of screening a biological sample susceptible to ataxia telangiectasia can be effectively performed, so that a biological sample susceptible to ataxia telangiectasia can be effectively screened. 根据本发明的第五方面，本发明提出了一种用于筛选易患共济失调毛细血管扩张症的生物样品的试剂盒，该试剂盒含有：适于检测ATM基因突变体的试剂，其中与SEQ IDNO：1相比，所述ATM基因突变体具有选自下列的至少一种突变：c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)，任选地，所述试剂为核酸探针或引物，任选地，所述核酸探针或引物具有如SEQ ID NO：7-16所示的核苷酸序列，任选地，所述是常染色体隐性遗传疾病。According to a fifth aspect of the present invention, the present invention provides a kit for screening biological samples susceptible to ataxia telangiectasia, the kit comprising: a reagent suitable for detecting ATM gene mutants, wherein the Compared with SEQ ID NO: 1, the ATM gene mutant has at least one mutation selected from the group consisting of: c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del), optionally, the reagent is a nucleic acid probe or primer, optionally, the nucleic acid probe or primer has a nucleotide sequence as shown in SEQ ID NOs: 7-16 , optionally, said is an autosomal recessive disorder. 根据本发明的第六方面，本发明还提出了一种构建体。根据本发明的实施例，该构建体包含前面所述的分离的编码ATM基因突变体的核酸。需要说明的是，“构建体包含前面所述的分离的编码ATM基因突变体的核酸”表示，本发明的构建体包含与SEQ ID NO：1相比具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)至少一种突变。由此，利用本发明的构建体转化受体细胞获得的重组细胞，能够有效地用作共济失调毛细血管扩张症相关研究的模型。According to the sixth aspect of the present invention, the present invention also proposes a construct. According to an embodiment of the present invention, the construct comprises the previously described isolated nucleic acid encoding an ATM gene mutant. It should be noted that 'the construct comprises the aforementioned isolated nucleic acid encoding an ATM gene mutant' means that the construct of the present invention comprises c.5697C>A, c.4777- 2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del) at least one mutation. Thus, recombinant cells obtained by transforming recipient cells with the construct of the present invention can be effectively used as models for studies related to ataxia telangiectasia. 根据本发明的第七方面，本发明还提出了一种重组细胞。根据本发明的实施例，该重组细胞是通过前面所述的构建体转化受体细胞而获得的。根据本发明的一些实施例，本发明的重组细胞，能够有效地用作共济失调毛细血管扩张症相关研究的模型。According to the seventh aspect of the present invention, the present invention also provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell is obtained by transforming the recipient cell with the aforementioned construct. According to some embodiments of the present invention, the recombinant cells of the present invention can be effectively used as a model for studies related to ataxia telangiectasia. 对于本发明中所述核酸，本领域技术人员应当理解，实际包括互补双链的任意一条，或者两条。为了方便，在本发明的实施例中，虽然多数情况下只给出了一条链，但实际上也公开了与之互补的另一条链。例如，提及SEQ ID NO:1，实际包括其互补序列。本领域技术人员还可以理解，利用一条链可以检测另一条链，反之亦然。For the nucleic acid described in the present invention, those skilled in the art should understand that it actually includes any one, or both, of the complementary double strands. For convenience, in the embodiments of the present invention, although only one chain is given in most cases, another chain complementary thereto is actually disclosed. For example, reference to SEQ ID NO: 1 actually includes its complement. It will also be understood by those skilled in the art that one chain can be used to detect another chain, and vice versa. 本发明的附加方面和优点将在下面的描述中部分给出，部分将从下面的描述中变得明显，或通过本发明的实践了解到。Additional aspects and advantages of the present invention will be set forth, in part, from the following description, and in part will be apparent from the following description, or may be learned by practice of the invention. 附图说明Description of drawings 本发明的上述和/或附加的方面和优点从结合下面附图对实施例的描述中将变得明显和容易理解，其中：The above and/or additional aspects and advantages of the present invention will become apparent and readily understood from the following description of embodiments taken in conjunction with the accompanying drawings, wherein: 图1：显示了根据本发明一个实施例的筛选易患共济失调毛细血管扩张症的生物样品的系统及其组成部分的示意图，其中，Figure 1 : shows a schematic diagram of a system and its components for screening biological samples susceptible to ataxia telangiectasia according to one embodiment of the present invention, wherein, A为根据本发明实施例的筛选易患共济失调毛细血管扩张症患者的生物样品的系统的示意图，A is a schematic diagram of a system for screening biological samples from patients with ataxia telangiectasia according to an embodiment of the present invention, B为根据本发明实施例的核酸提取装置的示意图，B is a schematic diagram of a nucleic acid extraction device according to an embodiment of the present invention, C为根据本发明实施例的核酸序列确定装置的示意图。C is a schematic diagram of an apparatus for determining a nucleic acid sequence according to an embodiment of the present invention. 图2：显示了根据本发明一个实施例的共济失调毛细血管扩张症患者的家系图谱。Figure 2: Shows a pedigree of a patient with ataxia telangiectasia according to one embodiment of the present invention. 图3：显示了根据本发明一个实施例的AT家系1的ATM基因突变体的Sanger法测序结果。Figure 3: shows the Sanger sequencing results of the ATM gene mutant of AT family 1 according to an embodiment of the present invention. 图4：显示了根据本发明一个实施例的AT家系2的ATM基因突变体的Sanger法测序结果。Figure 4: shows the Sanger sequencing results of the ATM gene mutant of AT family 2 according to an embodiment of the present invention. 图5：显示了根据本发明一个实施例的AT家系3的ATM基因突变体的Sanger法测序结果。Figure 5: shows the Sanger sequencing results of the ATM gene mutant of AT family 3 according to an embodiment of the present invention. 图6：显示了根据本发明一个实施例的AT家系1的ATM基因突变体的QPCR的结果图。Figure 6: A graph showing the results of QPCR of ATM gene mutants of AT family 1 according to one embodiment of the present invention. 图7：显示了根据本发明一个实施例的AT家系2的ATM基因突变体的Sanger法测序结果。Figure 7: shows the Sanger sequencing results of the ATM gene mutant of AT family 2 according to an embodiment of the present invention. 具体实施方式Detailed ways 下面详细描述本发明的实施例，所述实施例的示例在附图中示出，其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的，旨在用于解释本发明，而不能理解为对本发明的限制。The following describes in detail the embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein the same or similar reference numerals refer to the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary, and are intended to explain the present invention and should not be construed as limiting the present invention. ATM基因突变体ATM gene mutants 根据本发明的第一方面，本发明提出了一种分离的编码ATM基因突变体的核酸。根据本发明的实施例，所述核酸与SEQ ID NO：1相比，具有选自下列的至少一种突变：c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)。即相对于野生型ATM基因，本发明的ATM基因具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)突变的至少一种。根据本发明的实施例，发明人确定了ATM基因的新突变体，该突变体与共济失调毛细血管扩张症的发病密切相关，从而通过检测该新突变体在生物样品中是否存在，可以有效地检测生物样品是否易患共济失调毛细血管扩张症。According to a first aspect of the present invention, the present invention provides an isolated nucleic acid encoding an ATM gene mutant. According to an embodiment of the present invention, the nucleic acid has at least one mutation selected from the group consisting of: c.5697C>A, c.4777-2A>T, c.3078G>T, c. .7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del). That is, compared with the wild-type ATM gene, the ATM gene of the present invention has mutations c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del) at least one of. According to the embodiments of the present invention, the inventors identified a new mutant of the ATM gene, which is closely related to the onset of ataxia telangiectasia, so that by detecting whether the new mutant exists in a biological sample, it can effectively to test biological samples for susceptibility to ataxia telangiectasia. 在本文中所使用的表达方式“编码ATM突变体的核酸”，是指与编码ATM突变体的基因相对应的核酸物质，即核酸的类型不受特别限制，可以是任何包含与ATM突变体的编码基因相对应的脱氧核糖核苷酸和/或核糖核苷酸的聚合物，包括但不限于DNA、RNA或cDNA。根据本发明的一个具体示例，前面所述的编码ATM突变体的核酸为DNA。根据本发明的实施例，发明人确定了ATM基因的新突变体，这些新突变体与共济失调毛细血管扩张症的发病密切相关，从而通过检测该新突变体在生物样品中是否存在，可以有效地检测生物样品是否易患共济失调毛细血管扩张症，也可以通过检测这些突变体在生物体中是否存在，可以有效地预测生物体是否易患共济失调毛细血管扩张症。The expression 'nucleic acid encoding an ATM mutant' used herein refers to a nucleic acid substance corresponding to a gene encoding an ATM mutant, that is, the type of nucleic acid is not particularly limited, and can be any nucleic acid containing an ATM mutant. A polymer of deoxyribonucleotides and/or ribonucleotides encoding the corresponding genes, including but not limited to DNA, RNA or cDNA. According to a specific example of the present invention, the aforementioned nucleic acid encoding an ATM mutant is DNA. According to the embodiments of the present invention, the inventors have identified new mutants of the ATM gene, and these new mutants are closely related to the onset of ataxia telangiectasia. Whether the biological sample is susceptible to ataxia telangiectasia can be effectively detected, and whether the organism is susceptible to ataxia telangiectasia can be effectively predicted by detecting whether these mutants exist in the organism. 该编码ATM突变体的核酸，是本申请的发明人通过高通量外显子组测序联合候选基因突变验证的方法确定的共济失调毛细血管扩张症的致病基因上的新突变。该突变位点在现有技术中并未被提到。The nucleic acid encoding the ATM mutant is a novel mutation in the pathogenic gene of ataxia telangiectasia determined by the inventors of the present application through the method of high-throughput exome sequencing combined with candidate gene mutation verification. This mutation site has not been mentioned in the prior art. 其中，野生型ATM基因的cDNA具有如下所示的核苷酸序列：Wherein, the cDNA of the wild-type ATM gene has the following nucleotide sequence: ATGAGTCTAGTACTTAATGATCTGCTTATCTGCTGCCGTCAACTAGAACATGATAGAGCTACAGAACGAAAGAAAGAAGTTGAGAAATTTAAGCGCCTGATTCGAGATCCTGAAACAATTAAACATCTAGATCGGCATTCAGATTCCAAACAAGGAAAATATTTGAATTGGGATGCTGTTTTTAGATTTTTACAGAAATATATTCAGAAAGAAACAGAATGTCTGAGAATAGCAAAACCAAATGTATCAGCCTCAACACAAGCCTCCAGGCAGAAAAAGATGCAGGAAATCAGTAGTTTGGTCAAATACTTCATCAAATGTGCAAACAGAAGAGCACCTAGGCTAAAATGTCAAGAACTCTTAAATTATATCATGGATACAGTGAAAGATTCATCTAATGGTGCTATTTACGGAGCTGATTGTAGCAACATACTACTCAAAGACATTCTTTCTGTGAGAAAATACTGGTGTGAAATATCTCAGCAACAGTGGTTAGAATTGTTCTCTGTGTACTTCAGGCTCTATCTGAAACCTTCACAAGATGTTCATAGAGTTTTAGTGGCTAGAATAATTCATGCTGTTACCAAAGGATGCTGTTCTCAGACTGACGGATTAAATTCCAAATTTTTGGACTTTTTTTCCAAGGCTATTCAGTGTGCGAGACAAGAAAAGAGCTCTTCAGGTCTAAATCATATCTTAGCAGCTCTTACTATCTTCCTCAAGACTTTGGCTGTCAACTTTCGAATTCGAGTGTGTGAATTAGGAGATGAAATTCTTCCCACTTTGCTTTATATTTGGACTCAACATAGGCTTAATGATTCTTTAAAAGAAGTCATTATTGAATTATTTCAACTGCAAATTTATATCCATCATCCGAAAGGAGCCAAAACCCAAGAAAAAGGTGCTTATGAATCAACAAAATGGAGAAGTATTTTATACAACTTATATGATCTGCTAGTGAATGAGATAAGTCATATAGGAAGTAGAGGAAAGTATTCTTCAGGATTTCGTAATATTGCCGTCAAAGAAAATTTGATTGAATTGATGGCAGATATCTGTCACCAGGTTTTTAATGAAGATACCAGATCCTTGGAGATTTCTCAATCTTACACTACTACACAAAGAGAATCTAGTGATTACAGTGTCCCTTGCAAAAGGAAGAAAATAGAACTAGGCTGGGAAGTAATAAAAGATCACCTTCAGAAGTCACAGAATGATTTTGATCTTGTGCCTTGGCTACAGATTGCAACCCAATTAATATCAAAGTATCCTGCAAGTTTACCTAACTGTGAGCTGTCTCCATTACTGATGATACTATCTCAGCTTCTACCCCAACAGCGACATGGGGAACGTACACCATATGTGTTACGATGCCTTACGGAAGTTGCATTGTGTCAAGACAAGAGGTCAAACCTAGAAAGCTCACAAAAGTCAGATTTATTAAAACTCTGGAATAAAATTTGGTGTATTACCTTTCGTGGTATAAGTTCTGAGCAAATACAAGCTGAAAACTTTGGCTTACTTGGAGCCATAATTCAGGGTAGTTTAGTTGAGGTTGACAGAGAATTCTGGAAGTTATTTACTGGGTCAGCCTGCAGACCTTCATGTCCTGCAGTATGCTGTTTGACTTTGGCACTGACCACCAGTATAGTTCCAGGAACGGTAAAAATGGGAATAGAGCAAAATATGTGTGAAGTAAATAGAAGCTTTTCTTTAAAGGAATCAATAATGAAATGGCTCTTATTCTATCAGTTAGAGGGTGACTTAGAAAATAGCACAGAAGTGCCTCCAATTCTTCACAGTAATTTTCCTCATCTTGTACTGGAGAAAATTCTTGTGAGTCTCACTATGAAAAACTGTAAAGCTGCAATGAATTTTTTCCAAAGCGTGCCAGAATGTGAACACCACCAAAAAGATAAAGAAGAACTTTCATTCTCAGAAGTAGAAGAACTATTTCTTCAGACAACTTTTGACAAGATGGACTTTTTAACCATTGTGAGAGAATGTGGTATAGAAAAGCACCAGTCCAGTATTGGCTTCTCTGTCCACCAGAATCTCAAGGAATCACTGGATCGCTGTCTTCTGGGATTATCAGAACAGCTTCTGAATAATTACTCATCTGAGATTACAAATTCAGAAACTCTTGTCCGGTGTTCACGTCTTTTGGTGGGTGTCCTTGGCTGCTACTGTTACATGGGTGTAATAGCTGAAGAGGAAGCATATAAGTCAGAATTATTCCAGAAAGCCAAGTCTCTAATGCAATGTGCAGGAGAAAGTATCACTCTGTTTAAAAATAAGACAAATGAGGAATTCAGAATTGGTTCCTTGAGAAATATGATGCAGCTATGTACACGTTGCTTGAGCAACTGTACCAAGAAGAGTCCAAATAAGATTGCATCTGGCTTTTTCCTGCGATTGTTAACATCAAAGCTAATGAATGACATTGCAGATATTTGTAAAAGTTTAGCATCCTTCATCAAAAAGCCATTTGACCGTGGAGAAGTAGAATCAATGGAAGATGATACTAATGGAAATCTAATGGAGGTGGAGGATCAGTCATCCATGAATCTATTTAACGATTACCCTGATAGTAGTGTTAGTGATGCAAACGAACCTGGAGAGAGCCAAAGTACCATAGGTGCCATTAATCCTTTAGCTGAAGAATATCTGTCAAAGCAAGATCTACTTTTCTTAGACATGCTCAAGTTCTTGTGTTTGTGTGTAACTACTGCTCAGACCAATACTGTGTCCTTTAGGGCAGCTGATATTCGGAGGAAATTGTTAATGTTAATTGATTCTAGCACGCTAGAACCTACCAAATCCCTCCACCTGCATATGTATCTAATGCTTTTAAAGGAGCTTCCTGGAGAAGAGTACCCCTTGCCAATGGAAGATGTTCTTGAACTTCTGAAACCACTATCCAATGTGTGTTCTTTGTATCGTCGTGACCAAGATGTTTGTAAAACTATTTTAAACCATGTCCTTCATGTAGTGAAAAACCTAGGTCAAAGCAATATGGACTCTGAGAACACAAGGGATGCTCAAGGACAGTTTCTTACAGTAATTGGAGCATTTTGGCATCTAACAAAGGAGAGGAAATATATATTCTCTGTAAGAATGGCCCTAGTAAATTGCCTTAAAACTTTGCTTGAGGCTGATCCTTATTCAAAATGGGCCATTCTTAATGTAATGGGAAAAGACTTTCCTGTAAATGAAGTATTTACACAATTTCTTGCTGACAATCATCACCAAGTTCGCATGTTGGCTGCAGAGTCAATCAATAGATTGTTCCAGGACACGAAGGGAGATTCTTCCAGGTTACTGAAAGCACTTCCTTTGAAGCTTCAGCAAACAGCTTTTGAAAATGCATACTTGAAAGCTCAGGAAGGAATGAGAGAAATGTCCCATAGTGCTGAGAACCCTGAAACTTTGGATGAAATTTATAATAGAAAATCTGTTTTACTGACGTTGATAGCTGTGGTTTTATCCTGTAGCCCTATCTGCGAAAAACAGGCTTTGTTTGCCCTGTGTAAATCTGTGAAAGAGAATGGATTAGAACCTCACCTTGTGAAAAAGGTTTTAGAGAAAGTTTCTGAAACTTTTGGATATAGACGTTTAGAAGACTTTATGGCATCTCATTTAGATTATCTGGTTTTGGAATGGCTAAATCTTCAAGATACTGAATACAACTTATCTTCTTTTCCTTTTATTTTATTAAACTACACAAATATTGAGGATTTCTATAGATCTTGTTATAAGGTTTTGATTCCACATCTGGTGATTAGAAGTCATTTTGATGAGGTGAAGTCCATTGCTAATCAGATTCAAGAGGACTGGAAAAGTCTTCTAACAGACTGCTTTCCAAAGATTCTTGTAAATATTCTTCCTTATTTTGCCTATGAGGGTACCAGAGACAGTGGGATGGCACAGCAAAGAGAGACTGCTACCAAGGTCTATGATATGCTTAAAAGTGAAAACTTATTGGGAAAACAGATTGATCACTTATTCATTAGTAATTTACCAGAGATTGTGGTGGAGTTATTGATGACGTTACATGAGCCAGCAAATTCTAGTGCCAGTCAGAGCACTGACCTCTGTGACTTTTCAGGGGATTTGGATCCTGCTCCTAATCCACCTCATTTTCCATCGCATGTGATTAAAGCAACATTTGCCTATATCAGCAATTGTCATAAAACCAAGTTAAAAAGCATTTTAGAAATTCTTTCCAAAAGCCCTGATTCCTATCAGAAAATTCTTCTTGCCATATGTGAGCAAGCAGCTGAAACAAATAATGTTTATAAGAAGCACAGAATTCTTAAAATATATCACCTGTTTGTTAGTTTATTACTGAAAGATATAAAAAGTGGCTTAGGAGGAGCTTGGGCCTTTGTTCTTCGAGACGTTATTTATACTTTGATTCACTATATCAACCAAAGGCCTTCTTGTATCATGGATGTGTCATTACGTAGCTTCTCCCTTTGTTGTGACTTATTAAGTCAGGTTTGCCAGACAGCCGTGACTTACTGTAAGGATGCTCTAGAAAACCATCTTCATGTTATTGTTGGTACACTTATACCCCTTGTGTATGAGCAGGTGGAGGTTCAGAAACAGGTATTGGACTTGTTGAAATACTTAGTGATAGATAACAAGGATAATGAAAACCTCTATATCACGATTAAGCTTTTAGATCCTTTTCCTGACCATGTTGTTTTTAAGGATTTGCGTATTACTCAGCAAAAAATCAAATACAGTAGAGGACCCTTTTCACTCTTGGAGGAAATTAACCATTTTCTCTCAGTAAGTGTTTATGATGCACTTCCATTGACAAGACTTGAAGGACTAAAGGATCTTCGAAGACAACTGGAACTACATAAAGATCAGATGGTGGACATTATGAGAGCTTCTCAGGATAATCCGCAAGATGGGATTATGGTGAAACTAGTTGTCAATTTGTTGCAGTTATCCAAGATGGCAATAAACCACACTGGTGAAAAAGAAGTTCTAGAGGCTGTTGGAAGCTGCTTGGGAGAAGTGGGTCCTATAGATTTCTCTACCATAGCTATACAACATAGTAAAGATGCATCTTATACCAAGGCCCTTAAGTTATTTGAAGATAAAGAACTTCAGTGGACCTTCATAATGCTGACCTACCTGAATAACACACTGGTAGAAGATTGTGTCAAAGTTCGATCAGCAGCTGTTACCTGTTTGAAAAACATTTTAGCCACAAAGACTGGACATAGTTTCTGGGAGATTTATAAGATGACAACAGATCCAATGCTGGCCTATCTACAGCCTTTTAGAACATCAAGAAAAAAGTTTTTAGAAGTACCCAGATTTGACAAAGAAAACCCTTTTGAAGGCCTGGATGATATAAATCTGTGGATTCCTCTAAGTGAAAATCATGACATTTGGATAAAGACACTGACTTGTGCTTTTTTGGACAGTGGAGGCACAAAATGTGAAATTCTTCAATTATTAAAGCCAATGTGTGAAGTGAAAACTGACTTTTGTCAGACTGTACTTCCATACTTGATTCATGATATTTTACTCCAAGATACAAATGAATCATGGAGAAATCTGCTTTCTACACATGTTCAGGGATTTTTCACCAGCTGTCTTCGACACTTCTCGCAAACGAGCCGATCCACAACCCCTGCAAACTTGGATTCAGAGTCAGAGCACTTTTTCCGATGCTGTTTGGATAAAAAATCACAAAGAACAATGCTTGCTGTTGTGGACTACATGAGAAGACAAAAGAGACCTTCTTCAGGAACAATTTTTAATGATGCTTTCTGGCTGGATTTAAATTATCTAGAAGTTGCCAAGGTAGCTCAGTCTTGTGCTGCTCACTTTACAGCTTTACTCTATGCAGAAATCTATGCAGATAAGAAAAGTATGGATGATCAAGAGAAAAGAAGTCTTGCATTTGAAGAAGGAAGCCAGAATACAACTATTTCTAGCTTGAGTGAAAAAAGTAAAGAAGAAACTGGAATAAGTTTACAGGATCTTCTCTTAGAAATCTACAGAAGTATAGGGGAGCCAGATAGTTTGTATGGCTGTGGTGGAGGGAAGATGTTACAACCCATTACTAGACTACGAACATATGAACACGAAGCAATGTGGGGCAAAGCCCTAGTAACATATGACCTCGAAACAGCAATCCCCTCATCAACACGCCAGGCAGGAATCATTCAGGCCTTGCAGAATTTGGGACTCTGCCATATTCTTTCCGTCTATTTAAAAGGATTGGATTATGAAAATAAAGACTGGTGTCCTGAACTAGAAGAACTTCATTACCAAGCAGCATGGAGGAATATGCAGTGGGACCATTGCACTTCCGTCAGCAAAGAAGTAGAAGGAACCAGTTACCATGAATCATTGTACAATGCTCTACAATCTCTAAGAGACAGAGAATTCTCTACATTTTATGAAAGTCTCAAATATGCCAGAGTAAAAGAAGTGGAAGAGATGTGTAAGCGCAGCCTTGAGTCTGTGTATTCGCTCTATCCCACACTTAGCAGGTTGCAGGCCATTGGAGAGCTGGAAAGCATTGGGGAGCTTTTCTCAAGATCAGTCACACATAGACAACTCTCTGAAGTATATATTAAGTGGCAGAAACACTCCCAGCTTCTCAAGGACAGTGATTTTAGTTTTCAGGAGCCTATCATGGCTCTACGCACAGTCATTTTGGAGATCCTGATGGAAAAGGAAATGGACAACTCACAAAGAGAATGTATTAAGGACATTCTCACCAAACACCTTGTAGAACTCTCTATACTGGCCAGAACTTTCAAGAACACTCAGCTCCCTGAAAGGGCAATATTTCAAATTAAACAGTACAATTCAGTTAGCTGTGGAGTCTCTGAGTGGCAGCTGGAAGAAGCACAAGTATTCTGGGCAAAAAAGGAGCAGAGTCTTGCCCTGAGTATTCTCAAGCAAATGATCAAGAAGTTGGATGCCAGCTGTGCAGCGAACAATCCCAGCCTAAAACTTACATACACAGAATGTCTGAGGGTTTGTGGCAACTGGTTAGCAGAAACGTGCTTAGAAAATCCTGCGGTCATCATGCAGACCTATCTAGAAAAGGCAGTAGAAGTTGCTGGAAATTATGATGGAGAAAGTAGTGATGAGCTAAGAAATGGAAAAATGAAGGCATTTCTCTCATTAGCCCGGTTTTCAGATACTCAATACCAAAGAATTGAAAACTACATGAAATCATCGGAATTTGAAAACAAGCAAGCTCTCCTGAAAAGAGCCAAAGAGGAAGTAGGTCTCCTTAGGGAACATAAAATTCAGACAAACAGATACACAGTAAAGGTTCAGCGAGAGCTGGAGTTGGATGAATTAGCCCTGCGTGCACTGAAAGAGGATCGTAAACGCTTCTTATGTAAAGCAGTTGAAAATTATATCAACTGCTTATTAAGTGGAGAAGAACATGATATGTGGGTATTCCGACTTTGTTCCCTCTGGCTTGAAAATTCTGGAGTTTCTGAAGTCAATGGCATGATGAAGAGAGACGGAATGAAGATTCCAACATATAAATTTTTGCCTCTTATGTACCAATTGGCTGCTAGAATGGGGACCAAGATGATGGGAGGCCTAGGATTTCATGAAGTCCTCAATAATCTAATCTCTAGAATTTCAATGGATCACCCCCATCACACTTTGTTTATTATACTGGCCTTAGCAAATGCAAACAGAGATGAATTTCTGACTAAACCAGAGGTAGCCAGAAGAAGCAGAATAACTAAAAATGTGCCTAAACAAAGCTCTCAGCTTGATGAGGATCGAACAGAGGCTGCAAATAGAATAATATGTACTATCAGAAGTAGGAGACCTCAGATGGTCAGAAGTGTTGAGGCACTTTGTGATGCTTATATTATATTAGCAAACTTAGATGCCACTCAGTGGAAGACTCAGAGAAAAGGCATAAATATTCCAGCAGACCAGCCAATTACTAAACTTAAGAATTTAGAAGATGTTGTTGTCCCTACTATGGAAATTAAGGTGGACCACACAGGAGAATATGGAAATCTGGTGACTATACAGTCATTTAAAGCAGAATTTCGCTTAGCAGGAGGTGTAAATTTACCAAAAATAATAGATTGTGTAGGTTCCGATGGCAAGGAGAGGAGACAGCTTGTTAAGGGCCGTGATGACCTGAGACAAGATGCTGTCATGCAACAGGTCTTCCAGATGTGTAATACATTACTGCAGAGAAACACGGAAACTAGGAAGAGGAAATTAACTATCTGTACTTATAAGGTGGTTCCCCTCTCTCAGCGAAGTGGTGTTCTTGAATGGTGCACAGGAACTGTCCCCATTGGTGAATTTCTTGTTAACAATGAAGATGGTGCTCATAAAAGATACAGGCCAAATGATTTCAGTGCCTTTCAGTGCCAAAAGAAAATGATGGAGGTGCAAAAAAAGTCTTTTGAAGAGAAATATGAAGTCTTCATGGATGTTTGCCAAAATTTTCAACCAGTTTTCCGTTACTTCTGCATGGAAAAATTCTTGGATCCAGCTATTTGGTTTGAGAAGCGATTGGCTTATACGCGCAGTGTAGCTACTTCTTCTATTGTTGGTTACATACTTGGACTTGGTGATAGACATGTACAGAATATCTTGATAAATGAGCAGTCAGCAGAACTTGTACATATAGATCTAGGTGTTGCTTTTGAACAGGGCAAAATCCTTCCTACTCCTGAGACAGTTCCTTTTAGACTCACCAGAGATATTGTGGATGGCATGGGCATTACGGGTGTTGAAGGTGTCTTCAGAAGATGCTGTGAGAAAACCATGGAAGTGATGAGAAACTCTCAGGAAACTCTGTTAACCATTGTAGAGGTCCTTCTATATGATCCACTCTTTGACTGGACCATGAATCCTTTGAAAGCTTTGTATTTACAGCAGAGGCCGGAAGATGAAACTGAGCTTCACCCTACTCTGAATGCAGATGACCAAGAATGCAAACGAAATCTCAGTGATATTGACCAGAGTTTCAACAAAGTAGCTGAACGTGTCTTAATGAGACTACAAGAGAAACTGAAAGGAGTGGAAGAAGGCACTGTGCTCAGTGTTGGTGGACAAGTGAATTTGCTCATACAGCAGGCCATAGACCCCAAAAATCTCAGCCGACTTTTCCCAGGATGGAAAGCTTGGGTGTGA(SEQ ID NO：1)，ATGAGTCTAGTACTTAATGATCTGCTTATCTGCTGCCGTCAACTAGAACATGATAGAGCTACAGAACGAAAGAAAGAAGTTGAGAAATTTAAGCGCCTGATTCGAGATCCTGAAACAATTAAACATCTAGATCGGCATTCAGATTCCAAACAAGGAAAATATTTGAATTGGGATGCTGTTTTTAGATTTTTACAGAAATATATTCAGAAAGAAACAGAATGTCTGAGAATAGCAAAACCAAATGTATCAGCCTCAACACAAGCCTCCAGGCAGAAAAAGATGCAGGAAATCAGTAGTTTGGTCAAATACTTCATCAAATGTGCAAACAGAAGAGCACCTAGGCTAAAATGTCAAGAACTCTTAAATTATATCATGGATACAGTGAAAGATTCATCTAATGGTGCTATTTACGGAGCTGATTGTAGCAACATACTACTCAAAGACATTCTTTCTGTGAGAAAATACTGGTGTGAAATATCTCAGCAACAGTGGTTAGAATTGTTCTCTGTGTACTTCAGGCTCTATCTGAAACCTTCACAAGATGTTCATAGAGTTTTAGTGGCTAGAATAATTCATGCTGTTACCAAAGGATGCTGTTCTCAGACTGACGGATTAAATTCCAAATTTTTGGACTTTTTTTCCAAGGCTATTCAGTGTGCGAGACAAGAAAAGAGCTCTTCAGGTCTAAATCATATCTTAGCAGCTCTTACTATCTTCCTCAAGACTTTGGCTGTCAACTTTCGAATTCGAGTGTGTGAATTAGGAGATGAAATTCTTCCCACTTTGCTTTATATTTGGACTCAACATAGGCTTAATGATTCTTTAAAAGAAGTCATTATTGAATTATTTCAACTGCAAATTTATATCCATCATCCGAAAGGAGCCAAAACCCAAGAAAAAGGTGCTTATGAATCAACAAAATGGAGAAGTATTTTATACAACTTATATGATCTGCTAGTGAATGAGATAAGTCATATAGGAAGTAGAGGAAAGTATTCTT CAGGATTTCGTAATATTGCCGTCAAAGAAAATTTGATTGAATTGATGGCAGATATCTGTCACCAGGTTTTTAATGAAGATACCAGATCCTTGGAGATTTCTCAATCTTACACTACTACACAAAGAGAATCTAGTGATTACAGTGTCCCTTGCAAAAGGAAGAAAATAGAACTAGGCTGGGAAGTAATAAAAGATCACCTTCAGAAGTCACAGAATGATTTTGATCTTGTGCCTTGGCTACAGATTGCAACCCAATTAATATCAAAGTATCCTGCAAGTTTACCTAACTGTGAGCTGTCTCCATTACTGATGATACTATCTCAGCTTCTACCCCAACAGCGACATGGGGAACGTACACCATATGTGTTACGATGCCTTACGGAAGTTGCATTGTGTCAAGACAAGAGGTCAAACCTAGAAAGCTCACAAAAGTCAGATTTATTAAAACTCTGGAATAAAATTTGGTGTATTACCTTTCGTGGTATAAGTTCTGAGCAAATACAAGCTGAAAACTTTGGCTTACTTGGAGCCATAATTCAGGGTAGTTTAGTTGAGGTTGACAGAGAATTCTGGAAGTTATTTACTGGGTCAGCCTGCAGACCTTCATGTCCTGCAGTATGCTGTTTGACTTTGGCACTGACCACCAGTATAGTTCCAGGAACGGTAAAAATGGGAATAGAGCAAAATATGTGTGAAGTAAATAGAAGCTTTTCTTTAAAGGAATCAATAATGAAATGGCTCTTATTCTATCAGTTAGAGGGTGACTTAGAAAATAGCACAGAAGTGCCTCCAATTCTTCACAGTAATTTTCCTCATCTTGTACTGGAGAAAATTCTTGTGAGTCTCACTATGAAAAACTGTAAAGCTGCAATGAATTTTTTCCAAAGCGTGCCAGAATGTGAACACCACCAAAAAGATAAAGAAGAACTTTCATTCTCAGAAGTAGAAGAACTATTTCTTCAGACAACTTTTGACAAGATGGACTTTTTAACCATTGTGAG AGAATGTGGTATAGAAAAGCACCAGTCCAGTATTGGCTTCTCTGTCCACCAGAATCTCAAGGAATCACTGGATCGCTGTCTTCTGGGATTATCAGAACAGCTTCTGAATAATTACTCATCTGAGATTACAAATTCAGAAACTCTTGTCCGGTGTTCACGTCTTTTGGTGGGTGTCCTTGGCTGCTACTGTTACATGGGTGTAATAGCTGAAGAGGAAGCATATAAGTCAGAATTATTCCAGAAAGCCAAGTCTCTAATGCAATGTGCAGGAGAAAGTATCACTCTGTTTAAAAATAAGACAAATGAGGAATTCAGAATTGGTTCCTTGAGAAATATGATGCAGCTATGTACACGTTGCTTGAGCAACTGTACCAAGAAGAGTCCAAATAAGATTGCATCTGGCTTTTTCCTGCGATTGTTAACATCAAAGCTAATGAATGACATTGCAGATATTTGTAAAAGTTTAGCATCCTTCATCAAAAAGCCATTTGACCGTGGAGAAGTAGAATCAATGGAAGATGATACTAATGGAAATCTAATGGAGGTGGAGGATCAGTCATCCATGAATCTATTTAACGATTACCCTGATAGTAGTGTTAGTGATGCAAACGAACCTGGAGAGAGCCAAAGTACCATAGGTGCCATTAATCCTTTAGCTGAAGAATATCTGTCAAAGCAAGATCTACTTTTCTTAGACATGCTCAAGTTCTTGTGTTTGTGTGTAACTACTGCTCAGACCAATACTGTGTCCTTTAGGGCAGCTGATATTCGGAGGAAATTGTTAATGTTAATTGATTCTAGCACGCTAGAACCTACCAAATCCCTCCACCTGCATATGTATCTAATGCTTTTAAAGGAGCTTCCTGGAGAAGAGTACCCCTTGCCAATGGAAGATGTTCTTGAACTTCTGAAACCACTATCCAATGTGTGTTCTTTGTATCGTCGTGACCAAGATGTTTGTAAAACTATTTTAAACCATGTCCTTCATGTAGTGAAAAAC CTAGGTCAAAGCAATATGGACTCTGAGAACACAAGGGATGCTCAAGGACAGTTTCTTACAGTAATTGGAGCATTTTGGCATCTAACAAAGGAGAGGAAATATATATTCTCTGTAAGAATGGCCCTAGTAAATTGCCTTAAAACTTTGCTTGAGGCTGATCCTTATTCAAAATGGGCCATTCTTAATGTAATGGGAAAAGACTTTCCTGTAAATGAAGTATTTACACAATTTCTTGCTGACAATCATCACCAAGTTCGCATGTTGGCTGCAGAGTCAATCAATAGATTGTTCCAGGACACGAAGGGAGATTCTTCCAGGTTACTGAAAGCACTTCCTTTGAAGCTTCAGCAAACAGCTTTTGAAAATGCATACTTGAAAGCTCAGGAAGGAATGAGAGAAATGTCCCATAGTGCTGAGAACCCTGAAACTTTGGATGAAATTTATAATAGAAAATCTGTTTTACTGACGTTGATAGCTGTGGTTTTATCCTGTAGCCCTATCTGCGAAAAACAGGCTTTGTTTGCCCTGTGTAAATCTGTGAAAGAGAATGGATTAGAACCTCACCTTGTGAAAAAGGTTTTAGAGAAAGTTTCTGAAACTTTTGGATATAGACGTTTAGAAGACTTTATGGCATCTCATTTAGATTATCTGGTTTTGGAATGGCTAAATCTTCAAGATACTGAATACAACTTATCTTCTTTTCCTTTTATTTTATTAAACTACACAAATATTGAGGATTTCTATAGATCTTGTTATAAGGTTTTGATTCCACATCTGGTGATTAGAAGTCATTTTGATGAGGTGAAGTCCATTGCTAATCAGATTCAAGAGGACTGGAAAAGTCTTCTAACAGACTGCTTTCCAAAGATTCTTGTAAATATTCTTCCTTATTTTGCCTATGAGGGTACCAGAGACAGTGGGATGGCACAGCAAAGAGAGACTGCTACCAAGGTCTATGATATGCTTAAAAGTGAAAACTTATTGGGAAAACAGATTGATC ACTTATTCATTAGTAATTTACCAGAGATTGTGGTGGAGTTATTGATGACGTTACATGAGCCAGCAAATTCTAGTGCCAGTCAGAGCACTGACCTCTGTGACTTTTCAGGGGATTTGGATCCTGCTCCTAATCCACCTCATTTTCCATCGCATGTGATTAAAGCAACATTTGCCTATATCAGCAATTGTCATAAAACCAAGTTAAAAAGCATTTTAGAAATTCTTTCCAAAAGCCCTGATTCCTATCAGAAAATTCTTCTTGCCATATGTGAGCAAGCAGCTGAAACAAATAATGTTTATAAGAAGCACAGAATTCTTAAAATATATCACCTGTTTGTTAGTTTATTACTGAAAGATATAAAAAGTGGCTTAGGAGGAGCTTGGGCCTTTGTTCTTCGAGACGTTATTTATACTTTGATTCACTATATCAACCAAAGGCCTTCTTGTATCATGGATGTGTCATTACGTAGCTTCTCCCTTTGTTGTGACTTATTAAGTCAGGTTTGCCAGACAGCCGTGACTTACTGTAAGGATGCTCTAGAAAACCATCTTCATGTTATTGTTGGTACACTTATACCCCTTGTGTATGAGCAGGTGGAGGTTCAGAAACAGGTATTGGACTTGTTGAAATACTTAGTGATAGATAACAAGGATAATGAAAACCTCTATATCACGATTAAGCTTTTAGATCCTTTTCCTGACCATGTTGTTTTTAAGGATTTGCGTATTACTCAGCAAAAAATCAAATACAGTAGAGGACCCTTTTCACTCTTGGAGGAAATTAACCATTTTCTCTCAGTAAGTGTTTATGATGCACTTCCATTGACAAGACTTGAAGGACTAAAGGATCTTCGAAGACAACTGGAACTACATAAAGATCAGATGGTGGACATTATGAGAGCTTCTCAGGATAATCCGCAAGATGGGATTATGGTGAAACTAGTTGTCAATTTGTTGCAGTTATCCAAGATGGCAATAAACCACACTGGTGAAAAAGAAGT TCTAGAGGCTGTTGGAAGCTGCTTGGGAGAAGTGGGTCCTATAGATTTCTCTACCATAGCTATACAACATAGTAAAGATGCATCTTATACCAAGGCCCTTAAGTTATTTGAAGATAAAGAACTTCAGTGGACCTTCATAATGCTGACCTACCTGAATAACACACTGGTAGAAGATTGTGTCAAAGTTCGATCAGCAGCTGTTACCTGTTTGAAAAACATTTTAGCCACAAAGACTGGACATAGTTTCTGGGAGATTTATAAGATGACAACAGATCCAATGCTGGCCTATCTACAGCCTTTTAGAACATCAAGAAAAAAGTTTTTAGAAGTACCCAGATTTGACAAAGAAAACCCTTTTGAAGGCCTGGATGATATAAATCTGTGGATTCCTCTAAGTGAAAATCATGACATTTGGATAAAGACACTGACTTGTGCTTTTTTGGACAGTGGAGGCACAAAATGTGAAATTCTTCAATTATTAAAGCCAATGTGTGAAGTGAAAACTGACTTTTGTCAGACTGTACTTCCATACTTGATTCATGATATTTTACTCCAAGATACAAATGAATCATGGAGAAATCTGCTTTCTACACATGTTCAGGGATTTTTCACCAGCTGTCTTCGACACTTCTCGCAAACGAGCCGATCCACAACCCCTGCAAACTTGGATTCAGAGTCAGAGCACTTTTTCCGATGCTGTTTGGATAAAAAATCACAAAGAACAATGCTTGCTGTTGTGGACTACATGAGAAGACAAAAGAGACCTTCTTCAGGAACAATTTTTAATGATGCTTTCTGGCTGGATTTAAATTATCTAGAAGTTGCCAAGGTAGCTCAGTCTTGTGCTGCTCACTTTACAGCTTTACTCTATGCAGAAATCTATGCAGATAAGAAAAGTATGGATGATCAAGAGAAAAGAAGTCTTGCATTTGAAGAAGGAAGCCAGAATACAACTATTTCTAGCTTGAGTGAAAAAAGTAAAGAAGAAACTGGAATAAGT TTACAGGATCTTCTCTTAGAAATCTACAGAAGTATAGGGGAGCCAGATAGTTTGTATGGCTGTGGTGGAGGGAAGATGTTACAACCCATTACTAGACTACGAACATATGAACACGAAGCAATGTGGGGCAAAGCCCTAGTAACATATGACCTCGAAACAGCAATCCCCTCATCAACACGCCAGGCAGGAATCATTCAGGCCTTGCAGAATTTGGGACTCTGCCATATTCTTTCCGTCTATTTAAAAGGATTGGATTATGAAAATAAAGACTGGTGTCCTGAACTAGAAGAACTTCATTACCAAGCAGCATGGAGGAATATGCAGTGGGACCATTGCACTTCCGTCAGCAAAGAAGTAGAAGGAACCAGTTACCATGAATCATTGTACAATGCTCTACAATCTCTAAGAGACAGAGAATTCTCTACATTTTATGAAAGTCTCAAATATGCCAGAGTAAAAGAAGTGGAAGAGATGTGTAAGCGCAGCCTTGAGTCTGTGTATTCGCTCTATCCCACACTTAGCAGGTTGCAGGCCATTGGAGAGCTGGAAAGCATTGGGGAGCTTTTCTCAAGATCAGTCACACATAGACAACTCTCTGAAGTATATATTAAGTGGCAGAAACACTCCCAGCTTCTCAAGGACAGTGATTTTAGTTTTCAGGAGCCTATCATGGCTCTACGCACAGTCATTTTGGAGATCCTGATGGAAAAGGAAATGGACAACTCACAAAGAGAATGTATTAAGGACATTCTCACCAAACACCTTGTAGAACTCTCTATACTGGCCAGAACTTTCAAGAACACTCAGCTCCCTGAAAGGGCAATATTTCAAATTAAACAGTACAATTCAGTTAGCTGTGGAGTCTCTGAGTGGCAGCTGGAAGAAGCACAAGTATTCTGGGCAAAAAAGGAGCAGAGTCTTGCCCTGAGTATTCTCAAGCAAATGATCAAGAAGTTGGATGCCAGCTGTGCAGCGAACAATCCCAGCCTAAAACTTACAT ACACAGAATGTCTGAGGGTTTGTGGCAACTGGTTAGCAGAAACGTGCTTAGAAAATCCTGCGGTCATCATGCAGACCTATCTAGAAAAGGCAGTAGAAGTTGCTGGAAATTATGATGGAGAAAGTAGTGATGAGCTAAGAAATGGAAAAATGAAGGCATTTCTCTCATTAGCCCGGTTTTCAGATACTCAATACCAAAGAATTGAAAACTACATGAAATCATCGGAATTTGAAAACAAGCAAGCTCTCCTGAAAAGAGCCAAAGAGGAAGTAGGTCTCCTTAGGGAACATAAAATTCAGACAAACAGATACACAGTAAAGGTTCAGCGAGAGCTGGAGTTGGATGAATTAGCCCTGCGTGCACTGAAAGAGGATCGTAAACGCTTCTTATGTAAAGCAGTTGAAAATTATATCAACTGCTTATTAAGTGGAGAAGAACATGATATGTGGGTATTCCGACTTTGTTCCCTCTGGCTTGAAAATTCTGGAGTTTCTGAAGTCAATGGCATGATGAAGAGAGACGGAATGAAGATTCCAACATATAAATTTTTGCCTCTTATGTACCAATTGGCTGCTAGAATGGGGACCAAGATGATGGGAGGCCTAGGATTTCATGAAGTCCTCAATAATCTAATCTCTAGAATTTCAATGGATCACCCCCATCACACTTTGTTTATTATACTGGCCTTAGCAAATGCAAACAGAGATGAATTTCTGACTAAACCAGAGGTAGCCAGAAGAAGCAGAATAACTAAAAATGTGCCTAAACAAAGCTCTCAGCTTGATGAGGATCGAACAGAGGCTGCAAATAGAATAATATGTACTATCAGAAGTAGGAGACCTCAGATGGTCAGAAGTGTTGAGGCACTTTGTGATGCTTATATTATATTAGCAAACTTAGATGCCACTCAGTGGAAGACTCAGAGAAAAGGCATAAATATTCCAGCAGACCAGCCAATTACTAAACTTAAGAATTTAGAAGATGTTGTTGTCCCTACTAT GGAAATTAAGGTGGACCACACAGGAGAATATGGAAATCTGGTGACTATACAGTCATTTAAAGCAGAATTTCGCTTAGCAGGAGGTGTAAATTTACCAAAAATAATAGATTGTGTAGGTTCCGATGGCAAGGAGAGGAGACAGCTTGTTAAGGGCCGTGATGACCTGAGACAAGATGCTGTCATGCAACAGGTCTTCCAGATGTGTAATACATTACTGCAGAGAAACACGGAAACTAGGAAGAGGAAATTAACTATCTGTACTTATAAGGTGGTTCCCCTCTCTCAGCGAAGTGGTGTTCTTGAATGGTGCACAGGAACTGTCCCCATTGGTGAATTTCTTGTTAACAATGAAGATGGTGCTCATAAAAGATACAGGCCAAATGATTTCAGTGCCTTTCAGTGCCAAAAGAAAATGATGGAGGTGCAAAAAAAGTCTTTTGAAGAGAAATATGAAGTCTTCATGGATGTTTGCCAAAATTTTCAACCAGTTTTCCGTTACTTCTGCATGGAAAAATTCTTGGATCCAGCTATTTGGTTTGAGAAGCGATTGGCTTATACGCGCAGTGTAGCTACTTCTTCTATTGTTGGTTACATACTTGGACTTGGTGATAGACATGTACAGAATATCTTGATAAATGAGCAGTCAGCAGAACTTGTACATATAGATCTAGGTGTTGCTTTTGAACAGGGCAAAATCCTTCCTACTCCTGAGACAGTTCCTTTTAGACTCACCAGAGATATTGTGGATGGCATGGGCATTACGGGTGTTGAAGGTGTCTTCAGAAGATGCTGTGAGAAAACCATGGAAGTGATGAGAAACTCTCAGGAAACTCTGTTAACCATTGTAGAGGTCCTTCTATATGATCCACTCTTTGACTGGACCATGAATCCTTTGAAAGCTTTGTATTTACAGCAGAGGCCGGAAGATGAAACTGAGCTTCACCCTACTCTGAATGCAGATGACCAAGAATGCAAACGAAATCTCAGTGATATTGACCAG AGTTTCAACAAAGTAGCTGAACGTGTCTTAATGAGACTACAAGAGAAACTGAAAGGAGTGGAAGAAGGCACTGTGCTCAGTGTTGGTGGACAAGTGAATTTGCTCATACAGCAGGCCATAGACCCCAAAAATCTCAGCCGACTTTTCCCAGGATGGAAAGCTTGGGTGTGA (SEQ ID NO: 1), 其编码的蛋白质具有如下所示的氨基酸序列：The encoded protein has the amino acid sequence shown below: MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQNTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV(SEQ ID NO：2)。MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKN LGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQNTTISSLSEKSKEETGIS LQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQ SFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV (SEQ ID NO: 2). 与野生型ATM基因的cDNA相比，c.477_481del ATCTC突变基因的cDNA具有如下所示的核苷酸序列：Compared with the cDNA of the wild-type ATM gene, the cDNA of the c.477_481del ATCTC mutant gene has the nucleotide sequence shown below: ATGAGTCTAGTACTTAATGATCTGCTTATCTGCTGCCGTCAACTAGAACATGATAGAGCTACAGAACGAAAGAAAGAAGTTGAGAAATTTAAGCGCCTGATTCGAGATCCTGAAACAATTAAACATCTAGATCGGCATTCAGATTCCAAACAAGGAAAATATTTGAATTGGGATGCTGTTTTTAGATTTTTACAGAAATATATTCAGAAAGAAACAGAATGTCTGAGAATAGCAAAACCAAATGTATCAGCCTCAACACAAGCCTCCAGGCAGAAAAAGATGCAGGAAATCAGTAGTTTGGTCAAATACTTCATCAAATGTGCAAACAGAAGAGCACCTAGGCTAAAATGTCAAGAACTCTTAAATTATATCATGGATACAGTGAAAGATTCATCTAATGGTGCTATTTACGGAGCTGATTGTAGCAACATACTACTCAAAGACATTCTTTCTGTGAGAAAATACTGGTGTGAAATAGCAACAGTGGTTAGAATTGTTCTCTGTGTACTTCAGGCTCTATCTGAAACCTTCACAAGATGTTCA(SEQ ID NO：3)，ATGAGTCTAGTACTTAATGATCTGCTTATCTGCTGCCGTCAACTAGAACATGATAGAGCTACAGAACGAAAGAAAGAAGTTGAGAAATTTAAGCGCCTGATTCGAGATCCTGAAACAATTAAACATCTAGATCGGCATTCAGATTCCAAACAAGGAAAATATTTGAATTGGGATGCTGTTTTTAGATTTTTACAGAAATATATTCAGAAAGAAACAGAATGTCTGAGAATAGCAAAACCAAATGTATCAGCCTCAACACAAGCCTCCAGGCAGAAAAAGATGCAGGAAATCAGTAGTTTGGTCAAATACTTCATCAAATGTGCAAACAGAAGAGCACCTAGGCTAAAATGTCAAGAACTCTTAAATTATATCATGGATACAGTGAAAGATTCATCTAATGGTGCTATTTACGGAGCTGATTGTAGCAACATACTACTCAAAGACATTCTTTCTGTGAGAAAATACTGGTGTGAAATAGCAACAGTGGTTAGAATTGTTCTCTGTGTACTTCAGGCTCTATCTGAAACCTTCACAAGATGTTCA(SEQ ID NO：3)， 上述c.477_481del ATCTC突变基因编码的氨基酸序列如下：The amino acid sequence encoded by the above-mentioned c.477_481del ATCTC mutant gene is as follows: MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEIATVVRIVLCVLQALSETFTRCS(SEQ ID NO：4)。MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEIATVVRIVLCVLQALSETFTRCS (SEQ ID NO: 4). 与野生型ATM基因的cDNA相比，c.4777-2A>T的突变基因的cDNA具有如下所示的核苷酸序列：Compared with the cDNA of the wild-type ATM gene, the cDNA of the mutant gene of c.4777-2A>T has the nucleotide sequence shown below: ATGAGTCTAGTACTTAATGATCTGCTTATCTGCTGCCGTCAACTAGAACATGATAGAGCTACAGAACGAAAGAAAGAAGTTGAGAAATTTAAGCGCCTGATTCGAGATCCTGAAACAATTAAACATCTAGATCGGCATTCAGATTCCAAACAAGGAAAATATTTGAATTGGGATGCTGTTTTTAGATTTTTACAGAAATATATTCAGAAAGAAACAGAATGTCTGAGAATAGCAAAACCAAATGTATCAGCCTCAACACAAGCCTCCAGGCAGAAAAAGATGCAGGAAATCAGTAGTTTGGTCAAATACTTCATCAAATGTGCAAACAGAAGAGCACCTAGGCTAAAATGTCAAGAACTCTTAAATTATATCATGGATACAGTGAAAGATTCATCTAATGGTGCTATTTACGGAGCTGATTGTAGCAACATACTACTCAAAGACATTCTTTCTGTGAGAAAATACTGGTGTGAAATATCTCAGCAACAGTGGTTAGAATTGTTCTCTGTGTACTTCAGGCTCTATCTGAAACCTTCACAAGATGTTCATAGAGTTTTAGTGGCTAGAATAATTCATGCTGTTACCAAAGGATGCTGTTCTCAGACTGACGGATTAAATTCCAAATTTTTGGACTTTTTTTCCAAGGCTATTCAGTGTGCGAGACAAGAAAAGAGCTCTTCAGGTCTAAATCATATCTTAGCAGCTCTTACTATCTTCCTCAAGACTTTGGCTGTCAACTTTCGAATTCGAGTGTGTGAATTAGGAGATGAAATTCTTCCCACTTTGCTTTATATTTGGACTCAACATAGGCTTAATGATTCTTTAAAAGAAGTCATTATTGAATTATTTCAACTGCAAATTTATATCCATCATCCGAAAGGAGCCAAAACCCAAGAAAAAGGTGCTTATGAATCAACAAAATGGAGAAGTATTTTATACAACTTATATGATCTGCTAGTGAATGAGATAAGTCATATAGGAAGTAGAGGAAAGTATTCTTCAGGATTTCGTAATATTGCCGTCAAAGAAAATTTGATTGAATTGATGGCAGATATCTGTCACCAGGTTTTTAATGAAGATACCAGATCCTTGGAGATTTCTCAATCTTACACTACTACACAAAGAGAATCTAGTGATTACAGTGTCCCTTGCAAAAGGAAGAAAATAGAACTAGGCTGGGAAGTAATAAAAGATCACCTTCAGAAGTCACAGAATGATTTTGATCTTGTGCCTTGGCTACAGATTGCAACCCAATTAATATCAAAGTATCCTGCAAGTTTACCTAACTGTGAGCTGTCTCCATTACTGATGATACTATCTCAGCTTCTACCCCAACAGCGACATGGGGAACGTACACCATATGTGTTACGATGCCTTACGGAAGTTGCATTGTGTCAAGACAAGAGGTCAAACCTAGAAAGCTCACAAAAGTCAGATTTATTAAAACTCTGGAATAAAATTTGGTGTATTACCTTTCGTGGTATAAGTTCTGAGCAAATACAAGCTGAAAACTTTGGCTTACTTGGAGCCATAATTCAGGGTAGTTTAGTTGAGGTTGACAGAGAATTCTGGAAGTTATTTACTGGGTCAGCCTGCAGACCTTCATGTCCTGCAGTATGCTGTTTGACTTTGGCACTGACCACCAGTATAGTTCCAGGAACGGTAAAAATGGGAATAGAGCAAAATATGTGTGAAGTAAATAGAAGCTTTTCTTTAAAGGAATCAATAATGAAATGGCTCTTATTCTATCAGTTAGAGGGTGACTTAGAAAATAGCACAGAAGTGCCTCCAATTCTTCACAGTAATTTTCCTCATCTTGTACTGGAGAAAATTCTTGTGAGTCTCACTATGAAAAACTGTAAAGCTGCAATGAATTTTTTCCAAAGCGTGCCAGAATGTGAACACCACCAAAAAGATAAAGAAGAACTTTCATTCTCAGAAGTAGAAGAACTATTTCTTCAGACAACTTTTGACAAGATGGACTTTTTAACCATTGTGAGAGAATGTGGTATAGAAAAGCACCAGTCCAGTATTGGCTTCTCTGTCCACCAGAATCTCAAGGAATCACTGGATCGCTGTCTTCTGGGATTATCAGAACAGCTTCTGAATAATTACTCATCTGAGATTACAAATTCAGAAACTCTTGTCCGGTGTTCACGTCTTTTGGTGGGTGTCCTTGGCTGCTACTGTTACATGGGTGTAATAGCTGAAGAGGAAGCATATAAGTCAGAATTATTCCAGAAAGCCAAGTCTCTAATGCAATGTGCAGGAGAAAGTATCACTCTGTTTAAAAATAAGACAAATGAGGAATTCAGAATTGGTTCCTTGAGAAATATGATGCAGCTATGTACACGTTGCTTGAGCAACTGTACCAAGAAGAGTCCAAATAAGATTGCATCTGGCTTTTTCCTGCGATTGTTAACATCAAAGCTAATGAATGACATTGCAGATATTTGTAAAAGTTTAGCATCCTTCATCAAAAAGCCATTTGACCGTGGAGAAGTAGAATCAATGGAAGATGATACTAATGGAAATCTAATGGAGGTGGAGGATCAGTCATCCATGAATCTATTTAACGATTACCCTGATAGTAGTGTTAGTGATGCAAACGAACCTGGAGAGAGCCAAAGTACCATAGGTGCCATTAATCCTTTAGCTGAAGAATATCTGTCAAAGCAAGATCTACTTTTCTTAGACATGCTCAAGTTCTTGTGTTTGTGTGTAACTACTGCTCAGACCAATACTGTGTCCTTTAGGGCAGCTGATATTCGGAGGAAATTGTTAATGTTAATTGATTCTAGCACGCTAGAACCTACCAAATCCCTCCACCTGCATATGTATCTAATGCTTTTAAAGGAGCTTCCTGGAGAAGAGTACCCCTTGCCAATGGAAGATGTTCTTGAACTTCTGAAACCACTATCCAATGTGTGTTCTTTGTATCGTCGTGACCAAGATGTTTGTAAAACTATTTTAAACCATGTCCTTCATGTAGTGAAAAACCTAGGTCAAAGCAATATGGACTCTGAGAACACAAGGGATGCTCAAGGACAGTTTCTTACAGTAATTGGAGCATTTTGGCATCTAACAAAGGAGAGGAAATATATATTCTCTGTAAGAATGGCCCTAGTAAATTGCCTTAAAACTTTGCTTGAGGCTGATCCTTATTCAAAATGGGCCATTCTTAATGTAATGGGAAAAGACTTTCCTGTAAATGAAGTATTTACACAATTTCTTGCTGACAATCATCACCAAGTTCGCATGTTGGCTGCAGAGTCAATCAATAGATTGTTCCAGGACACGAAGGGAGATTCTTCCAGGTTACTGAAAGCACTTCCTTTGAAGCTTCAGCAAACAGCTTTTGAAAATGCATACTTGAAAGCTCAGGAAGGAATGAGAGAAATGTCCCATAGTGCTGAGAACCCTGAAACTTTGGATGAAATTTATAATAGAAAATCTGTTTTACTGACGTTGATAGCTGTGGTTTTATCCTGTAGCCCTATCTGCGAAAAACAGGCTTTGTTTGCCCTGTGTAAATCTGTGAAAGAGAATGGATTAGAACCTCACCTTGTGAAAAAGGTTTTAGAGAAAGTTTCTGAAACTTTTGGATATAGACGTTTAGAAGACTTTATGGCATCTCATTTAGATTATCTGGTTTTGGAATGGCTAAATCTTCAAGATACTGAATACAACTTATCTTCTTTTCCTTTTATTTTATTAAACTACACAAATATTGAGGATTTCTATAGATCTTGTTATAAGGTTTTGATTCCACATCTGGTGATTAGAAGTCATTTTGATGAGGTGAAGTCCATTGCTAATCAGATTCAAGAGGACTGGAAAAGTCTTCTAACAGACTGCTTTCCAAAGATTCTTGTAAATATTCTTCCTTATTTTGCCTATGAGGGTACCAGAGACAGTGGGATGGCACAGCAAAGAGAGACTGCTACCAAGGTCTATGATATGCTTAAAAGTGAAAACTTATTGGGAAAACAGATTGATCACTTATTCATTAGTAATTTACCAGAGATTGTGGTGGAGTTATTGATGACGTTACATGAGCCAGCAAATTCTAGTGCCAGTCAGAGCACTGACCTCTGTGACTTTTCAGGGGATTTGGATCCTGCTCCTAATCCACCTCATTTTCCATCGCATGTGATTAAAGCAACATTTGCCTATATCAGCAATTGTCATAAAACCAAGTTAAAAAGCATTTTAGAAATTCTTTCCAAAAGCCCTGATTCCTATCAGAAAATTCTTCTTGCCATATGTGAGCAAGCAGCTGAAACAAATAATGTTTATAAGAAGCACAGAATTCTTAAAATATATCACCTGTTTGTTAGTTTATTACTGAAAGATATAAAAAGTGGCTTAGGAGGAGCTTGGGCCTTTGTTCTTCGAGACGTTATTTATACTTTGATTCACTATATCAACCAAAGGCCTTCTTGTATCATGGATGTGTCATTACGTAGCTTCTCCCTTTGTTGTGACTTATTAAGTCAGGTTTGCCAGACAGCCGTGACTTACTGTAAGGATGCTCTAGAAAACCATCTTCATGTTATTGTTGGTACACTTATACCCCTTGTGTATGAGCAGGTGGAGGTTCAGAAACAGGTATTGGACTTGTTGAAATACTTAGTGATAGATAACAAGGATAATGAAAACCTCTATATCACGATTAAGCTTTTAGATCCTTTTCCTGACCATGTTGTTTTTAAGGATTTGCGTATTACTCAGCAAAAAATCAAATACAGTAGAGGACCCTTTTCACTCTTGGAGTTCTCAGGA(SEQ ID NO：5)，ATGAGTCTAGTACTTAATGATCTGCTTATCTGCTGCCGTCAACTAGAACATGATAGAGCTACAGAACGAAAGAAAGAAGTTGAGAAATTTAAGCGCCTGATTCGAGATCCTGAAACAATTAAACATCTAGATCGGCATTCAGATTCCAAACAAGGAAAATATTTGAATTGGGATGCTGTTTTTAGATTTTTACAGAAATATATTCAGAAAGAAACAGAATGTCTGAGAATAGCAAAACCAAATGTATCAGCCTCAACACAAGCCTCCAGGCAGAAAAAGATGCAGGAAATCAGTAGTTTGGTCAAATACTTCATCAAATGTGCAAACAGAAGAGCACCTAGGCTAAAATGTCAAGAACTCTTAAATTATATCATGGATACAGTGAAAGATTCATCTAATGGTGCTATTTACGGAGCTGATTGTAGCAACATACTACTCAAAGACATTCTTTCTGTGAGAAAATACTGGTGTGAAATATCTCAGCAACAGTGGTTAGAATTGTTCTCTGTGTACTTCAGGCTCTATCTGAAACCTTCACAAGATGTTCATAGAGTTTTAGTGGCTAGAATAATTCATGCTGTTACCAAAGGATGCTGTTCTCAGACTGACGGATTAAATTCCAAATTTTTGGACTTTTTTTCCAAGGCTATTCAGTGTGCGAGACAAGAAAAGAGCTCTTCAGGTCTAAATCATATCTTAGCAGCTCTTACTATCTTCCTCAAGACTTTGGCTGTCAACTTTCGAATTCGAGTGTGTGAATTAGGAGATGAAATTCTTCCCACTTTGCTTTATATTTGGACTCAACATAGGCTTAATGATTCTTTAAAAGAAGTCATTATTGAATTATTTCAACTGCAAATTTATATCCATCATCCGAAAGGAGCCAAAACCCAAGAAAAAGGTGCTTATGAATCAACAAAATGGAGAAGTATTTTATACAACTTATATGATCTGCTAGTGAATGAGATAAGTCATATAGGAAGTAGAGGAAAGTATTCTT CAGGATTTCGTAATATTGCCGTCAAAGAAAATTTGATTGAATTGATGGCAGATATCTGTCACCAGGTTTTTAATGAAGATACCAGATCCTTGGAGATTTCTCAATCTTACACTACTACACAAAGAGAATCTAGTGATTACAGTGTCCCTTGCAAAAGGAAGAAAATAGAACTAGGCTGGGAAGTAATAAAAGATCACCTTCAGAAGTCACAGAATGATTTTGATCTTGTGCCTTGGCTACAGATTGCAACCCAATTAATATCAAAGTATCCTGCAAGTTTACCTAACTGTGAGCTGTCTCCATTACTGATGATACTATCTCAGCTTCTACCCCAACAGCGACATGGGGAACGTACACCATATGTGTTACGATGCCTTACGGAAGTTGCATTGTGTCAAGACAAGAGGTCAAACCTAGAAAGCTCACAAAAGTCAGATTTATTAAAACTCTGGAATAAAATTTGGTGTATTACCTTTCGTGGTATAAGTTCTGAGCAAATACAAGCTGAAAACTTTGGCTTACTTGGAGCCATAATTCAGGGTAGTTTAGTTGAGGTTGACAGAGAATTCTGGAAGTTATTTACTGGGTCAGCCTGCAGACCTTCATGTCCTGCAGTATGCTGTTTGACTTTGGCACTGACCACCAGTATAGTTCCAGGAACGGTAAAAATGGGAATAGAGCAAAATATGTGTGAAGTAAATAGAAGCTTTTCTTTAAAGGAATCAATAATGAAATGGCTCTTATTCTATCAGTTAGAGGGTGACTTAGAAAATAGCACAGAAGTGCCTCCAATTCTTCACAGTAATTTTCCTCATCTTGTACTGGAGAAAATTCTTGTGAGTCTCACTATGAAAAACTGTAAAGCTGCAATGAATTTTTTCCAAAGCGTGCCAGAATGTGAACACCACCAAAAAGATAAAGAAGAACTTTCATTCTCAGAAGTAGAAGAACTATTTCTTCAGACAACTTTTGACAAGATGGACTTTTTAACCATTGTGAG AGAATGTGGTATAGAAAAGCACCAGTCCAGTATTGGCTTCTCTGTCCACCAGAATCTCAAGGAATCACTGGATCGCTGTCTTCTGGGATTATCAGAACAGCTTCTGAATAATTACTCATCTGAGATTACAAATTCAGAAACTCTTGTCCGGTGTTCACGTCTTTTGGTGGGTGTCCTTGGCTGCTACTGTTACATGGGTGTAATAGCTGAAGAGGAAGCATATAAGTCAGAATTATTCCAGAAAGCCAAGTCTCTAATGCAATGTGCAGGAGAAAGTATCACTCTGTTTAAAAATAAGACAAATGAGGAATTCAGAATTGGTTCCTTGAGAAATATGATGCAGCTATGTACACGTTGCTTGAGCAACTGTACCAAGAAGAGTCCAAATAAGATTGCATCTGGCTTTTTCCTGCGATTGTTAACATCAAAGCTAATGAATGACATTGCAGATATTTGTAAAAGTTTAGCATCCTTCATCAAAAAGCCATTTGACCGTGGAGAAGTAGAATCAATGGAAGATGATACTAATGGAAATCTAATGGAGGTGGAGGATCAGTCATCCATGAATCTATTTAACGATTACCCTGATAGTAGTGTTAGTGATGCAAACGAACCTGGAGAGAGCCAAAGTACCATAGGTGCCATTAATCCTTTAGCTGAAGAATATCTGTCAAAGCAAGATCTACTTTTCTTAGACATGCTCAAGTTCTTGTGTTTGTGTGTAACTACTGCTCAGACCAATACTGTGTCCTTTAGGGCAGCTGATATTCGGAGGAAATTGTTAATGTTAATTGATTCTAGCACGCTAGAACCTACCAAATCCCTCCACCTGCATATGTATCTAATGCTTTTAAAGGAGCTTCCTGGAGAAGAGTACCCCTTGCCAATGGAAGATGTTCTTGAACTTCTGAAACCACTATCCAATGTGTGTTCTTTGTATCGTCGTGACCAAGATGTTTGTAAAACTATTTTAAACCATGTCCTTCATGTAGTGAAAAAC CTAGGTCAAAGCAATATGGACTCTGAGAACACAAGGGATGCTCAAGGACAGTTTCTTACAGTAATTGGAGCATTTTGGCATCTAACAAAGGAGAGGAAATATATATTCTCTGTAAGAATGGCCCTAGTAAATTGCCTTAAAACTTTGCTTGAGGCTGATCCTTATTCAAAATGGGCCATTCTTAATGTAATGGGAAAAGACTTTCCTGTAAATGAAGTATTTACACAATTTCTTGCTGACAATCATCACCAAGTTCGCATGTTGGCTGCAGAGTCAATCAATAGATTGTTCCAGGACACGAAGGGAGATTCTTCCAGGTTACTGAAAGCACTTCCTTTGAAGCTTCAGCAAACAGCTTTTGAAAATGCATACTTGAAAGCTCAGGAAGGAATGAGAGAAATGTCCCATAGTGCTGAGAACCCTGAAACTTTGGATGAAATTTATAATAGAAAATCTGTTTTACTGACGTTGATAGCTGTGGTTTTATCCTGTAGCCCTATCTGCGAAAAACAGGCTTTGTTTGCCCTGTGTAAATCTGTGAAAGAGAATGGATTAGAACCTCACCTTGTGAAAAAGGTTTTAGAGAAAGTTTCTGAAACTTTTGGATATAGACGTTTAGAAGACTTTATGGCATCTCATTTAGATTATCTGGTTTTGGAATGGCTAAATCTTCAAGATACTGAATACAACTTATCTTCTTTTCCTTTTATTTTATTAAACTACACAAATATTGAGGATTTCTATAGATCTTGTTATAAGGTTTTGATTCCACATCTGGTGATTAGAAGTCATTTTGATGAGGTGAAGTCCATTGCTAATCAGATTCAAGAGGACTGGAAAAGTCTTCTAACAGACTGCTTTCCAAAGATTCTTGTAAATATTCTTCCTTATTTTGCCTATGAGGGTACCAGAGACAGTGGGATGGCACAGCAAAGAGAGACTGCTACCAAGGTCTATGATATGCTTAAAAGTGAAAACTTATTGGGAAAACAGATTGATC ACTTATTCATTAGTAATTTACCAGAGATTGTGGTGGAGTTATTGATGACGTTACATGAGCCAGCAAATTCTAGTGCCAGTCAGAGCACTGACCTCTGTGACTTTTCAGGGGATTTGGATCCTGCTCCTAATCCACCTCATTTTCCATCGCATGTGATTAAAGCAACATTTGCCTATATCAGCAATTGTCATAAAACCAAGTTAAAAAGCATTTTAGAAATTCTTTCCAAAAGCCCTGATTCCTATCAGAAAATTCTTCTTGCCATATGTGAGCAAGCAGCTGAAACAAATAATGTTTATAAGAAGCACAGAATTCTTAAAATATATCACCTGTTTGTTAGTTTATTACTGAAAGATATAAAAAGTGGCTTAGGAGGAGCTTGGGCCTTTGTTCTTCGAGACGTTATTTATACTTTGATTCACTATATCAACCAAAGGCCTTCTTGTATCATGGATGTGTCATTACGTAGCTTCTCCCTTTGTTGTGACTTATTAAGTCAGGTTTGCCAGACAGCCGTGACTTACTGTAAGGATGCTCTAGAAAACCATCTTCATGTTATTGTTGGTACACTTATACCCCTTGTGTATGAGCAGGTGGAGGTTCAGAAACAGGTATTGGACTTGTTGAAATACTTAGTGATAGATAACAAGGATAATGAAAACCTCTATATCACGATTAAGCTTTTAGATCCTTTTCCTGACCATGTTGTTTTTAAGGATTTGCGTATTACTCAGCAAAAAATCAAATACAGTAGAGGACCCTTTTCACTCTTGGAGTTCTCAGGA(SEQ ID NO：5)， 上述c.4777-2A>T的突变基因编码的氨基酸序列如下：The amino acid sequence encoded by the mutant gene of c.4777-2A>T is as follows: MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEFSG(SEQ ID NO：6)。MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKN LGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEFSG(SEQ ID NO：6)。 发明人发现的ATM基因突变体与SEQ ID NO：1相比，本发明的ATM基因具有一个c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC、exon65del突变的至少一种。Compared with SEQ ID NO: 1, the ATM gene mutant discovered by the inventor has one c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c. At least one of 477_481delATCTC, exon65del mutations. 具体地，ATM基因突变体的c.5697C>A突变相对于野生型ATM基因的cDNA的第5697位的C突变为A，由此，导致其编码的蛋白发生p.Cys1899X无义突变。c.4777-2A>T突变后的基因序列为SEQ ID NO：5，p.Glu2950fs突变蛋白的序列为SEQ ID NO：6。c.3078G>T突变相对于野生型ATM基因的cDNA的第3078位的G突变为T，由此，导致其编码的蛋白发生了p.Trp1026Cys错义突变。c.7983_7985delTGT突变相对于野生型ATM基因cDNA的第7983_7985位的TGT缺失了，因而导致其编码的蛋白发生了p.Val2662del的缺失突变。c.477_481delATCTC突变相对于野生型ATM基因的cDNA的第477_481位的ATCTC缺失了，因而发生了移码突变p.Ile159fs，其突变后的基因以及蛋序列为SEQ ID NO：3和SEQ ID NO：4。c.8851_8987del(exon 65del)突变相对于野生型ATM基因的cDNA的第8851-8987位的基因序列：Specifically, the c.5697C>A mutation of the ATM gene mutant is compared to the C mutation at position 5697 of the cDNA of the wild-type ATM gene, which results in the p.Cys1899X nonsense mutation of the encoded protein. The gene sequence after c.4777-2A>T mutation is SEQ ID NO:5, and the sequence of p.Glu2950fs mutant protein is SEQ ID NO:6. The c.3078G>T mutation is compared to the G mutation at position 3078 of the cDNA of the wild-type ATM gene, which results in the p.Trp1026Cys missense mutation of the encoded protein. The c.7983_7985delTGT mutation is relative to the deletion of TGT at position 7983_7985 of the wild-type ATM gene cDNA, thus resulting in a deletion mutation of p.Val2662del in the encoded protein. The c.477_481delATCTC mutation is relative to the deletion of ATCTC at position 477_481 of the cDNA of the wild-type ATM gene, so a frameshift mutation p.Ile159fs occurs, and the mutated gene and egg sequences are SEQ ID NO: 3 and SEQ ID NO: 4. c. 8851_8987del (exon 65del) mutation relative to the gene sequence of positions 8851-8987 of the cDNA of the wild-type ATM gene: GTCCTTCTATATGATCCACTCTTTGACTGGACCATGAATCCTTTGAAAGCTTTGTATTTACAGCAGAGGCCGGAAGATGAAACTGAGCTTCACCCTACTCTGAATGCAGATGACCAAGAATGCAAACGAAATCTCAG缺失了，在缺失序列后即是终止密码子TGA，突变的cDNA包含8853个碱基；由此导致编码的蛋白在第2951-2995位的VLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNL缺失，并随即翻译终止，突变蛋白包含2950个氨基酸，即p.2951_2995del。GTCCTTCTATATGATCCACTCTTTGACTGGACCATGAATCCTTTGAAAGCTTTGTATTTACAGCAGAGGCCGGAAGATGAAACTGAGCTTCACCCTACTCTGAATGCAGATGACCAAGAATGCAAACGAAATCTCAG缺失了，在缺失序列后即是终止密码子TGA，突变的cDNA包含8853个碱基；由此导致编码的蛋白在第2951-2995位的VLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNL缺失，并随即翻译终止，突变蛋白包含2950个Amino acid, i.e. p.2951_2995del. 因此根据本发明的具体实施例，共济失调毛细血管扩张症是常染色体隐性遗传病，具有上述至少一种突变为共济失调毛细血管扩张症疾病的携带者或者患者。Therefore, according to a specific embodiment of the present invention, ataxia telangiectasia is an autosomal recessive genetic disease, and carriers or patients with at least one of the above mutations are ataxia telangiectasia disease. 根据本发明的一个实施例，通过检测是否具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC、c.8851_8987del的至少一种突变，可以准确有效地预测生物体是否患常染色体隐性遗传型共济失调毛细血管扩张症。According to an embodiment of the present invention, by detecting whether there is at least one mutation of c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC, c.8851_8987del, it can be Accurately and efficiently predicts whether an organism suffers from autosomal recessive ataxia telangiectasia. 根据本发明的第二个方面，本发明提出了一种分离的多肽。根据本发明的实施例，与SEQ ID NO：2相比，该多肽具有选自下列的至少一种突变：p.Cys1899X、p.Glu2950fs、p.Trp1026Cys、p.Val2662del、p.Ile159fs、p.2951_2995del。根据本发明的具体实施例，该多肽是由前述分离的编码ATM基因突变体的核酸编码的。通过检测生物样品中是否表达该多肽，可以有效地检测生物样品是否易感共济失调毛细血管扩张症，也可以通过检测这些多肽在生物体中是否存在，可以有效地预测生物体是否易感共济失调毛细血管扩张症。According to a second aspect of the present invention, the present invention provides an isolated polypeptide. According to an embodiment of the present invention, compared with SEQ ID NO: 2, the polypeptide has at least one mutation selected from the group consisting of: p.Cys1899X, p.Glu2950fs, p.Trp1026Cys, p.Val2662del, p.Ile159fs, p. 2951_2995del. According to a specific embodiment of the present invention, the polypeptide is encoded by the aforementioned isolated nucleic acid encoding an ATM gene mutant. By detecting whether the polypeptide is expressed in the biological sample, it can effectively detect whether the biological sample is susceptible to ataxia telangiectasia, and it can also effectively predict whether the organism is susceptible to ataxia telangiectasia by detecting whether these polypeptides exist in the organism. Ataxic telangiectasia. 筛选易患共济失调毛细血管扩张症的生物样品的方法Methods of screening biological samples susceptible to ataxia telangiectasia 根据本发明的第三个方面，本发明提出了一种筛选易患共济失调毛细血管扩张症的生物样品的方法。根据本发明的实施例，该筛选易患共济失调毛细血管扩张症的生物样品的方法可以包括以下步骤：According to a third aspect of the present invention, the present invention proposes a method of screening a biological sample susceptible to ataxia telangiectasia. According to an embodiment of the present invention, the method of screening a biological sample susceptible to ataxia telangiectasia may comprise the steps of: 首先，从所述生物样品提取核酸样本。根据本发明的实施例，生物样品的类型并不受特别限制，只要从该生物样品中能够提取到反映生物样品ATM是否存在突变的核酸样本即可。根据本发明的实施例，生物样品可以为选自人体血液。由此，可以方便地进行取样和检测，从而能够进一步提高筛选易患共济失调毛细血管扩张症的生物样品的效率。根据本发明的实施例，这里所使用的术语“核酸样本”应做广义理解，其可以是任何能够反映生物样品中ATM是否存在突变的样本，例如可以是从生物样品中直接提取的全基因组DNA，也可以是该全基因组中包含ATM编码序列的一部分，可以是从生物样品中提取的总RNA，也可以是从生物样品中提取的mRNA。根据本发明的一个实施例，所述核酸样本为全基因组DNA。由此，可以扩大生物样品的来源范围，并且可以同时对生物样品的多种信息进行确定，从而能够提高筛选易患共济失调毛细血管扩张症的生物样品的效率。另外，根据本发明的实施例，针对采用RNA作为核酸样本，从生物样品提取核酸样本可以进一步包括：从生物样品提取RNA样本，优选RNA样本为mRNA；以及基于所得到的RNA样本，通过反转录反应，获得cDNA样本，所得到的cDNA样本构成核酸样本。由此，可以进一步提高利用RNA作为核酸样本筛选易患共济失调毛细血管扩张症的生物样品的效率。First, a nucleic acid sample is extracted from the biological sample. According to the embodiment of the present invention, the type of the biological sample is not particularly limited, as long as a nucleic acid sample reflecting whether there is a mutation in the ATM of the biological sample can be extracted from the biological sample. According to an embodiment of the present invention, the biological sample may be selected from human blood. As a result, sampling and detection can be conveniently performed, thereby further improving the efficiency of screening biological samples susceptible to ataxia telangiectasia. According to the embodiment of the present invention, the term 'nucleic acid sample' used herein should be understood in a broad sense, and it can be any sample that can reflect whether there is a mutation in ATM in a biological sample, for example, it can be whole genome DNA directly extracted from a biological sample , or it can be a part of the whole genome that contains the ATM coding sequence, can be total RNA extracted from biological samples, or can be mRNA extracted from biological samples. According to an embodiment of the present invention, the nucleic acid sample is whole genome DNA. Thereby, the source range of biological samples can be expanded, and various information of biological samples can be determined at the same time, so that the efficiency of screening biological samples susceptible to ataxia telangiectasia can be improved. In addition, according to an embodiment of the present invention, for using RNA as a nucleic acid sample, extracting a nucleic acid sample from a biological sample may further include: extracting an RNA sample from the biological sample, preferably the RNA sample is mRNA; and based on the obtained RNA sample, by inverting The transcription reaction is performed to obtain a cDNA sample, and the obtained cDNA sample constitutes a nucleic acid sample. Thereby, the efficiency of screening biological samples susceptible to ataxia telangiectasia using RNA as a nucleic acid sample can be further improved. 接下来，在得到核酸样本之后，可以对核酸样本进行分析，从而能够确定所得到核酸样本的核酸序列。根据本发明的实施例，确定所得到核酸样本的核酸序列的方法和设备并不受特别限制。根据本发明的具体实施例，可以通过测序方法，确定核酸样本的核酸序列。根据本发明的实施例，可以用于进行测序的方法和设备并不受特别限制。根据本发明的实施例，可以采用第二代测序技术，也可以采用第三代以及第四代或者更先进的测序技术。根据本发明的具体示例，可以利用选自Hiseq2000、SOLiD、454和单分子测序装置的至少一种对核酸序列进行测序。由此，结合最新的测序技术，针对单个位点可以达到较高的测序深度，检测灵敏度和准确性大大提高，因而能够利用这些测序装置的高通量、深度测序的特点，进一步提高对核酸样本进行检测分析的效率。从而，能够提高后续对测序数据进行分析时的精确性和准确度。由此，根据本发明的实施例，确定核酸样本的核酸序列可以进一步包括：首先，针对所得到的核酸样本，构建核酸测序文库；以及对所得到的核酸测序文库进行测序，以便获得由多个测序数据构成的测序结果。根据本发明的一些实施例，可以采用选自Hiseq2000、SOLiD、454和单分子测序装置的至少一种对所得到的核酸测序文库进行测序。另外，根据本发明的实施例，可以对核酸样本进行筛选，富集ATM外显子，该筛选富集可以在构建测序文库之前，构建测序文库过程中，或者构建测序文库之后进行。根据本发明的一个实施例，针对核酸样本，构建核酸测序文库进一步包括：利用ATM基因外显子特异性引物，对核酸样本进行PCR扩增；以及针对所得到的扩增产物，构建核酸测序文库。由此，可以通过PCR扩增，富集ATM基因外显子，从而能够进一步提高筛选易感共济失调毛细血管扩张症的生物样品的效率。根据本发明的实施例，ATM基因外显子特异性引物的序列不受特别限制，根据本发明的优选实施例，这些ATM基因外显子特异性引物具有如下表所示的核苷酸序列，即SEQ ID NO：7-16所示的核苷酸序列。发明人惊奇地发现，通过采用这些引物，可以在PCR反应体系中显著有效地完成对ATM外显子尤其是c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)突变所在的外显子序列的扩增。需要说明的是，这些SEQ ID NO：7-16所示的核苷酸序列是本发明的发明人在付出了艰苦的劳动后，意外获得的。Next, after the nucleic acid sample is obtained, the nucleic acid sample can be analyzed, so that the nucleic acid sequence of the obtained nucleic acid sample can be determined. According to the embodiments of the present invention, the method and apparatus for determining the nucleic acid sequence of the obtained nucleic acid sample are not particularly limited. According to a specific embodiment of the present invention, the nucleic acid sequence of a nucleic acid sample can be determined by a sequencing method. According to embodiments of the present invention, methods and apparatuses that can be used to perform sequencing are not particularly limited. According to the embodiments of the present invention, the second-generation sequencing technology may be used, and the third-generation and fourth-generation or more advanced sequencing technologies may also be used. According to a specific example of the present invention, the nucleic acid sequence can be sequenced using at least one selected from the group consisting of Hiseq2000, SOLiD, 454, and single-molecule sequencing devices. Therefore, combined with the latest sequencing technology, a higher sequencing depth can be achieved for a single site, and the detection sensitivity and accuracy are greatly improved. Therefore, the high-throughput and deep sequencing features of these sequencing devices can be used to further improve the detection of nucleic acid samples. Efficiency of assay analysis. Therefore, the precision and accuracy of subsequent analysis of the sequencing data can be improved. Thus, according to an embodiment of the present invention, determining the nucleic acid sequence of the nucleic acid sample may further include: first, constructing a nucleic acid sequencing library for the obtained nucleic acid sample; and sequencing the obtained nucleic acid sequencing library, so as to obtain a plurality of Sequencing data consists of sequencing results. According to some embodiments of the present invention, the obtained nucleic acid sequencing library can be sequenced using at least one selected from Hiseq2000, SOLiD, 454, and single-molecule sequencing devices. In addition, according to embodiments of the present invention, nucleic acid samples can be screened to enrich for ATM exons, and the screening and enrichment can be performed before, during, or after the construction of the sequencing library. According to one embodiment of the present invention, for nucleic acid samples, constructing a nucleic acid sequencing library further includes: using ATM gene exon-specific primers to amplify the nucleic acid samples by PCR; and for the obtained amplification products, constructing a nucleic acid sequencing library . Thus, the ATM gene exons can be enriched by PCR amplification, thereby further improving the efficiency of screening biological samples susceptible to ataxia telangiectasia. According to the embodiments of the present invention, the sequences of the ATM gene exon-specific primers are not particularly limited. According to a preferred embodiment of the present invention, these ATM gene exon-specific primers have the nucleotide sequences shown in the following table, That is, the nucleotide sequences shown in SEQ ID NOs: 7-16. The inventors have surprisingly found that by using these primers, the PCR reaction system can effectively complete the detection of ATM exons, especially c.5697C>A, c.4777-2A>T, c.3078G>T, c. Amplification of exon sequences where 7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del) mutations are located. It should be noted that the nucleotide sequences shown in SEQ ID NOs: 7-16 were obtained by accident by the inventor of the present invention after hard work. 根据本发明的具体实施例，上述的共济失调毛细血管扩张症是常染色体隐性遗传疾病。According to a specific embodiment of the present invention, the above-mentioned ataxia telangiectasia is an autosomal recessive disorder. 关于针对核酸样本，构建测序文库的方法和流程，本领域技术人员可以根据不同的测序技术进行适当选择，关于流程的细节，可以参见测序仪器的厂商例如Illumina公司所提供的规程，例如参见Illumina公司Multiplexing Sample Preparation Guide(Part#1005361；Feb2010)或Paired-End SamplePrep Guide(Part#1005063；Feb 2010)，通过参照将其并入本文。根据本发明的实施例，从生物样品提取核酸样本的方法和设备，也不受特别限制，可以采用商品化的核酸提取试剂盒进行。Regarding the methods and procedures for constructing a sequencing library for nucleic acid samples, those skilled in the art can make appropriate selections according to different sequencing technologies. For details of the procedures, please refer to the procedures provided by the manufacturers of sequencing instruments such as Illumina, for example, see Illumina Multiplexing Sample Preparation Guide (Part #1005361; Feb 2010) or Paired-End SamplePrep Guide (Part #1005063; Feb 2010), incorporated herein by reference. According to the embodiments of the present invention, the method and device for extracting nucleic acid samples from biological samples are also not particularly limited, and commercial nucleic acid extraction kits can be used. 需要说明的是，在这里所使用的术语“核酸序列”应作广义理解，其可以是在对核酸样本进行测序得到的测序数据进行组装后，得到的完整的核酸序列信息，也可以是直接采用通过对核酸样本进行测序所得到的测序数据(reads)作为核酸序列，只要这些核酸序列中含有对应ATM基因的编码序列即可。It should be noted that the term 'nucleic acid sequence' used here should be understood in a broad sense. It can be the complete nucleic acid sequence information obtained after assembling the sequencing data obtained by sequencing the nucleic acid sample, or it can be directly used The sequencing data (reads) obtained by sequencing the nucleic acid samples are regarded as nucleic acid sequences, as long as these nucleic acid sequences contain the coding sequence corresponding to the ATM gene. 最后，在确定核酸样本的核酸序列之后，将所得到的核酸样本的核酸序列与SEQID NO：1的序列相比对。如果在所得到的核酸序列中具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)突变的至少一种，则指示生物样品易患共济失调毛细血管扩张症。由此，通过根据本发明实施例的筛选易患共济失调毛细血管扩张症的生物样品的方法，可以有效地筛选易患共济失调毛细血管扩张症的生物样品。根据本发明的实施例，对核酸序列与SEQ ID NO：1进行比对的方法和设备并不受特别限制，可以采用任意常规的软件进行操作，根据本发明的具体实例，可以采用SOAP软件进行比对。Finally, after determining the nucleic acid sequence of the nucleic acid sample, the nucleic acid sequence of the obtained nucleic acid sample is compared with the sequence of SEQ ID NO: 1. If there is at least one of c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del) mutations in the obtained nucleic acid sequence, This indicates that the biological sample is susceptible to ataxia telangiectasia. Thus, by the method for screening biological samples susceptible to ataxia telangiectasia according to an embodiment of the present invention, biological samples susceptible to ataxia telangiectasia can be effectively screened. According to the embodiments of the present invention, the method and device for aligning the nucleic acid sequence with SEQ ID NO: 1 are not particularly limited, and any conventional software can be used to perform the operation. According to a specific example of the present invention, SOAP software can be used to perform the operation. Comparison. 需要说明的是，根据本发明实施例的“筛选易患共济失调毛细血管扩张症的生物样品的方法”的用途不受特别限制，例如可以用作非诊断目的的筛选方法。It should be noted that the use of the 'method for screening biological samples susceptible to ataxia telangiectasia' according to the embodiments of the present invention is not particularly limited, and for example, it can be used as a screening method for non-diagnostic purposes. 筛选易患共济失调毛细血管扩张症的生物样品的系统和试剂盒System and kit for screening biological samples susceptible to ataxia telangiectasia 根据本发明的第四个方面，本发明提出了一种筛选易患共济失调毛细血管扩张症的生物样品的系统。According to a fourth aspect of the present invention, the present invention proposes a system for screening biological samples susceptible to ataxia telangiectasia. 参考图1，根据本发明的实施例，该筛选易患共济失调毛细血管扩张症的生物样品的系统1000包括核酸提取装置100、核酸序列确定装置200以及判断装置300。1 , according to an embodiment of the present invention, the system 1000 for screening biological samples susceptible to ataxia telangiectasia includes a nucleic acid extraction device 100 , a nucleic acid sequence determination device 200 and a determination device 300 . 根据本发明的实施例，核酸提取装置100用于从生物样品提取核酸样本。如前所述，根据本发明的实施例，核酸样本的类型并不受特别限制，对于采用RNA作为核酸样本，则核酸提取装置进一步包括RNA提取单元101和反转录单元102，其中，提取单元101用于从生物样品提取RNA样本，反转录单元102与RNA提取单元101相连，用于对RNA样本进行反转录反应，以便获得cDNA样本，所得到的cDNA样本构成核酸样本。According to an embodiment of the present invention, the nucleic acid extraction apparatus 100 is used for extracting nucleic acid samples from biological samples. As mentioned above, according to the embodiment of the present invention, the type of nucleic acid sample is not particularly limited. For using RNA as the nucleic acid sample, the nucleic acid extraction apparatus further includes an RNA extraction unit 101 and a reverse transcription unit 102, wherein the extraction unit 101 is used for extracting RNA samples from biological samples, and the reverse transcription unit 102 is connected to the RNA extraction unit 101 for performing reverse transcription reaction on the RNA samples to obtain cDNA samples, and the obtained cDNA samples constitute nucleic acid samples. 根据本发明的实施例，核酸序列确定装置200与核酸提取装置100相连，用于对核酸样本进行分析，以便确定核酸样本的核酸序列。如前所示，可以采用测序的方法确定核酸样本的核酸序列。由此，根据本发明的一个实施例，所述核酸序列确定装置200可以进一步包括：文库构建单元201以及测序单元202。文库构建单元201用于针对核酸样本，构建核酸测序文库；测序单元202与文库构建单元201相连，用于对核酸测序文库进行测序，以便获得由多个测序数据构成的测序结果。如前所述，可以通过PCR扩增，富集ATM外显子，进一步提高筛选易患共济失调毛细血管扩张症的生物样品的效率。由此，文库构建单元201可以进一步包括PCR扩增模块(图中未示出)，在该PCR扩增模块中设置有ATM外显子特异性引物，以便利用ATM外显子特异性引物，对所述核酸样本进行PCR扩增，根据本发明的具体实施例，ATM基因外显子特异性引物具有如SEQ ID NO：7-16所示的核苷酸序列。根据本发明的实施例，测序单元202可以包括选自HISEQ2000、SOLiD、454和单分子测序装置的至少一种。由此，结合最新的测序技术，针对单个位点可以达到较高的测序深度，检测灵敏度和准确性大大提高，因而能够利用这些测序装置的高通量、深度测序的特点，进一步提高对核酸样本进行检测分析的效率。从而，提高后续对测序数据进行分析时的精确性和准确度。According to an embodiment of the present invention, the nucleic acid sequence determination device 200 is connected to the nucleic acid extraction device 100 for analyzing the nucleic acid sample, so as to determine the nucleic acid sequence of the nucleic acid sample. As previously indicated, the nucleic acid sequence of a nucleic acid sample can be determined by sequencing. Thus, according to an embodiment of the present invention, the nucleic acid sequence determination apparatus 200 may further include: a library construction unit 201 and a sequencing unit 202 . The library construction unit 201 is used for constructing a nucleic acid sequencing library for nucleic acid samples; the sequencing unit 202 is connected to the library construction unit 201 and is used for sequencing the nucleic acid sequencing library, so as to obtain a sequencing result composed of multiple sequencing data. As previously described, ATM exons can be enriched by PCR amplification to further improve the efficiency of screening biological samples susceptible to ataxia telangiectasia. Therefore, the library construction unit 201 may further include a PCR amplification module (not shown in the figure), in which the PCR amplification module is provided with ATM exon-specific primers, so that the ATM exon-specific primers can be used to The nucleic acid sample is subjected to PCR amplification. According to a specific embodiment of the present invention, the ATM gene exon-specific primers have the nucleotide sequences shown in SEQ ID NOs: 7-16. According to an embodiment of the present invention, the sequencing unit 202 may include at least one selected from the group consisting of HISEQ2000, SOLiD, 454 and single-molecule sequencing devices. Therefore, combined with the latest sequencing technology, a higher sequencing depth can be achieved for a single site, and the detection sensitivity and accuracy are greatly improved. Therefore, the high-throughput and deep sequencing features of these sequencing devices can be used to further improve the detection of nucleic acid samples. Efficiency of assay analysis. Thus, the precision and accuracy of subsequent analysis of the sequencing data are improved. 根据本发明的实施例，判断装置300与核酸序列确定装置200相连，适于将核酸样本的核酸序列进行比对，以便基于核酸样本的核酸序列与SEQ ID NO：1的区别判断生物样品是否易患共济失调毛细血管扩张症。具体地，基于核酸样本的核酸序列与SEQ ID NO：1相比，是否具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)的至少一种突变，判断生物样品是否易患共济失调毛细血管扩张症。如前所述，根据本发明的一个实施例，核酸样本的核酸序列与SEQID NO：1相比，具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)的至少一种突变，是生物样品易患共济失调毛细血管扩张症的指示。如前所述，根据本发明的实施例，对核酸序列与SEQ ID NO：1进行比对的设备并不受特别限制，可以采用任意常规的软件进行操作，根据本发明的具体实例，可以采用SOAP软件进行比对。According to an embodiment of the present invention, the judging device 300 is connected to the nucleic acid sequence determining device 200, and is adapted to compare the nucleic acid sequences of the nucleic acid samples, so as to determine whether the biological samples are susceptible based on the difference between the nucleic acid sequences of the nucleic acid samples and SEQ ID NO: 1 Suffering from ataxia telangiectasia. Specifically, based on the nucleic acid sequence of the nucleic acid sample compared with SEQ ID NO: 1, whether it has c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c. At least one mutation in 8851_8987del (exon 65del) to determine whether a biological sample is susceptible to ataxia telangiectasia. As mentioned above, according to an embodiment of the present invention, the nucleic acid sequence of the nucleic acid sample has c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT compared with SEQ ID NO: 1 , at least one mutation of c.477_481delATCTC and c.8851_8987del (exon 65del) is indicative of a biological sample being susceptible to ataxia telangiectasia. As mentioned above, according to the embodiment of the present invention, the device for aligning the nucleic acid sequence with SEQ ID NO: 1 is not particularly limited, and any conventional software can be used for operation. SOAP software for comparison. 由此，利用该系统，能够有效地实施前述筛选易患共济失调毛细血管扩张症的生物样品的方法，从而可以有效地筛选易患共济失调毛细血管扩张症的生物样品。Thus, using this system, the aforementioned method of screening a biological sample susceptible to ataxia telangiectasia can be effectively performed, and thus, a biological sample susceptible to ataxia telangiectasia can be efficiently screened. 根据本发明的第五方面，本发明提出了一种用于筛选易患共济失调毛细血管扩张症的生物样品的试剂盒。根据本发明的实施例，该用于筛选易患共济失调毛细血管扩张症的生物样品的试剂盒包括：适于检测ATM基因突变体的试剂，其中与SEQ ID NO：1相比，该ATM基因突变体具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)的至少一种突变。利用根据本发明的实施例的试剂盒，能够有效地筛选易患共济失调毛细血管扩张症的生物样品。在本文中，所使用的术语“适于检测ATM基因突变体的试剂”应做广义理解，即可以是检测ATM编码基因的试剂，也可以是检测ATM突变体多肽的试剂，例如可以采用识别特异性位点的抗体。根据本发明的一个实施例，所述试剂为核酸探针，由此，可以高效地筛选易患共济失调毛细血管扩张症的生物样品。根据本发明的具体实施例，上述共济失调毛细血管扩张症为常染色体隐性遗传疾病。According to a fifth aspect of the present invention, the present invention provides a kit for screening biological samples susceptible to ataxia telangiectasia. According to an embodiment of the present invention, the kit for screening a biological sample susceptible to ataxia telangiectasia comprises: a reagent suitable for detecting an ATM gene mutant, wherein the ATM compared with SEQ ID NO: 1 The gene mutant has at least one mutation of c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del). Using the kit according to the embodiment of the present invention, biological samples susceptible to ataxia telangiectasia can be efficiently screened. In this article, the term 'reagent suitable for detecting ATM gene mutant' should be understood in a broad sense, that is, it can be a reagent for detecting ATM-encoding gene or a reagent for detecting ATM mutant polypeptide. Sex site antibodies. According to an embodiment of the present invention, the reagent is a nucleic acid probe, whereby biological samples susceptible to ataxia telangiectasia can be efficiently screened. According to a specific embodiment of the present invention, the above-mentioned ataxia telangiectasia is an autosomal recessive disorder. 需要说明的是，在本文前面筛选易患共济失调毛细血管扩张症的生物样品的方法部分中所描述的特征和优点，同样适用于筛选易患共济失调毛细血管扩张症的生物样品的系统或者试剂盒，在此不再赘述。It should be noted that the features and advantages described earlier herein in the Methods section for screening biological samples susceptible to ataxia telangiectasia are equally applicable to the system for screening biological samples susceptible to ataxia telangiectasia Or the kit, which will not be repeated here. 构建体及重组细胞Constructs and recombinant cells 根据本发明的第六方面，本发明还提出了一种构建体。根据本发明的实施例，该构建体包含前面所述的分离的编码ATM基因突变体的核酸。需要说明的是，“构建体包含前面所述的分离的编码ATM基因突变体的核酸”表示，本发明的构建体包含与SEQ ID NO：1相比具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)至少一种突变。由此，利用本发明的构建体转化受体细胞获得的重组细胞，能够有效地用作共济失调毛细血管扩张症相关研究的模型。其中，所述受体细胞的种类不受特别限制，例如可以为大肠杆菌细胞、哺乳动物细胞，优选该受体细胞来源于哺乳动物。According to the sixth aspect of the present invention, the present invention also proposes a construct. According to an embodiment of the present invention, the construct comprises the previously described isolated nucleic acid encoding an ATM gene mutant. It should be noted that 'the construct comprises the aforementioned isolated nucleic acid encoding an ATM gene mutant' means that the construct of the present invention comprises c.5697C>A, c.4777- 2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del) at least one mutation. Thus, recombinant cells obtained by transforming recipient cells with the construct of the present invention can be effectively used as models for studies related to ataxia telangiectasia. The type of the recipient cell is not particularly limited, for example, it can be Escherichia coli cells or mammalian cells, and preferably, the recipient cell is derived from mammals. 在本发明中所使用的术语“构建体”是指这样的一种遗传载体，其包含特定核酸序列，并且能够将目的核酸序列转入宿主细胞中，以获得重组细胞。根据本发明的实施例，构建体的形式不受特别限制。根据本发明的实施例，其可以为质粒、噬菌体、人工染色体、粘粒(Cosmid)、病毒的至少一种，优选质粒。质粒作为遗传载体，具有操作简单，可以携带较大片段的性质，便于操作和处理。质粒的形式也不受特别限制，既可以是环形质粒，也可以是线性质粒，即可以是单链的，也可以是双链的。本领域技术人员可以根据需要进行选择。在本发明中所使用的术语“核酸”可以是任何包含脱氧核糖核苷酸或者核糖核苷酸的聚合物，包括但不限于经过修饰的或者未经修饰的DNA、RNA，其长度不受任何特别限制。对于用于构建重组细胞的构建体，优选所述核酸为DNA，因为DNA相对于RNA而言，其更稳定，并且易于操作。The term 'construct' as used in the present invention refers to a genetic vector comprising a specific nucleic acid sequence and capable of transferring the nucleic acid sequence of interest into a host cell to obtain a recombinant cell. According to the embodiment of the present invention, the form of the construct is not particularly limited. According to the embodiment of the present invention, it can be at least one of plasmid, phage, artificial chromosome, cosmid (Cosmid), virus, preferably a plasmid. As a genetic carrier, plasmid has the property of being simple to operate, can carry larger fragments, and is easy to operate and handle. The form of the plasmid is also not particularly limited, it can be either a circular plasmid or a linear plasmid, that is, it can be single-stranded or double-stranded. Those skilled in the art can make selections as needed. The term 'nucleic acid' as used in the present invention may be any polymer comprising deoxyribonucleotides or ribonucleotides, including but not limited to modified or unmodified DNA, RNA, the length of which is not limited by any Special restrictions. For constructs used to construct recombinant cells, the nucleic acid is preferably DNA because DNA is more stable and easier to manipulate than RNA. 根据本发明的第七方面，本发明还提出了一种重组细胞。根据本发明的实施例，该重组细胞是通过前面所述的构建体转化受体细胞而获得的。从而，本发明的重组细胞能够有效表达构建体所携带的ATM基因突变体。根据本发明的一些实施例，本发明的重组细胞，能够有效地用作共济失调毛细血管扩张症相关研究的模型。根据本发明的实施例，受体细胞的种类不受特别限制，例如可以为大肠杆菌细胞、哺乳动物细胞，优选所述受体细胞来源于非人哺乳动物。According to the seventh aspect of the present invention, the present invention also provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell is obtained by transforming the recipient cell with the aforementioned construct. Thus, the recombinant cells of the present invention can efficiently express the ATM gene mutant carried by the construct. According to some embodiments of the present invention, the recombinant cells of the present invention can be effectively used as a model for studies related to ataxia telangiectasia. According to the embodiment of the present invention, the type of recipient cells is not particularly limited, for example, it can be E. coli cells, mammalian cells, and preferably, the recipient cells are derived from non-human mammals. 对于本发明中所述核酸，本领域技术人员应当理解，实际包括互补双链的任意一条，或者两条。为了方便，在本发明的实施例中，虽然多数情况下只给出了一条链，但实际上也公开了与之互补的另一条链。例如，提及SEQ ID NO:1，实际包括其互补序列。本领域技术人员还可以理解，利用一条链可以检测另一条链，反之亦然。For the nucleic acid described in the present invention, those skilled in the art should understand that it actually includes any one, or both, of the complementary double strands. For convenience, in the embodiments of the present invention, although only one chain is given in most cases, another chain complementary thereto is actually disclosed. For example, reference to SEQ ID NO: 1 actually includes its complement. It will also be understood by those skilled in the art that one chain can be used to detect another chain, and vice versa. 下面参考具体实施例，对本发明进行说明，需要说明的是，这些实施例仅仅是说明性的，而不能理解为对本发明的限制。The present invention will be described below with reference to specific embodiments. It should be noted that these embodiments are merely illustrative and should not be construed as limiting the present invention. 若未特别指明，实施例中所采用的技术手段为本领域技术人员所熟知的常规手段，可以参照《分子克隆实验指南》第三版或者相关产品进行，所采用的试剂和产品也均为可商业获得的。未详细描述的各种过程和方法是本领域中公知的常规方法，所用试剂的来源、商品名以及有必要列出其组成成分者，均在首次出现时标明，其后所用相同试剂如无特殊说明，均与首次标明的内容相同。Unless otherwise specified, the technical means used in the examples are conventional means known to those skilled in the art, and can be carried out with reference to the third edition of the 'Molecular Cloning Experiment Guide' or related products, and the reagents and products used are also available commercially obtained. Various processes and methods that are not described in detail are conventional methods well known in the art. The sources and trade names of the reagents used, as well as those necessary to list their constituents, are indicated when they first appear, and the same reagents used thereafter, unless otherwise specified. The descriptions are the same as those indicated for the first time. 实施例1确定共济失调毛细血管扩张症的致病基因Example 1 Identification of the causative gene of ataxia telangiectasia 1、样本收集1. Sample collection 发明人收集到了三个两代的共济失调毛细血管扩张症(本文中也可以称将共济失调毛细血管扩张症简称为AT)的患者家系，以及随即收集的该家系外的500名正常人的基因。图2显示了AT家系1、AT家系2以及AT家系3的家系图谱。如图2所示，其中，□表示正常男性，○表示正常女性，■表示男性患者，●表示女性患者。由图2可知，每个家系共有3名成员，其中第二代子女为AT患者，第一代的父母为正常成员。The inventors collected three two-generation families of patients with ataxia telangiectasia (this article can also be referred to as ataxia telangiectasia abbreviated as AT), and then collected 500 normal people outside the family. gene. Figure 2 shows the pedigree of AT family 1, AT family 2, and AT family 3. As shown in FIG. 2 , □ represents a normal male, ○ represents a normal female, ■ represents a male patient, and ● represents a female patient. It can be seen from Figure 2 that there are 3 members in each family, among which the second generation children are AT patients, and the first generation parents are normal members. 三个家系中的三名患者均表现为儿童期出现行走不稳症状，同时伴有眼球结膜处血丝，面部和关节多处色素沉着及皮肤结节形成。体检发现体态偏瘦，多处明显色素沉着，尤其在耳后和双肘关节等处可见结痂形成；明显的眼球结膜毛细血管扩张和面颊部毛细血管扩张，并且对头部进行核磁共振检查(MRI)发现小脑萎缩。Three patients in three families presented with symptoms of unsteady walking in childhood, accompanied by bloodshot conjunctiva, multiple pigmentation on the face and joints, and skin nodules. Physical examination revealed a thin body with obvious pigmentation in many places, especially the formation of scabs behind the ears and elbow joints; obvious telangiectasia of eyeball conjunctiva and cheek telangiectasia, and MRI of the head ( MRI) found cerebellar atrophy. 1、DNA提取1. DNA extraction 采用OMEGA Blood DNA Midi Kit全血DNA提取试剂盒从外周血样品中提取DNA,提取步骤如下：DNA was extracted from peripheral blood samples using the OMEGA Blood DNA Midi Kit whole blood DNA extraction kit. The extraction steps were as follows: 1)取2ml全血样本，加入150ul OB Protease，2.1ml Buffer BL和20ul RNase A，最大速度漩涡1分钟，彻底混匀。1) Take 2ml of whole blood sample, add 150ul OB Protease, 2.1ml Buffer BL and 20ul RNase A, vortex at maximum speed for 1 minute, and mix thoroughly. 2)65摄氏度水浴15-20分钟，并在水浴过程中漩涡5次。2) 65°C water bath for 15-20 minutes and vortex 5 times during the water bath. 3)加入2.2ml无水乙醇，最大速度漩涡30秒，彻底混匀。3) Add 2.2 ml of absolute ethanol, vortex at maximum speed for 30 seconds, and mix thoroughly. 4)将3.5ml裂解液移入带过滤柱的15ml离心管，4000转离心5分钟，取出过滤柱，倒掉过滤液体，放回过滤柱。4) Transfer 3.5ml of the lysate into a 15ml centrifuge tube with a filter column, centrifuge at 4000 rpm for 5 minutes, take out the filter column, pour off the filter liquid, and put it back into the filter column. 5)将第3步剩余裂解液加入带过滤柱的15ml离心管，4000转离心5分钟，取出过滤柱，倒掉过滤液体，放回过滤柱。5) Add the remaining lysate from step 3 to a 15ml centrifuge tube with a filter column, centrifuge at 4000 rpm for 5 minutes, take out the filter column, pour out the filter liquid, and put it back into the filter column. 6)加入3ml HB Buffer，洗涤过滤柱，4000转离心5分钟，取出过滤柱，倒掉过滤液体，放回过滤柱。6) Add 3ml HB Buffer, wash the filter column, centrifuge at 4000 rpm for 5 minutes, take out the filter column, pour off the filter liquid, and put it back into the filter column. 7)加入3ml DNA Wash Buffer，4000转离心5分钟，取出过滤柱，倒掉过滤液体，放回过滤柱。7) Add 3ml DNA Wash Buffer, centrifuge at 4000 rpm for 5 minutes, take out the filter column, pour off the filter liquid, and put it back into the filter column. 8)再次加入3ml DNA Wash Buffer，4000转离心5分钟，取出过滤柱，倒掉过滤液体，放回过滤柱。8) Add 3ml DNA Wash Buffer again, centrifuge at 4000 rpm for 5 minutes, take out the filter column, pour off the filter liquid, and put it back into the filter column. 9)4000转离心15分钟，甩干过滤柱。9) Centrifuge at 4000 rpm for 15 minutes, and spin dry the filter column. 10)将过滤柱移至新的15ml离心管，加入500ul 70摄氏度的Elution Buffer，室温静置5分钟，4000转离心5分钟，收集含有DNA的过滤液。10) Transfer the filter column to a new 15ml centrifuge tube, add 500ul of Elution Buffer at 70 degrees Celsius, stand at room temperature for 5 minutes, centrifuge at 4000 rpm for 5 minutes, and collect the filtrate containing DNA. 11)再次将过滤柱移至新的15ml离心管，加入500ul 70摄氏度的Elution Buffer，室温静置5分钟，4000转离心5分钟，收集含有DNA的过滤液。11) Move the filter column to a new 15ml centrifuge tube again, add 500ul of Elution Buffer at 70 degrees Celsius, stand at room temperature for 5 minutes, centrifuge at 4000 rpm for 5 minutes, and collect the filtrate containing DNA. 2、外显子捕获与测序2. Exon capture and sequencing 我们挑选了三名患者进行外显子组测序及数据分析，具体做法如下。We selected three patients for exome sequencing and data analysis as follows. 随后，发明人用Agilent SureSelect Human All Exon Kit结合Solexa高通量测序技术对病例AT家系1-II：1、AT家系2-II：1、AT家系3-II：1的外显子组序列进行了测序，具体如下：Subsequently, the inventors used the Agilent SureSelect Human All Exon Kit combined with Solexa high-throughput sequencing technology to sequence the exome sequences of the cases AT family 1-II:1, AT family 2-II:1, and AT family 3-II:1. sequenced as follows: 1)将基因组DNA随机打断成150-200bp左右的片段，随后在片段两端分别连接上接头制备杂交文库(参见http://www.illumina.com/提供的Illumina/Solexa标准建库说明书)。1) Randomly break the genomic DNA into fragments of about 150-200 bp, and then connect adapters at both ends of the fragments to prepare a hybrid library (refer to the Illumina/Solexa standard library construction instructions provided by http://www.illumina.com/ ) . 2)文库经纯化后经过ligation-mediated PCR(LM-PCR)的线性扩增与SureSelectBiotiny lated RNA Library(BAITS)进行杂交富集，再经过LM-PCR的线性扩增后进行上机测序。测序平台为Illumina Hiseq 2000，读取长度为90bp,每个样本的平均测序深度最少为80×。2) After purification, the library was subjected to linear amplification by ligation-mediated PCR (LM-PCR) for hybridization and enrichment with SureSelect Biotiny lated RNA Library (BAITS), and then on-machine sequencing was performed after linear amplification by LM-PCR. The sequencing platform was Illumina Hiseq 2000, the read length was 90 bp, and the average sequencing depth of each sample was at least 80×. 3)测序后获得的原始数据由Illumina basecalling Software 1.7进行处理，经过过滤去污染、使用SOAPaligner 2.20比对参考基因组，获得比对到基因组上的Uniquemapped reads。靶区域的基因型由SOAPsnp。3) The raw data obtained after sequencing was processed by Illumina basecalling Software 1.7, filtered to remove contamination, and SOAPaligner 2.20 was used to align the reference genome to obtain Uniquemapped reads aligned to the genome. The genotype of the target region was determined by SOAPsnp. 3、结论3. Conclusion 在病例AT家系1-II：1中均发现有60711个单核苷酸多态性(SNPs)和3916处的插入/缺失。在病例AT家系2-II：1中发现了62518个单核苷酸多态性(SNPs)和4118处的插入/缺失，病例AT家系3-II：1中发现了58283个单核苷酸多态性(SNPs)和3687处的插入/缺失，将结果与dbSNP数据库(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/ snp132.txt.gz)，HapMap数据库(ftp://ftp.ncbi.nlm.nih.gov/hapmap)，千人基因组数据库(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp)，炎黄数据库(http:// yh.genomics.org.cn/)等公共数据库进行比较，过滤掉所有已知变异。利用SIFT软件进行SNP功能预测.60711 single nucleotide polymorphisms (SNPs) and 3916 insertions/deletions were found in all cases AT families 1-II:1. 62518 single nucleotide polymorphisms (SNPs) and 4118 insertions/deletions were found in case AT family 2-II:1, and 58283 SNPs were found in case AT family 3-II:1 morphisms (SNPs) and indels at 3687, compare the results with the dbSNP database ( http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/snp132.txt.gz ), the HapMap database ( ftp:/ /ftp.ncbi.nlm.nih.gov/hapmap ) , Thousand Genomes Database ( ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp ), Yanhuang Database ( http://yh.genomics.org .cn/ ) and other public databases to filter out all known variants. SNP function prediction was performed using SIFT software. 分别发现患者AT家系1-II：1在ATM基因存在一个复合杂合的突变c.5697C>A(p.Cys1899X，无义突变)、exon 65del，其中患者父亲携带杂合突变c.5697C>A，患者母亲携带杂合缺失exon 65del。It was found that there is a compound heterozygous mutation c.5697C>A (p.Cys1899X, nonsense mutation) and exon 65del in the ATM gene of the patient's AT family 1-II:1, of which the patient's father carries a heterozygous mutation c.5697C>A , the patient's mother carries a heterozygous deletion of exon 65del. AT家系2-II：1在ATM基因存在一个复合杂合的突变c.477_481del ATCTC(移码突变)、c.4777-2A>T(剪切位点突变)，其中患者父亲携带杂合缺失c.477_481del ATCTC，患者母亲携带杂合突变c.4777-2A>T。AT family 2-II:1 has a compound heterozygous mutation c.477_481del ATCTC (frameshift mutation), c.4777-2A>T (splice site mutation) in the ATM gene, in which the patient's father carries a heterozygous deletionc .477_481del ATCTC, the mother of the patient carries the heterozygous mutation c.4777-2A>T. AT家系3-II：1在ATM基因存在一个复合杂合的突变c.3078G>T(p.Trp1026Cys，错义突变)、c.7983_7985delTGT，其中患者父亲携带杂合突变c.3078G>T，患者母亲携带杂合缺失c.7983_7985delTGT。AT family 3-II:1 has a compound heterozygous mutation c.3078G>T (p.Trp1026Cys, missense mutation), c.7983_7985delTGT in the ATM gene, in which the patient's father carries the heterozygous mutation c.3078G>T, the patient The mother carries the heterozygous deletion c.7983_7985delTGT. 研究表明，通过家族中疾病共分离和正常人SNP筛查，这三个复合杂合位点突变可引起常染色体隐性遗传性的AT疾病，因此可能是致病位点。Studies have shown that these three compound heterozygous site mutations can cause autosomal recessive AT disease through disease co-segregation in the family and SNP screening in normal people, so they may be pathogenic loci. 实施例2 Sanger法测序验证共济失调毛细血管扩张症的致病基因Example 2 Sanger sequencing to verify the causative gene of ataxia telangiectasia 采集3例AT患者及其父母外周血，利用常规酚-氯仿法抽提外周血白细胞中的基因组DNA，利用分光光度计测量DNA的浓度及纯度，所得的每个标本基因组DNA的OD260/OD280均位于1.7-2.0之间，浓度不少于200ng/ul，总量不少于30μg。The peripheral blood of 3 AT patients and their parents was collected, the genomic DNA in the peripheral blood leukocytes was extracted by the conventional phenol-chloroform method, and the concentration and purity of the DNA were measured by a spectrophotometer. Located between 1.7-2.0, the concentration is not less than 200ng/ul, and the total amount is not less than 30μg. 分别对3名患者(即图2中的患者II：1)、6名家系内正常人(即该3例患者的父母，均未发病)和500名家系外正常人(即与表中所有患者无血缘关系的对照)基因进行检测，针对ATM基因所有外显子序列设计引物，通过PCR扩增，产物纯化，测序的方法获得ATM有关序列，根据序列测定结果属于突变型还是野生型，验证ATM与AT疾病之间相关性。具体方法步骤如下：For 3 patients (ie, patient II: 1 in Figure 2), 6 normal people in the family (ie, the parents of the 3 patients, none of them had the disease) and 500 normal people outside the family (ie, the same as all the patients in the table). Unrelated control) genes are detected, primers are designed for all exon sequences of ATM gene, ATM related sequences are obtained by PCR amplification, product purification, and sequencing methods, according to whether the sequence determination results belong to mutant or wild type, verify ATM Correlation with AT disease. The specific method steps are as follows: 1、DNA提取：1. DNA extraction: 分别采取3名家系内患者、6名家系内正常人和500名家系外正常人外周静脉血按照上述方法提取基因组DNA，分光光度计测DNA含量。The peripheral venous blood of 3 patients in the family, 6 normal people in the family and 500 normal people outside the family were collected according to the above method to extract genomic DNA, and the DNA content was measured spectrophotometrically. 2、引物设计及PCR反应2. Primer design and PCR reaction 引物设计参考人类基因组序列数据库hg19/build37.1，具体见下。The primer design refers to the human genome sequence database hg19/build37.1, see below for details. 引物序列：Primer sequence: b)反应体系：10μLb) Reaction system: 10 μL 试剂reagent 体积volume 2×GC BufferⅠ2×GC BufferⅠ 5.0μl5.0μl dNTPs(10mM)dNTPs (10mM) 0.4μl0.4μl LA Taq酶(5U/μl)LA Taq enzyme (5U/μl) 0.1μl0.1μl Primers(100ng/μl)Primers(100ng/μl) 0.2μl/个0.2μl/pc gDNA模板(50ng/μl)gDNA template (50ng/μl) 1.0μl1.0μl ddH2O Add toddH2O Add to 10.0μl10.0μl c)反应条件：c) Reaction conditions: 3)将步骤2中获得的获自3例AT患者、6名家系内正常人和500名家系外正常人PCR扩增产物直接进行DNA测序。3) DNA sequencing was performed directly on the PCR amplification products obtained in step 2 from 3 AT patients, 6 normal persons within the family, and 500 normal persons outside the family. 表1 AT家系中的患者情况Table 1 Patients in the AT family 在患者家族成员中对ATM基因突变位点所在编码序列及侧翼序列进行突变排查，分别发现患者AT家系1-II：1在ATM基因存在一个复合杂合的突变c.5697C>A(p.Cys1899X，无义突变)、exon 65del，其中患者父亲携带杂合突变c.5697C>A，患者母亲携带杂合缺失exon 65del。Mutation screening of the coding sequence and flanking sequence of the ATM gene mutation site was carried out in the family members of the patient, and it was found that there was a compound heterozygous mutation c.5697C>A (p.Cys1899X) in the ATM gene of the patient AT family 1-II:1. , nonsense mutation), exon 65del, in which the patient's father carries the heterozygous mutation c.5697C>A, and the patient's mother carries the heterozygous deletion exon 65del. AT家系2-II：1在ATM基因存在一个复合杂合的突变c.477_481del ATCTC(移码突变)、c.4777-2A>T(剪切位点突变)，其中患者父亲携带杂合缺失c.477_481del ATCTC，患者母亲携带杂合突变c.4777-2A>T。AT family 2-II:1 has a compound heterozygous mutation c.477_481del ATCTC (frameshift mutation), c.4777-2A>T (splice site mutation) in the ATM gene, in which the patient's father carries a heterozygous deletionc .477_481del ATCTC, the mother of the patient carries the heterozygous mutation c.4777-2A>T. AT家系3-II：1在ATM基因存在一个复合杂合的突变c.3078G>T(p.Trp1026Cys，错义突变)、c.7983_7985delTGT，其中患者父亲携带杂合突变c.3078G>T，患者母亲携带杂合缺失c.7983_7985delTGT。(见表2及图3-5)。AT family 3-II:1 has a compound heterozygous mutation c.3078G>T (p.Trp1026Cys, missense mutation), c.7983_7985delTGT in the ATM gene, in which the patient's father carries the heterozygous mutation c.3078G>T, the patient The mother carries the heterozygous deletion c.7983_7985delTGT. (See Table 2 and Figure 3-5). 同时，我们在500个家族外无关正常对照中排查未检测到的突变位点。At the same time, we screened for undetected mutation sites in 500 out-of-familial unrelated normal controls. 表2 AT家系成员的基因突变情况Table 2 Gene mutation of AT family members 本发明的ATM基因中的是否具有c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)突变的至少一种，可判断此家族中未发病的人群患病的可能性，同时可用于家族后代患病几率的评估与诊断，为患者及家庭提供遗传咨询及产前诊断避免携带该突变的下一代出生。Whether the ATM gene of the present invention has at least one mutation of c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC and c.8851_8987del (exon 65del), It can judge the possibility of the disease in the unaffected people in the family, and can also be used for the evaluation and diagnosis of the disease probability of the offspring of the family, providing genetic counseling and prenatal diagnosis for patients and families to avoid the birth of the next generation carrying the mutation. 研究证实ATM基因突变可以引起共济失调毛细血管扩张症。我们的研究表明：ATM基因中的c.5697C>A、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT、c.477_481delATCTC和c.8851_8987del(exon 65del)突变是引起常染色体隐性遗传性AT疾病的突变。Studies have confirmed that ATM gene mutations can cause ataxia telangiectasia. Our study showed that c.5697C>A, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT, c.477_481delATCTC, and c.8851_8987del(exon 65del) mutations in the ATM gene are autosomal recessive Mutations in sexually inherited AT disease. 本发明公开了六种已知耳聋基因(ATM)的新突变，证实了其为常染色体隐性遗传性的分子病因，在500例中国正常人群中进行该位点的筛查，均为阴性。本研究丰富了ATM基因突变谱，为开展遗传性AT疾病的分子诊断提供了基因学依据。The invention discloses new mutations of six known deafness genes (ATM), which are confirmed to be the molecular etiology of autosomal recessive inheritance. The screening of this locus in 500 Chinese normal people is negative. This study enriched the ATM gene mutation spectrum and provided a genetic basis for molecular diagnosis of hereditary AT diseases. 实施例3检测试剂盒Example 3 Detection Kit 制备检测试剂盒，其中含有检测突变的c.5679C>A、c.477_481delATCTC、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT的引物对见下表：A detection kit was prepared, which contained the primer pairs for detecting mutations c.5679C>A, c.477_481delATCTC, c.4777-2A>T, c.3078G>T, and c.7983_7985delTGT: 按照实施例1所述的方法提取待测者DNA，以所提取的DNA为模板与上述引物进行PCR反应，按照本领域常规方法对PCR产物纯化，将纯化的产物测序。观察测序所得到的序列是否有c.5679C>A、c.477_481delATCTC、c.4777-2A>T、c.3078G>T、c.7983_7985delTGT突变。The DNA of the test subject was extracted according to the method described in Example 1, and the extracted DNA was used as a template to carry out a PCR reaction with the above primers, and the PCR product was purified according to conventional methods in the art, and the purified product was sequenced. Observe whether the sequence obtained by sequencing has c.5679C>A, c.477_481delATCTC, c.4777-2A>T, c.3078G>T, c.7983_7985delTGT mutations. 实施例4Example 4 分别对AT家系1内1个患者样本和1个患者的母亲(非患者)样本进行QPCR。具体方法步骤如下：QPCR was performed on one patient sample and one patient's mother (non-patient) sample within AT family 1, respectively. The specific method steps are as follows: 1、DNA提取：1. DNA extraction: 采集患者和其母亲的外周静脉血用QIAamp DNA BloodMiNi Kit(Qiagen,Hilden,Germany)方法提取基因组DNA。Genomic DNA was extracted from peripheral venous blood of patients and their mothers using the QIAamp DNA BloodMiNi Kit (Qiagen, Hilden, Germany) method. 2、引物设计及PCR反应2. Primer design and PCR reaction 1)QPCR引物：1) QPCR primers: 2)QPCR实验仪器及条件：ABI 7500荧光定量PCR仪2) QPCR experimental equipment and conditions: ABI 7500 fluorescence quantitative PCR instrument 3)实验用量及试剂：模板为1ul每个做三个平行样。3) Experiment dosage and reagents: The template is 1 ul for each of three parallel samples. 3、最低循环数值(Ct)比较法计算ATM基因的65号外显子的相对拷贝数应用v vCt法，与内对照ALB基因比较可以得出ATM基因的65号外显子的相对拷贝数(图6)。3. The lowest cycle value (Ct) comparison method was used to calculate the relative copy number of exon 65 of the ATM gene. The v vCt method was used to compare the relative copy number of exon 65 of the ATM gene with the internal control ALB gene (Figure 6). ). 在患者家族成员中对ATM基因突变位点所在编码序列及侧翼序列进行突变排查，分别发现患者AT家系1-II：1在ATM基因存在exon 65del，其中患者父亲无该突变，患者母亲携带杂合缺失exon 65del。Mutation screening of the coding sequence and flanking sequence of the ATM gene mutation site in the patient's family members showed that the patient's AT family 1-II:1 had exon 65del in the ATM gene, the patient's father did not have this mutation, and the patient's mother carried heterozygous Deletion of exon 65del. 实施例5Example 5 c.4777-2A>T的验证Verification of c.4777-2A>T 分别对AT家系2内1个患者样本和2个非患者样本进行PCR。具体方法步骤如下：PCR was performed on 1 patient sample and 2 non-patient samples in AT family 2, respectively. The specific method steps are as follows: 1、RNA提取以CDNA制备：采集患者和其父母亲的外周静脉血，使用QIAGEN公司生产的RNA提取试剂盒提取总RNA，并反转录为cDNA。1. RNA extraction Prepared by cDNA: collect peripheral venous blood of patients and their parents, extract total RNA using RNA extraction kit produced by QIAGEN Company, and reverse transcribed into cDNA. 2、引物设计及PCR反应2. Primer design and PCR reaction a)AT家系2剪切位点变异位点验证引物a) AT family 2 cleavage site variant site verification primers b)反应体系：10μLb) Reaction system: 10 μL 试剂reagent 体积volume 2×GC BufferⅠ2×GC BufferⅠ 5.0μl5.0μl dNTPs(10mM)dNTPs (10mM) 0.4μl0.4μl LA Taq酶(5U/μl)LA Taq enzyme (5U/μl) 0.1μl0.1μl Primers(100ng/μl)Primers(100ng/μl) 0.2μl/个0.2μl/pc gDNA模板(50ng/μl)gDNA template (50ng/μl) 1.0μl1.0μl ddH2O Add toddH2O Add to 10.0μl10.0μl c)反应条件：c) Reaction conditions: 3、将步骤1所得的cDNA进行PCR扩增然后直接进行DNA测序，发现患者及母亲的cDNA序列发生了杂合的改变，患者父亲未有改变(图7)，由此认为该突变会造成cDNA序列的改变从而影响氨基酸的改变。3. The cDNA obtained in step 1 was amplified by PCR and then directly sequenced by DNA. It was found that the cDNA sequences of the patient and mother had a heterozygous change, and the father of the patient had not changed (Fig. 7). Therefore, it is believed that this mutation will cause the cDNA sequence. Sequence changes thus affect amino acid changes. 在本说明书的描述中，参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不一定指的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。In the description of this specification, description with reference to the terms 'one embodiment,' 'some embodiments,' 'example,' 'specific example,' or 'some examples', etc., mean specific features described in connection with the embodiment or example , structure, material or feature is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. 尽管上面已经示出和描述了本发明的实施例，可以理解的是，上述实施例是示例性的，不能理解为对本发明的限制，本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。Although the embodiments of the present invention have been shown and described above, it should be understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and those of ordinary skill in the art will not depart from the principles and spirit of the present invention Variations, modifications, substitutions, and alterations to the above-described embodiments are possible within the scope of the present invention without departing from the scope of the present invention. SEQUENCE LISTINGSEQUENCE LISTING <110> 中南大学湘雅医院<110> Central South University Xiangya Hospital 深圳华大基因科技有限公司Shenzhen Huada Gene Technology Co., Ltd. <120> ATM基因突变体及其应用<120> ATM gene mutant and its application <130> PIDC131299-1<130> PIDC131299-1 <160> 22<160> 22 <170> PatentIn version 3.3<170> PatentIn version 3.3 <210> 1<210> 1 <211> 9171<211> 9171 <212> DNA<212> DNA <213> Homo sapiens<213> Homo sapiens <400> 1<400> 1 atgagtctag tacttaatga tctgcttatc tgctgccgtc aactagaaca tgatagagct 60atgagtctag tacttaatga tctgcttatc tgctgccgtc aactagaaca tgatagagct 60 acagaacgaa agaaagaagt tgagaaattt aagcgcctga ttcgagatcc tgaaacaatt 120acagaacgaa agaaagaagt tgagaaattt aagcgcctga ttcgagatcc tgaaacaatt 120 aaacatctag atcggcattc agattccaaa caaggaaaat atttgaattg ggatgctgtt 180aaacatctag atcggcattc agattccaaa caaggaaaat atttgaattg ggatgctgtt 180 tttagatttt tacagaaata tattcagaaa gaaacagaat gtctgagaat agcaaaacca 240tttagatttt tacagaaata tattcagaaa gaaacagaat gtctgagaat agcaaaacca 240 aatgtatcag cctcaacaca agcctccagg cagaaaaaga tgcaggaaat cagtagtttg 300aatgtatcag cctcaacaca agcctccagg cagaaaaaga tgcaggaaat cagtagtttg 300 gtcaaatact tcatcaaatg tgcaaacaga agagcaccta ggctaaaatg tcaagaactc 360gtcaaatact tcatcaaatg tgcaaacaga agagcaccta ggctaaaatg tcaagaactc 360 ttaaattata tcatggatac agtgaaagat tcatctaatg gtgctattta cggagctgat 420ttaaattata tcatggatac agtgaaagat tcatctaatg gtgctattta cggagctgat 420 tgtagcaaca tactactcaa agacattctt tctgtgagaa aatactggtg tgaaatatct 480tgtagcaaca tactactcaa agacattctt tctgtgagaa aatactggtg tgaaatatct 480 cagcaacagt ggttagaatt gttctctgtg tacttcaggc tctatctgaa accttcacaa 540cagcaacagt ggttagaatt gttctctgtg tacttcaggc tctatctgaa accttcacaa 540 gatgttcata gagttttagt ggctagaata attcatgctg ttaccaaagg atgctgttct 600gatgttcata gagttttagt ggctagaata attcatgctg ttaccaaagg atgctgttct 600 cagactgacg gattaaattc caaatttttg gacttttttt ccaaggctat tcagtgtgcg 660cagactgacg gattaaattc caaatttttg gacttttttt ccaaggctat tcagtgtgcg 660 agacaagaaa agagctcttc aggtctaaat catatcttag cagctcttac tatcttcctc 720agacaagaaa agagctcttc aggtctaaat catatcttag cagctcttac tatcttcctc 720 aagactttgg ctgtcaactt tcgaattcga gtgtgtgaat taggagatga aattcttccc 780aagactttgg ctgtcaactt tcgaattcga gtgtgtgaat taggagatga aattcttccc 780 actttgcttt atatttggac tcaacatagg cttaatgatt ctttaaaaga agtcattatt 840actttgcttt atatttggac tcaacatagg cttaatgatt ctttaaaaga agtcattatt 840 gaattatttc aactgcaaat ttatatccat catccgaaag gagccaaaac ccaagaaaaa 900gaattatttc aactgcaaat ttatatccat catccgaaag gagccaaaac ccaagaaaaa 900 ggtgcttatg aatcaacaaa atggagaagt attttataca acttatatga tctgctagtg 960ggtgcttatg aatcaacaaa atggagaagt attttataca acttatatga tctgctagtg 960 aatgagataa gtcatatagg aagtagagga aagtattctt caggatttcg taatattgcc 1020aatgagataa gtcatatagg aagtagagga aagtattctt caggatttcg taatattgcc 1020 gtcaaagaaa atttgattga attgatggca gatatctgtc accaggtttt taatgaagat 1080gtcaaagaaa atttgattga attgatggca gatatctgtc accaggtttt taatgaagat 1080 accagatcct tggagatttc tcaatcttac actactacac aaagagaatc tagtgattac 1140accagatcct tggagatttc tcaatcttac actactacac aaagagaatc tagtgattac 1140 agtgtccctt gcaaaaggaa gaaaatagaa ctaggctggg aagtaataaa agatcacctt 1200agtgtccctt gcaaaaggaa gaaaatagaa ctaggctggg aagtaataaa agatcacctt 1200 cagaagtcac agaatgattt tgatcttgtg ccttggctac agattgcaac ccaattaata 1260cagaagtcac agaatgattt tgatcttgtg ccttggctac agattgcaac ccaattaata 1260 tcaaagtatc ctgcaagttt acctaactgt gagctgtctc cattactgat gatactatct 1320tcaaagtatc ctgcaagttt acctaactgt gagctgtctc cattactgat gatactatct 1320 cagcttctac cccaacagcg acatggggaa cgtacaccat atgtgttacg atgccttacg 1380cagcttctac cccaacagcg acatggggaa cgtacaccat atgtgttacg atgccttacg 1380 gaagttgcat tgtgtcaaga caagaggtca aacctagaaa gctcacaaaa gtcagattta 1440gaagttgcat tgtgtcaaga caagaggtca aacctagaaa gctcacaaaa gtcagattta 1440 ttaaaactct ggaataaaat ttggtgtatt acctttcgtg gtataagttc tgagcaaata 1500ttaaaactct ggaataaaat ttggtgtatt acctttcgtg gtataagttc tgagcaaata 1500 caagctgaaa actttggctt acttggagcc ataattcagg gtagtttagt tgaggttgac 1560caagctgaaa actttggctt acttggagcc ataattcagg gtagtttagt tgaggttgac 1560 agagaattct ggaagttatt tactgggtca gcctgcagac cttcatgtcc tgcagtatgc 1620agagaattct ggaagttatt tactgggtca gcctgcagac cttcatgtcc tgcagtatgc 1620 tgtttgactt tggcactgac caccagtata gttccaggaa cggtaaaaat gggaatagag 1680tgtttgactt tggcactgac caccagtata gttccaggaa cggtaaaaat gggaatagag 1680 caaaatatgt gtgaagtaaa tagaagcttt tctttaaagg aatcaataat gaaatggctc 1740caaaatatgt gtgaagtaaa tagaagcttt tctttaaagg aatcaataat gaaatggctc 1740 ttattctatc agttagaggg tgacttagaa aatagcacag aagtgcctcc aattcttcac 1800ttattctatc agttagaggg tgacttagaa aatagcacag aagtgcctcc aattcttcac 1800 agtaattttc ctcatcttgt actggagaaa attcttgtga gtctcactat gaaaaactgt 1860agtaattttc ctcatcttgt actggagaaa attcttgtga gtctcactat gaaaaactgt 1860 aaagctgcaa tgaatttttt ccaaagcgtg ccagaatgtg aacaccacca aaaagataaa 1920aaagctgcaa tgaatttttt ccaaagcgtg ccagaatgtg aacaccacca aaaagataaa 1920 gaagaacttt cattctcaga agtagaagaa ctatttcttc agacaacttt tgacaagatg 1980gaagaacttt cattctcaga agtagaagaa ctatttcttc agacaacttt tgacaagatg 1980 gactttttaa ccattgtgag agaatgtggt atagaaaagc accagtccag tattggcttc 2040gactttttaa ccattgtgag agaatgtggt atagaaaagc accagtccag tattggcttc 2040 tctgtccacc agaatctcaa ggaatcactg gatcgctgtc ttctgggatt atcagaacag 2100tctgtccacc agaatctcaa ggaatcactg gatcgctgtc ttctgggatt atcagaacag 2100 cttctgaata attactcatc tgagattaca aattcagaaa ctcttgtccg gtgttcacgt 2160cttctgaata attactcatc tgagattaca aattcagaaa ctcttgtccg gtgttcacgt 2160 cttttggtgg gtgtccttgg ctgctactgt tacatgggtg taatagctga agaggaagca 2220cttttggtgg gtgtccttgg ctgctactgt tacatgggtg taatagctga agaggaagca 2220 tataagtcag aattattcca gaaagccaag tctctaatgc aatgtgcagg agaaagtatc 2280tataagtcag aattattcca gaaagccaag tctctaatgc aatgtgcagg agaaagtatc 2280 actctgttta aaaataagac aaatgaggaa ttcagaattg gttccttgag aaatatgatg 2340actctgttta aaaataagac aaatgaggaa ttcagaattg gttccttgag aaatatgatg 2340 cagctatgta cacgttgctt gagcaactgt accaagaaga gtccaaataa gattgcatct 2400cagctatgta cacgttgctt gagcaactgt accaagaaga gtccaaataa gattgcatct 2400 ggctttttcc tgcgattgtt aacatcaaag ctaatgaatg acattgcaga tatttgtaaa 2460ggctttttcc tgcgattgtt aacatcaaag ctaatgaatg acattgcaga tatttgtaaa 2460 agtttagcat ccttcatcaa aaagccattt gaccgtggag aagtagaatc aatggaagat 2520agtttagcat ccttcatcaa aaagccattt gaccgtggag aagtagaatc aatggaagat 2520 gatactaatg gaaatctaat ggaggtggag gatcagtcat ccatgaatct atttaacgat 2580gatactaatg gaaatctaat ggaggtggag gatcagtcat ccatgaatct atttaacgat 2580 taccctgata gtagtgttag tgatgcaaac gaacctggag agagccaaag taccataggt 2640taccctgata gtagtgttag tgatgcaaac gaacctggag agagccaaag taccataggt 2640 gccattaatc ctttagctga agaatatctg tcaaagcaag atctactttt cttagacatg 2700gccattaatc ctttagctga agaatatctg tcaaagcaag atctactttt cttagacatg 2700 ctcaagttct tgtgtttgtg tgtaactact gctcagacca atactgtgtc ctttagggca 2760ctcaagttct tgtgtttgtg tgtaactact gctcagacca atactgtgtc ctttagggca 2760 gctgatattc ggaggaaatt gttaatgtta attgattcta gcacgctaga acctaccaaa 2820gctgatattc ggaggaaatt gttaatgtta attgattcta gcacgctaga acctaccaaa 2820 tccctccacc tgcatatgta tctaatgctt ttaaaggagc ttcctggaga agagtacccc 2880tccctccacc tgcatatgta tctaatgctt ttaaaggagc ttcctggaga agagtacccc 2880 ttgccaatgg aagatgttct tgaacttctg aaaccactat ccaatgtgtg ttctttgtat 2940ttgccaatgg aagatgttct tgaacttctg aaaccactat ccaatgtgtg ttctttgtat 2940 cgtcgtgacc aagatgtttg taaaactatt ttaaaccatg tccttcatgt agtgaaaaac 3000cgtcgtgacc aagatgtttg taaaactatt ttaaaccatg tccttcatgt agtgaaaaac 3000 ctaggtcaaa gcaatatgga ctctgagaac acaagggatg ctcaaggaca gtttcttaca 3060ctaggtcaaa gcaatatgga ctctgagaac acaagggatg ctcaaggaca gtttcttaca 3060 gtaattggag cattttggca tctaacaaag gagaggaaat atatattctc tgtaagaatg 3120gtaattggag cattttggca tctaacaaag gagaggaaat atatattctc tgtaagaatg 3120 gccctagtaa attgccttaa aactttgctt gaggctgatc cttattcaaa atgggccatt 3180gccctagtaa attgccttaa aactttgctt gaggctgatc cttattcaaa atgggccatt 3180 cttaatgtaa tgggaaaaga ctttcctgta aatgaagtat ttacacaatt tcttgctgac 3240cttaatgtaa tgggaaaaga ctttcctgta aatgaagtat ttacacaatt tcttgctgac 3240 aatcatcacc aagttcgcat gttggctgca gagtcaatca atagattgtt ccaggacacg 3300aatcatcacc aagttcgcat gttggctgca gagtcaatca atagattgtt ccaggacacg 3300 aagggagatt cttccaggtt actgaaagca cttcctttga agcttcagca aacagctttt 3360aagggagatt cttccaggtt actgaaagca cttcctttga agcttcagca aacagctttt 3360 gaaaatgcat acttgaaagc tcaggaagga atgagagaaa tgtcccatag tgctgagaac 3420gaaaatgcat acttgaaagc tcaggaagga atgagagaaa tgtcccatag tgctgagaac 3420 cctgaaactt tggatgaaat ttataataga aaatctgttt tactgacgtt gatagctgtg 3480cctgaaactt tggatgaaat ttataataga aaatctgttt tactgacgtt gatagctgtg 3480 gttttatcct gtagccctat ctgcgaaaaa caggctttgt ttgccctgtg taaatctgtg 3540gttttatcct gtagccctat ctgcgaaaaa caggctttgt ttgccctgtg taaatctgtg 3540 aaagagaatg gattagaacc tcaccttgtg aaaaaggttt tagagaaagt ttctgaaact 3600aaagagaatg gattagaacc tcaccttgtg aaaaaggttt tagagaaagt ttctgaaact 3600 tttggatata gacgtttaga agactttatg gcatctcatt tagattatct ggttttggaa 3660tttggatata gacgtttaga agactttatg gcatctcatt tagattatct ggttttggaa 3660 tggctaaatc ttcaagatac tgaatacaac ttatcttctt ttccttttat tttattaaac 3720tggctaaatc ttcaagatac tgaatacaac ttatcttctt ttccttttat tttattaaac 3720 tacacaaata ttgaggattt ctatagatct tgttataagg ttttgattcc acatctggtg 3780tacacaaata ttgaggattt ctatagatct tgttataagg ttttgattcc acatctggtg 3780 attagaagtc attttgatga ggtgaagtcc attgctaatc agattcaaga ggactggaaa 3840attagaagtc attttgatga ggtgaagtcc attgctaatc agattcaaga ggactggaaa 3840 agtcttctaa cagactgctt tccaaagatt cttgtaaata ttcttcctta ttttgcctat 3900agtcttctaa cagactgctt tccaaagatt cttgtaaata ttcttcctta ttttgcctat 3900 gagggtacca gagacagtgg gatggcacag caaagagaga ctgctaccaa ggtctatgat 3960gagggtacca gagacagtgg gatggcacag caaagagaga ctgctaccaa ggtctatgat 3960 atgcttaaaa gtgaaaactt attgggaaaa cagattgatc acttattcat tagtaattta 4020atgcttaaaa gtgaaaactt attgggaaaa cagattgatc acttattcat tagtaattta 4020 ccagagattg tggtggagtt attgatgacg ttacatgagc cagcaaattc tagtgccagt 4080ccagagattg tggtggagtt attgatgacg ttacatgagc cagcaaattc tagtgccagt 4080 cagagcactg acctctgtga cttttcaggg gatttggatc ctgctcctaa tccacctcat 4140cagagcactg acctctgtga cttttcaggg gatttggatc ctgctcctaa tccacctcat 4140 tttccatcgc atgtgattaa agcaacattt gcctatatca gcaattgtca taaaaccaag 4200tttccatcgc atgtgattaa agcaacattt gcctatatca gcaattgtca taaaaccaag 4200 ttaaaaagca ttttagaaat tctttccaaa agccctgatt cctatcagaa aattcttctt 4260ttaaaaagca ttttagaaat tctttccaaa agccctgatt cctatcagaa aattcttctt 4260 gccatatgtg agcaagcagc tgaaacaaat aatgtttata agaagcacag aattcttaaa 4320gccatatgtg agcaagcagc tgaaacaaat aatgtttata agaagcacag aattcttaaa 4320 atatatcacc tgtttgttag tttattactg aaagatataa aaagtggctt aggaggagct 4380atatatcacc tgtttgttag tttattactg aaagatataa aaagtggctt aggaggagct 4380 tgggcctttg ttcttcgaga cgttatttat actttgattc actatatcaa ccaaaggcct 4440tgggcctttg ttcttcgaga cgttatttat actttgattc actatatcaa ccaaaggcct 4440 tcttgtatca tggatgtgtc attacgtagc ttctcccttt gttgtgactt attaagtcag 4500tcttgtatca tggatgtgtc attacgtagc ttctcccttt gttgtgactt attaagtcag 4500 gtttgccaga cagccgtgac ttactgtaag gatgctctag aaaaccatct tcatgttatt 4560gtttgccaga cagccgtgac ttactgtaag gatgctctag aaaaccatct tcatgttatt 4560 gttggtacac ttatacccct tgtgtatgag caggtggagg ttcagaaaca ggtattggac 4620gttggtacac ttatacccct tgtgtatgag caggtggagg ttcagaaaca ggtattggac 4620 ttgttgaaat acttagtgat agataacaag gataatgaaa acctctatat cacgattaag 4680ttgttgaaat acttagtgat agataacaag gataatgaaa acctctatat cacgattaag 4680 cttttagatc cttttcctga ccatgttgtt tttaaggatt tgcgtattac tcagcaaaaa 4740cttttagatc cttttcctga ccatgttgtt tttaaggatt tgcgtattac tcagcaaaaa 4740 atcaaataca gtagaggacc cttttcactc ttggaggaaa ttaaccattt tctctcagta 4800atcaaataca gtagaggacc cttttcactc ttggaggaaa ttaaccattt tctctcagta 4800 agtgtttatg atgcacttcc attgacaaga cttgaaggac taaaggatct tcgaagacaa 4860agtgtttatg atgcacttcc attgacaaga cttgaaggac taaaggatct tcgaagacaa 4860 ctggaactac ataaagatca gatggtggac attatgagag cttctcagga taatccgcaa 4920ctggaactac ataaagatca gatggtggac attatgagag cttctcagga taatccgcaa 4920 gatgggatta tggtgaaact agttgtcaat ttgttgcagt tatccaagat ggcaataaac 4980gatgggatta tggtgaaact agttgtcaat ttgttgcagt tatccaagat ggcaataaac 4980 cacactggtg aaaaagaagt tctagaggct gttggaagct gcttgggaga agtgggtcct 5040cacactggtg aaaaagaagt tctagaggct gttggaagct gcttgggaga agtgggtcct 5040 atagatttct ctaccatagc tatacaacat agtaaagatg catcttatac caaggccctt 5100atagatttct ctaccatagc tatacaacat agtaaagatg catcttatac caaggccctt 5100 aagttatttg aagataaaga acttcagtgg accttcataa tgctgaccta cctgaataac 5160aagttatttg aagataaaga acttcagtgg accttcataa tgctgaccta cctgaataac 5160 acactggtag aagattgtgt caaagttcga tcagcagctg ttacctgttt gaaaaacatt 5220acactggtag aagattgtgt caaagttcga tcagcagctg ttacctgttt gaaaaacatt 5220 ttagccacaa agactggaca tagtttctgg gagatttata agatgacaac agatccaatg 5280ttagccacaa agactggaca tagtttctgg gagatttata agatgacaac agatccaatg 5280 ctggcctatc tacagccttt tagaacatca agaaaaaagt ttttagaagt acccagattt 5340ctggcctatc tacagccttt tagaacatca agaaaaaagt ttttagaagt acccagattt 5340 gacaaagaaa acccttttga aggcctggat gatataaatc tgtggattcc tctaagtgaa 5400gacaaagaaa acccttttga aggcctggat gatataaatc tgtggattcc tctaagtgaa 5400 aatcatgaca tttggataaa gacactgact tgtgcttttt tggacagtgg aggcacaaaa 5460aatcatgaca tttggataaa gacactgact tgtgcttttt tggacagtgg aggcacaaaa 5460 tgtgaaattc ttcaattatt aaagccaatg tgtgaagtga aaactgactt ttgtcagact 5520tgtgaaattc ttcaattatt aaagccaatg tgtgaagtga aaactgactt ttgtcagact 5520 gtacttccat acttgattca tgatatttta ctccaagata caaatgaatc atggagaaat 5580gtacttccat acttgattca tgatatttta ctccaagata caaatgaatc atggagaaat 5580 ctgctttcta cacatgttca gggatttttc accagctgtc ttcgacactt ctcgcaaacg 5640ctgctttcta cacatgttca gggatttttc accagctgtc ttcgacactt ctcgcaaacg 5640 agccgatcca caacccctgc aaacttggat tcagagtcag agcacttttt ccgatgctgt 5700agccgatcca caacccctgc aaacttggat tcagagtcag agcacttttt ccgatgctgt 5700 ttggataaaa aatcacaaag aacaatgctt gctgttgtgg actacatgag aagacaaaag 5760ttggataaaa aatcacaaag aacaatgctt gctgttgtgg actacatgag aagacaaaag 5760 agaccttctt caggaacaat ttttaatgat gctttctggc tggatttaaa ttatctagaa 5820agaccttctt caggaacaat ttttaatgat gctttctggc tggatttaaa ttatctagaa 5820 gttgccaagg tagctcagtc ttgtgctgct cactttacag ctttactcta tgcagaaatc 5880gttgccaagg tagctcagtc ttgtgctgct cactttacag ctttactcta tgcagaaatc 5880 tatgcagata agaaaagtat ggatgatcaa gagaaaagaa gtcttgcatt tgaagaagga 5940tatgcagata agaaaagtat ggatgatcaa gagaaaagaa gtcttgcatt tgaagaagga 5940 agccagaata caactatttc tagcttgagt gaaaaaagta aagaagaaac tggaataagt 6000agccagaata caactatttc tagcttgagt gaaaaaagta aagaagaaac tggaataagt 6000 ttacaggatc ttctcttaga aatctacaga agtatagggg agccagatag tttgtatggc 6060ttacaggatc ttctcttaga aatctacaga agtatagggg agccagatag tttgtatggc 6060 tgtggtggag ggaagatgtt acaacccatt actagactac gaacatatga acacgaagca 6120tgtggtggag ggaagatgtt acaacccatt actagactac gaacatatga acacgaagca 6120 atgtggggca aagccctagt aacatatgac ctcgaaacag caatcccctc atcaacacgc 6180atgtggggca aagccctagt aacatatgac ctcgaaacag caatcccctc atcaacacgc 6180 caggcaggaa tcattcaggc cttgcagaat ttgggactct gccatattct ttccgtctat 6240caggcaggaa tcattcaggc cttgcagaat ttgggactct gccatattct ttccgtctat 6240 ttaaaaggat tggattatga aaataaagac tggtgtcctg aactagaaga acttcattac 6300ttaaaaggat tggattatga aaataaagac tggtgtcctg aactagaaga acttcattac 6300 caagcagcat ggaggaatat gcagtgggac cattgcactt ccgtcagcaa agaagtagaa 6360caagcagcat ggaggaatat gcagtgggac cattgcactt ccgtcagcaa agaagtagaa 6360 ggaaccagtt accatgaatc attgtacaat gctctacaat ctctaagaga cagagaattc 6420ggaaccagtt accatgaatc attgtacaat gctctacaat ctctaagaga cagagaattc 6420 tctacatttt atgaaagtct caaatatgcc agagtaaaag aagtggaaga gatgtgtaag 6480tctacatttt atgaaagtct caaatatgcc agagtaaaag aagtggaaga gatgtgtaag 6480 cgcagccttg agtctgtgta ttcgctctat cccacactta gcaggttgca ggccattgga 6540cgcagccttg agtctgtgta ttcgctctat cccacactta gcaggttgca ggccattgga 6540 gagctggaaa gcattgggga gcttttctca agatcagtca cacatagaca actctctgaa 6600gagctggaaa gcattgggga gcttttctca agatcagtca cacatagaca actctctgaa 6600 gtatatatta agtggcagaa acactcccag cttctcaagg acagtgattt tagttttcag 6660gtatatatta agtggcagaa acactcccag cttctcaagg acagtgattt tagttttcag 6660 gagcctatca tggctctacg cacagtcatt ttggagatcc tgatggaaaa ggaaatggac 6720gagcctatca tggctctacg cacagtcatt ttggagatcc tgatggaaaa ggaaatggac 6720 aactcacaaa gagaatgtat taaggacatt ctcaccaaac accttgtaga actctctata 6780aactcacaaa gagaatgtat taaggacatt ctcaccaaac accttgtaga actctctata 6780 ctggccagaa ctttcaagaa cactcagctc cctgaaaggg caatatttca aattaaacag 6840ctggccagaa ctttcaagaa cactcagctc cctgaaaggg caatatttca aattaaacag 6840 tacaattcag ttagctgtgg agtctctgag tggcagctgg aagaagcaca agtattctgg 6900tacaattcag ttagctgtgg agtctctgag tggcagctgg aagaagcaca agtattctgg 6900 gcaaaaaagg agcagagtct tgccctgagt attctcaagc aaatgatcaa gaagttggat 6960gcaaaaaagg agcagagtct tgccctgagt attctcaagc aaatgatcaa gaagttggat 6960 gccagctgtg cagcgaacaa tcccagccta aaacttacat acacagaatg tctgagggtt 7020gccagctgtg cagcgaacaa tcccagccta aaacttacat acacagaatg tctgagggtt 7020 tgtggcaact ggttagcaga aacgtgctta gaaaatcctg cggtcatcat gcagacctat 7080tgtggcaact ggttagcaga aacgtgctta gaaaatcctg cggtcatcat gcagacctat 7080 ctagaaaagg cagtagaagt tgctggaaat tatgatggag aaagtagtga tgagctaaga 7140ctagaaaagg cagtagaagt tgctggaaat tatgatggag aaagtagtga tgagctaaga 7140 aatggaaaaa tgaaggcatt tctctcatta gcccggtttt cagatactca ataccaaaga 7200aatggaaaaa tgaaggcatt tctctcatta gcccggtttt cagatactca ataccaaaga 7200 attgaaaact acatgaaatc atcggaattt gaaaacaagc aagctctcct gaaaagagcc 7260attgaaaact acatgaaatc atcggaattt gaaaacaagc aagctctcct gaaaagagcc 7260 aaagaggaag taggtctcct tagggaacat aaaattcaga caaacagata cacagtaaag 7320aaagaggaag taggtctcct tagggaacat aaaattcaga caaacagata cacagtaaag 7320 gttcagcgag agctggagtt ggatgaatta gccctgcgtg cactgaaaga ggatcgtaaa 7380gttcagcgag agctggagtt ggatgaatta gccctgcgtg cactgaaaga ggatcgtaaa 7380 cgcttcttat gtaaagcagt tgaaaattat atcaactgct tattaagtgg agaagaacat 7440cgcttcttat gtaaagcagt tgaaaattat atcaactgct tattaagtgg agaagaacat 7440 gatatgtggg tattccgact ttgttccctc tggcttgaaa attctggagt ttctgaagtc 7500gatatgtggg tattccgact ttgttccctc tggcttgaaa attctggagt ttctgaagtc 7500 aatggcatga tgaagagaga cggaatgaag attccaacat ataaattttt gcctcttatg 7560aatggcatga tgaagagaga cggaatgaag attccaacat ataaattttt gcctcttatg 7560 taccaattgg ctgctagaat ggggaccaag atgatgggag gcctaggatt tcatgaagtc 7620taccaattgg ctgctagaat ggggaccaag atgatgggag gcctaggatt tcatgaagtc 7620 ctcaataatc taatctctag aatttcaatg gatcaccccc atcacacttt gtttattata 7680ctcaataatc taatctctag aatttcaatg gatcaccccc atcacacttt gtttattata 7680 ctggccttag caaatgcaaa cagagatgaa tttctgacta aaccagaggt agccagaaga 7740ctggccttag caaatgcaaa cagagatgaa tttctgacta aaccagaggt agccagaaga 7740 agcagaataa ctaaaaatgt gcctaaacaa agctctcagc ttgatgagga tcgaacagag 7800agcagaataa ctaaaaatgt gcctaaacaa agctctcagc ttgatgagga tcgaacagag 7800 gctgcaaata gaataatatg tactatcaga agtaggagac ctcagatggt cagaagtgtt 7860gctgcaaata gaataatatg tactatcaga agtaggagac ctcagatggt cagaagtgtt 7860 gaggcacttt gtgatgctta tattatatta gcaaacttag atgccactca gtggaagact 7920gaggcacttt gtgatgctta tattatatta gcaaacttag atgccactca gtggaagact 7920 cagagaaaag gcataaatat tccagcagac cagccaatta ctaaacttaa gaatttagaa 7980cagagaaaag gcataaatat tccagcagac cagccaatta ctaaacttaa gaatttagaa 7980 gatgttgttg tccctactat ggaaattaag gtggaccaca caggagaata tggaaatctg 8040gatgttgttg tccctactat ggaaattaag gtggaccaca caggagaata tggaaatctg 8040 gtgactatac agtcatttaa agcagaattt cgcttagcag gaggtgtaaa tttaccaaaa 8100gtgactatac agtcatttaa agcagaattt cgcttagcag gaggtgtaaa tttaccaaaa 8100 ataatagatt gtgtaggttc cgatggcaag gagaggagac agcttgttaa gggccgtgat 8160ataatagatt gtgtaggttc cgatggcaag gagaggagac agcttgttaa gggccgtgat 8160 gacctgagac aagatgctgt catgcaacag gtcttccaga tgtgtaatac attactgcag 8220gacctgagac aagatgctgt catgcaacag gtcttccaga tgtgtaatac attactgcag 8220 agaaacacgg aaactaggaa gaggaaatta actatctgta cttataaggt ggttcccctc 8280agaaacacgg aaactaggaa gaggaaatta actatctgta cttataaggt ggttcccctc 8280 tctcagcgaa gtggtgttct tgaatggtgc acaggaactg tccccattgg tgaatttctt 8340tctcagcgaa gtggtgttct tgaatggtgc acaggaactg tccccattgg tgaatttctt 8340 gttaacaatg aagatggtgc tcataaaaga tacaggccaa atgatttcag tgcctttcag 8400gttaacaatg aagatggtgc tcataaaaga tacaggccaa atgatttcag tgcctttcag 8400 tgccaaaaga aaatgatgga ggtgcaaaaa aagtcttttg aagagaaata tgaagtcttc 8460tgccaaaaga aaatgatgga ggtgcaaaaa aagtcttttg aagagaaata tgaagtcttc 8460 atggatgttt gccaaaattt tcaaccagtt ttccgttact tctgcatgga aaaattcttg 8520atggatgttt gccaaaattt tcaaccagtt ttccgttact tctgcatgga aaaattcttg 8520 gatccagcta tttggtttga gaagcgattg gcttatacgc gcagtgtagc tacttcttct 8580gatccagcta tttggtttga gaagcgattg gcttatacgc gcagtgtagc tacttcttct 8580 attgttggtt acatacttgg acttggtgat agacatgtac agaatatctt gataaatgag 8640attgttggtt acatacttgg acttggtgat agacatgtac agaatatctt gataaatgag 8640 cagtcagcag aacttgtaca tatagatcta ggtgttgctt ttgaacaggg caaaatcctt 8700cagtcagcag aacttgtaca tatagatcta ggtgttgctt ttgaacaggg caaaatcctt 8700 cctactcctg agacagttcc ttttagactc accagagata ttgtggatgg catgggcatt 8760cctactcctg agacagttcc ttttagactc accagagata ttgtggatgg catgggcatt 8760 acgggtgttg aaggtgtctt cagaagatgc tgtgagaaaa ccatggaagt gatgagaaac 8820acgggtgttg aaggtgtctt cagaagatgc tgtgagaaaa ccatggaagt gatgagaaac 8820 tctcaggaaa ctctgttaac cattgtagag gtccttctat atgatccact ctttgactgg 8880tctcaggaaa ctctgttaac cattgtagag gtccttctat atgatccact ctttgactgg 8880 accatgaatc ctttgaaagc tttgtattta cagcagaggc cggaagatga aactgagctt 8940accatgaatc ctttgaaagc tttgtattta cagcagaggc cggaagatga aactgagctt 8940 caccctactc tgaatgcaga tgaccaagaa tgcaaacgaa atctcagtga tattgaccag 9000caccctactc tgaatgcaga tgaccaagaa tgcaaacgaa atctcagtga tattgaccag 9000 agtttcaaca aagtagctga acgtgtctta atgagactac aagagaaact gaaaggagtg 9060agtttcaaca aagtagctga acgtgtctta atgagactac aagagaaact gaaaggagtg 9060 gaagaaggca ctgtgctcag tgttggtgga caagtgaatt tgctcataca gcaggccata 9120gaagaaggca ctgtgctcag tgttggtgga caagtgaatt tgctcataca gcaggccata 9120 gaccccaaaa atctcagccg acttttccca ggatggaaag cttgggtgtg a 9171gaccccaaaa atctcagccg acttttccca ggatggaaag cttgggtgtg a 9171 <210> 2<210> 2 <211> 3056<211> 3056 <212> PRT<212> PRT <213> Homo sapiens<213> Homo sapiens <400> 2<400> 2 Met Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu GluMet Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu Glu 1 5 10 151 5 10 15 His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys ArgHis Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys Arg 20 25 30 20 25 30 Leu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser AspLeu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser Asp 35 40 45 35 40 45 Ser Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe LeuSer Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu 50 55 60 50 55 60 Gln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys ProGln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys Pro 65 70 75 8065 70 75 80 Asn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln GluAsn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln Glu 85 90 95 85 90 95 Ile Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg AlaIle Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg Ala 100 105 110 100 105 110 Pro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr ValPro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr Val 115 120 125 115 120 125 Lys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn IleLys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn Ile 130 135 140 130 135 140 Leu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile SerLeu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile Ser 145 150 155 160145 150 155 160 Gln Gln Gln Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr LeuGln Gln Gln Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr Leu 165 170 175 165 170 175 Lys Pro Ser Gln Asp Val His Arg Val Leu Val Ala Arg Ile Ile HisLys Pro Ser Gln Asp Val His Arg Val Leu Val Ala Arg Ile Ile His 180 185 190 180 185 190 Ala Val Thr Lys Gly Cys Cys Ser Gln Thr Asp Gly Leu Asn Ser LysAla Val Thr Lys Gly Cys Cys Ser Gln Thr Asp Gly Leu Asn Ser Lys 195 200 205 195 200 205 Phe Leu Asp Phe Phe Ser Lys Ala Ile Gln Cys Ala Arg Gln Glu LysPhe Leu Asp Phe Phe Ser Lys Ala Ile Gln Cys Ala Arg Gln Glu Lys 210 215 220 210 215 220 Ser Ser Ser Gly Leu Asn His Ile Leu Ala Ala Leu Thr Ile Phe LeuSer Ser Ser Gly Leu Asn His Ile Leu Ala Ala Leu Thr Ile Phe Leu 225 230 235 240225 230 235 240 Lys Thr Leu Ala Val Asn Phe Arg Ile Arg Val Cys Glu Leu Gly AspLys Thr Leu Ala Val Asn Phe Arg Ile Arg Val Cys Glu Leu Gly Asp 245 250 255 245 250 255 Glu Ile Leu Pro Thr Leu Leu Tyr Ile Trp Thr Gln His Arg Leu AsnGlu Ile Leu Pro Thr Leu Leu Tyr Ile Trp Thr Gln His Arg Leu Asn 260 265 270 260 265 270 Asp Ser Leu Lys Glu Val Ile Ile Glu Leu Phe Gln Leu Gln Ile TyrAsp Ser Leu Lys Glu Val Ile Ile Glu Leu Phe Gln Leu Gln Ile Tyr 275 280 285 275 280 285 Ile His His Pro Lys Gly Ala Lys Thr Gln Glu Lys Gly Ala Tyr GluIle His His Pro Lys Gly Ala Lys Thr Gln Glu Lys Gly Ala Tyr Glu 290 295 300 290 295 300 Ser Thr Lys Trp Arg Ser Ile Leu Tyr Asn Leu Tyr Asp Leu Leu ValSer Thr Lys Trp Arg Ser Ile Leu Tyr Asn Leu Tyr Asp Leu Leu Val 305 310 315 320305 310 315 320 Asn Glu Ile Ser His Ile Gly Ser Arg Gly Lys Tyr Ser Ser Gly PheAsn Glu Ile Ser His Ile Gly Ser Arg Gly Lys Tyr Ser Ser Gly Phe 325 330 335 325 330 335 Arg Asn Ile Ala Val Lys Glu Asn Leu Ile Glu Leu Met Ala Asp IleArg Asn Ile Ala Val Lys Glu Asn Leu Ile Glu Leu Met Ala Asp Ile 340 345 350 340 345 350 Cys His Gln Val Phe Asn Glu Asp Thr Arg Ser Leu Glu Ile Ser GlnCys His Gln Val Phe Asn Glu Asp Thr Arg Ser Leu Glu Ile Ser Gln 355 360 365 355 360 365 Ser Tyr Thr Thr Thr Gln Arg Glu Ser Ser Asp Tyr Ser Val Pro CysSer Tyr Thr Thr Thr Gln Arg Glu Ser Ser Asp Tyr Ser Val Pro Cys 370 375 380 370 375 380 Lys Arg Lys Lys Ile Glu Leu Gly Trp Glu Val Ile Lys Asp His LeuLys Arg Lys Lys Ile Glu Leu Gly Trp Glu Val Ile Lys Asp His Leu 385 390 395 400385 390 395 400 Gln Lys Ser Gln Asn Asp Phe Asp Leu Val Pro Trp Leu Gln Ile AlaGln Lys Ser Gln Asn Asp Phe Asp Leu Val Pro Trp Leu Gln Ile Ala 405 410 415 405 410 415 Thr Gln Leu Ile Ser Lys Tyr Pro Ala Ser Leu Pro Asn Cys Glu LeuThr Gln Leu Ile Ser Lys Tyr Pro Ala Ser Leu Pro Asn Cys Glu Leu 420 425 430 420 425 430 Ser Pro Leu Leu Met Ile Leu Ser Gln Leu Leu Pro Gln Gln Arg HisSer Pro Leu Leu Met Ile Leu Ser Gln Leu Leu Pro Gln Gln Arg His 435 440 445 435 440 445 Gly Glu Arg Thr Pro Tyr Val Leu Arg Cys Leu Thr Glu Val Ala LeuGly Glu Arg Thr Pro Tyr Val Leu Arg Cys Leu Thr Glu Val Ala Leu 450 455 460 450 455 460 Cys Gln Asp Lys Arg Ser Asn Leu Glu Ser Ser Gln Lys Ser Asp LeuCys Gln Asp Lys Arg Ser Asn Leu Glu Ser Ser Gln Lys Ser Asp Leu 465 470 475 480465 470 475 480 Leu Lys Leu Trp Asn Lys Ile Trp Cys Ile Thr Phe Arg Gly Ile SerLeu Lys Leu Trp Asn Lys Ile Trp Cys Ile Thr Phe Arg Gly Ile Ser 485 490 495 485 490 495 Ser Glu Gln Ile Gln Ala Glu Asn Phe Gly Leu Leu Gly Ala Ile IleSer Glu Gln Ile Gln Ala Glu Asn Phe Gly Leu Leu Gly Ala Ile Ile 500 505 510 500 505 510 Gln Gly Ser Leu Val Glu Val Asp Arg Glu Phe Trp Lys Leu Phe ThrGln Gly Ser Leu Val Glu Val Asp Arg Glu Phe Trp Lys Leu Phe Thr 515 520 525 515 520 525 Gly Ser Ala Cys Arg Pro Ser Cys Pro Ala Val Cys Cys Leu Thr LeuGly Ser Ala Cys Arg Pro Ser Cys Pro Ala Val Cys Cys Leu Thr Leu 530 535 540 530 535 540 Ala Leu Thr Thr Ser Ile Val Pro Gly Thr Val Lys Met Gly Ile GluAla Leu Thr Thr Ser Ile Val Pro Gly Thr Val Lys Met Gly Ile Glu 545 550 555 560545 550 555 560 Gln Asn Met Cys Glu Val Asn Arg Ser Phe Ser Leu Lys Glu Ser IleGln Asn Met Cys Glu Val Asn Arg Ser Phe Ser Leu Lys Glu Ser Ile 565 570 575 565 570 575 Met Lys Trp Leu Leu Phe Tyr Gln Leu Glu Gly Asp Leu Glu Asn SerMet Lys Trp Leu Leu Phe Tyr Gln Leu Glu Gly Asp Leu Glu Asn Ser 580 585 590 580 585 590 Thr Glu Val Pro Pro Ile Leu His Ser Asn Phe Pro His Leu Val LeuThr Glu Val Pro Pro Ile Leu His Ser Asn Phe Pro His Leu Val Leu 595 600 605 595 600 605 Glu Lys Ile Leu Val Ser Leu Thr Met Lys Asn Cys Lys Ala Ala MetGlu Lys Ile Leu Val Ser Leu Thr Met Lys Asn Cys Lys Ala Ala Met 610 615 620 610 615 620 Asn Phe Phe Gln Ser Val Pro Glu Cys Glu His His Gln Lys Asp LysAsn Phe Phe Gln Ser Val Pro Glu Cys Glu His His Gln Lys Asp Lys 625 630 635 640625 630 635 640 Glu Glu Leu Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gln Thr ThrGlu Glu Leu Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gln Thr Thr 645 650 655 645 650 655 Phe Asp Lys Met Asp Phe Leu Thr Ile Val Arg Glu Cys Gly Ile GluPhe Asp Lys Met Asp Phe Leu Thr Ile Val Arg Glu Cys Gly Ile Glu 660 665 670 660 665 670 Lys His Gln Ser Ser Ile Gly Phe Ser Val His Gln Asn Leu Lys GluLys His Gln Ser Ser Ile Gly Phe Ser Val His Gln Asn Leu Lys Glu 675 680 685 675 680 685 Ser Leu Asp Arg Cys Leu Leu Gly Leu Ser Glu Gln Leu Leu Asn AsnSer Leu Asp Arg Cys Leu Leu Gly Leu Ser Glu Gln Leu Leu Asn Asn 690 695 700 690 695 700 Tyr Ser Ser Glu Ile Thr Asn Ser Glu Thr Leu Val Arg Cys Ser ArgTyr Ser Ser Glu Ile Thr Asn Ser Glu Thr Leu Val Arg Cys Ser Arg 705 710 715 720705 710 715 720 Leu Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly Val Ile AlaLeu Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly Val Ile Ala 725 730 735 725 730 735 Glu Glu Glu Ala Tyr Lys Ser Glu Leu Phe Gln Lys Ala Lys Ser LeuGlu Glu Glu Ala Tyr Lys Ser Glu Leu Phe Gln Lys Ala Lys Ser Leu 740 745 750 740 745 750 Met Gln Cys Ala Gly Glu Ser Ile Thr Leu Phe Lys Asn Lys Thr AsnMet Gln Cys Ala Gly Glu Ser Ile Thr Leu Phe Lys Asn Lys Thr Asn 755 760 765 755 760 765 Glu Glu Phe Arg Ile Gly Ser Leu Arg Asn Met Met Gln Leu Cys ThrGlu Glu Phe Arg Ile Gly Ser Leu Arg Asn Met Met Gln Leu Cys Thr 770 775 780 770 775 780 Arg Cys Leu Ser Asn Cys Thr Lys Lys Ser Pro Asn Lys Ile Ala SerArg Cys Leu Ser Asn Cys Thr Lys Lys Ser Pro Asn Lys Ile Ala Ser 785 790 795 800785 790 795 800 Gly Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp Ile AlaGly Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp Ile Ala 805 810 815 805 810 815 Asp Ile Cys Lys Ser Leu Ala Ser Phe Ile Lys Lys Pro Phe Asp ArgAsp Ile Cys Lys Ser Leu Ala Ser Phe Ile Lys Lys Pro Phe Asp Arg 820 825 830 820 825 830 Gly Glu Val Glu Ser Met Glu Asp Asp Thr Asn Gly Asn Leu Met GluGly Glu Val Glu Ser Met Glu Asp Asp Thr Asn Gly Asn Leu Met Glu 835 840 845 835 840 845 Val Glu Asp Gln Ser Ser Met Asn Leu Phe Asn Asp Tyr Pro Asp SerVal Glu Asp Gln Ser Ser Met Asn Leu Phe Asn Asp Tyr Pro Asp Ser 850 855 860 850 855 860 Ser Val Ser Asp Ala Asn Glu Pro Gly Glu Ser Gln Ser Thr Ile GlySer Val Ser Asp Ala Asn Glu Pro Gly Glu Ser Gln Ser Thr Ile Gly 865 870 875 880865 870 875 880 Ala Ile Asn Pro Leu Ala Glu Glu Tyr Leu Ser Lys Gln Asp Leu LeuAla Ile Asn Pro Leu Ala Glu Glu Tyr Leu Ser Lys Gln Asp Leu Leu 885 890 895 885 890 895 Phe Leu Asp Met Leu Lys Phe Leu Cys Leu Cys Val Thr Thr Ala GlnPhe Leu Asp Met Leu Lys Phe Leu Cys Leu Cys Val Thr Thr Ala Gln 900 905 910 900 905 910 Thr Asn Thr Val Ser Phe Arg Ala Ala Asp Ile Arg Arg Lys Leu LeuThr Asn Thr Val Ser Phe Arg Ala Ala Asp Ile Arg Arg Lys Leu Leu 915 920 925 915 920 925 Met Leu Ile Asp Ser Ser Thr Leu Glu Pro Thr Lys Ser Leu His LeuMet Leu Ile Asp Ser Ser Thr Leu Glu Pro Thr Lys Ser Leu His Leu 930 935 940 930 935 940 His Met Tyr Leu Met Leu Leu Lys Glu Leu Pro Gly Glu Glu Tyr ProHis Met Tyr Leu Met Leu Leu Lys Glu Leu Pro Gly Glu Glu Tyr Pro 945 950 955 960945 950 955 960 Leu Pro Met Glu Asp Val Leu Glu Leu Leu Lys Pro Leu Ser Asn ValLeu Pro Met Glu Asp Val Leu Glu Leu Leu Lys Pro Leu Ser Asn Val 965 970 975 965 970 975 Cys Ser Leu Tyr Arg Arg Asp Gln Asp Val Cys Lys Thr Ile Leu AsnCys Ser Leu Tyr Arg Arg Asp Gln Asp Val Cys Lys Thr Ile Leu Asn 980 985 990 980 985 990 His Val Leu His Val Val Lys Asn Leu Gly Gln Ser Asn Met Asp SerHis Val Leu His Val Val Lys Asn Leu Gly Gln Ser Asn Met Asp Ser 995 1000 1005 995 1000 1005 Glu Asn Thr Arg Asp Ala Gln Gly Gln Phe Leu Thr Val Ile GlyGlu Asn Thr Arg Asp Ala Gln Gly Gln Phe Leu Thr Val Ile Gly 1010 1015 1020 1010 1015 1020 Ala Phe Trp His Leu Thr Lys Glu Arg Lys Tyr Ile Phe Ser ValAla Phe Trp His Leu Thr Lys Glu Arg Lys Tyr Ile Phe Ser Val 1025 1030 1035 1025 1030 1035 Arg Met Ala Leu Val Asn Cys Leu Lys Thr Leu Leu Glu Ala AspArg Met Ala Leu Val Asn Cys Leu Lys Thr Leu Leu Glu Ala Asp 1040 1045 1050 1040 1045 1050 Pro Tyr Ser Lys Trp Ala Ile Leu Asn Val Met Gly Lys Asp PhePro Tyr Ser Lys Trp Ala Ile Leu Asn Val Met Gly Lys Asp Phe 1055 1060 1065 1055 1060 1065 Pro Val Asn Glu Val Phe Thr Gln Phe Leu Ala Asp Asn His HisPro Val Asn Glu Val Phe Thr Gln Phe Leu Ala Asp Asn His His 1070 1075 1080 1070 1075 1080 Gln Val Arg Met Leu Ala Ala Glu Ser Ile Asn Arg Leu Phe GlnGln Val Arg Met Leu Ala Ala Glu Ser Ile Asn Arg Leu Phe Gln 1085 1090 1095 1085 1090 1095 Asp Thr Lys Gly Asp Ser Ser Arg Leu Leu Lys Ala Leu Pro LeuAsp Thr Lys Gly Asp Ser Ser Arg Leu Leu Lys Ala Leu Pro Leu 1100 1105 1110 1100 1105 1110 Lys Leu Gln Gln Thr Ala Phe Glu Asn Ala Tyr Leu Lys Ala GlnLys Leu Gln Gln Thr Ala Phe Glu Asn Ala Tyr Leu Lys Ala Gln 1115 1120 1125 1115 1120 1125 Glu Gly Met Arg Glu Met Ser His Ser Ala Glu Asn Pro Glu ThrGlu Gly Met Arg Glu Met Ser His Ser Ala Glu Asn Pro Glu Thr 1130 1135 1140 1130 1135 1140 Leu Asp Glu Ile Tyr Asn Arg Lys Ser Val Leu Leu Thr Leu IleLeu Asp Glu Ile Tyr Asn Arg Lys Ser Val Leu Leu Thr Leu Ile 1145 1150 1155 1145 1150 1155 Ala Val Val Leu Ser Cys Ser Pro Ile Cys Glu Lys Gln Ala LeuAla Val Val Leu Ser Cys Ser Pro Ile Cys Glu Lys Gln Ala Leu 1160 1165 1170 1160 1165 1170 Phe Ala Leu Cys Lys Ser Val Lys Glu Asn Gly Leu Glu Pro HisPhe Ala Leu Cys Lys Ser Val Lys Glu Asn Gly Leu Glu Pro His 1175 1180 1185 1175 1180 1185 Leu Val Lys Lys Val Leu Glu Lys Val Ser Glu Thr Phe Gly TyrLeu Val Lys Lys Val Leu Glu Lys Val Ser Glu Thr Phe Gly Tyr 1190 1195 1200 1190 1195 1200 Arg Arg Leu Glu Asp Phe Met Ala Ser His Leu Asp Tyr Leu ValArg Arg Leu Glu Asp Phe Met Ala Ser His Leu Asp Tyr Leu Val 1205 1210 1215 1205 1210 1215 Leu Glu Trp Leu Asn Leu Gln Asp Thr Glu Tyr Asn Leu Ser SerLeu Glu Trp Leu Asn Leu Gln Asp Thr Glu Tyr Asn Leu Ser Ser 1220 1225 1230 1220 1225 1230 Phe Pro Phe Ile Leu Leu Asn Tyr Thr Asn Ile Glu Asp Phe TyrPhe Pro Phe Ile Leu Leu Asn Tyr Thr Asn Ile Glu Asp Phe Tyr 1235 1240 1245 1235 1240 1245 Arg Ser Cys Tyr Lys Val Leu Ile Pro His Leu Val Ile Arg SerArg Ser Cys Tyr Lys Val Leu Ile Pro His Leu Val Ile Arg Ser 1250 1255 1260 1250 1255 1260 His Phe Asp Glu Val Lys Ser Ile Ala Asn Gln Ile Gln Glu AspHis Phe Asp Glu Val Lys Ser Ile Ala Asn Gln Ile Gln Glu Asp 1265 1270 1275 1265 1270 1275 Trp Lys Ser Leu Leu Thr Asp Cys Phe Pro Lys Ile Leu Val AsnTrp Lys Ser Leu Leu Thr Asp Cys Phe Pro Lys Ile Leu Val Asn 1280 1285 1290 1280 1285 1290 Ile Leu Pro Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Gly MetIle Leu Pro Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Gly Met 1295 1300 1305 1295 1300 1305 Ala Gln Gln Arg Glu Thr Ala Thr Lys Val Tyr Asp Met Leu LysAla Gln Gln Arg Glu Thr Ala Thr Lys Val Tyr Asp Met Leu Lys 1310 1315 1320 1310 1315 1320 Ser Glu Asn Leu Leu Gly Lys Gln Ile Asp His Leu Phe Ile SerSer Glu Asn Leu Leu Gly Lys Gln Ile Asp His Leu Phe Ile Ser 1325 1330 1335 1325 1330 1335 Asn Leu Pro Glu Ile Val Val Glu Leu Leu Met Thr Leu His GluAsn Leu Pro Glu Ile Val Val Glu Leu Leu Met Thr Leu His Glu 1340 1345 1350 1340 1345 1350 Pro Ala Asn Ser Ser Ala Ser Gln Ser Thr Asp Leu Cys Asp PhePro Ala Asn Ser Ser Ala Ser Gln Ser Thr Asp Leu Cys Asp Phe 1355 1360 1365 1355 1360 1365 Ser Gly Asp Leu Asp Pro Ala Pro Asn Pro Pro His Phe Pro SerSer Gly Asp Leu Asp Pro Ala Pro Asn Pro Pro His Phe Pro Ser 1370 1375 1380 1370 1375 1380 His Val Ile Lys Ala Thr Phe Ala Tyr Ile Ser Asn Cys His LysHis Val Ile Lys Ala Thr Phe Ala Tyr Ile Ser Asn Cys His Lys 1385 1390 1395 1385 1390 1395 Thr Lys Leu Lys Ser Ile Leu Glu Ile Leu Ser Lys Ser Pro AspThr Lys Leu Lys Ser Ile Leu Glu Ile Leu Ser Lys Ser Pro Asp 1400 1405 1410 1400 1405 1410 Ser Tyr Gln Lys Ile Leu Leu Ala Ile Cys Glu Gln Ala Ala GluSer Tyr Gln Lys Ile Leu Leu Ala Ile Cys Glu Gln Ala Ala Glu 1415 1420 1425 1415 1420 1425 Thr Asn Asn Val Tyr Lys Lys His Arg Ile Leu Lys Ile Tyr HisThr Asn Asn Val Tyr Lys Lys His Arg Ile Leu Lys Ile Tyr His 1430 1435 1440 1430 1435 1440 Leu Phe Val Ser Leu Leu Leu Lys Asp Ile Lys Ser Gly Leu GlyLeu Phe Val Ser Leu Leu Leu Lys Asp Ile Lys Ser Gly Leu Gly 1445 1450 1455 1445 1450 1455 Gly Ala Trp Ala Phe Val Leu Arg Asp Val Ile Tyr Thr Leu IleGly Ala Trp Ala Phe Val Leu Arg Asp Val Ile Tyr Thr Leu Ile 1460 1465 1470 1460 1465 1470 His Tyr Ile Asn Gln Arg Pro Ser Cys Ile Met Asp Val Ser LeuHis Tyr Ile Asn Gln Arg Pro Ser Cys Ile Met Asp Val Ser Leu 1475 1480 1485 1475 1480 1485 Arg Ser Phe Ser Leu Cys Cys Asp Leu Leu Ser Gln Val Cys GlnArg Ser Phe Ser Leu Cys Cys Asp Leu Leu Ser Gln Val Cys Gln 1490 1495 1500 1490 1495 1500 Thr Ala Val Thr Tyr Cys Lys Asp Ala Leu Glu Asn His Leu HisThr Ala Val Thr Tyr Cys Lys Asp Ala Leu Glu Asn His Leu His 1505 1510 1515 1505 1510 1515 Val Ile Val Gly Thr Leu Ile Pro Leu Val Tyr Glu Gln Val GluVal Ile Val Gly Thr Leu Ile Pro Leu Val Tyr Glu Gln Val Glu 1520 1525 1530 1520 1525 1530 Val Gln Lys Gln Val Leu Asp Leu Leu Lys Tyr Leu Val Ile AspVal Gln Lys Gln Val Leu Asp Leu Leu Lys Tyr Leu Val Ile Asp 1535 1540 1545 1535 1540 1545 Asn Lys Asp Asn Glu Asn Leu Tyr Ile Thr Ile Lys Leu Leu AspAsn Lys Asp Asn Glu Asn Leu Tyr Ile Thr Ile Lys Leu Leu Asp 1550 1555 1560 1550 1555 1560 Pro Phe Pro Asp His Val Val Phe Lys Asp Leu Arg Ile Thr GlnPro Phe Pro Asp His Val Val Phe Lys Asp Leu Arg Ile Thr Gln 1565 1570 1575 1565 1570 1575 Gln Lys Ile Lys Tyr Ser Arg Gly Pro Phe Ser Leu Leu Glu GluGln Lys Ile Lys Tyr Ser Arg Gly Pro Phe Ser Leu Leu Glu Glu 1580 1585 1590 1580 1585 1590 Ile Asn His Phe Leu Ser Val Ser Val Tyr Asp Ala Leu Pro LeuIle Asn His Phe Leu Ser Val Ser Val Tyr Asp Ala Leu Pro Leu 1595 1600 1605 1595 1600 1605 Thr Arg Leu Glu Gly Leu Lys Asp Leu Arg Arg Gln Leu Glu LeuThr Arg Leu Glu Gly Leu Lys Asp Leu Arg Arg Gln Leu Glu Leu 1610 1615 1620 1610 1615 1620 His Lys Asp Gln Met Val Asp Ile Met Arg Ala Ser Gln Asp AsnHis Lys Asp Gln Met Val Asp Ile Met Arg Ala Ser Gln Asp Asn 1625 1630 1635 1625 1630 1635 Pro Gln Asp Gly Ile Met Val Lys Leu Val Val Asn Leu Leu GlnPro Gln Asp Gly Ile Met Val Lys Leu Val Val Asn Leu Leu Gln 1640 1645 1650 1640 1645 1650 Leu Ser Lys Met Ala Ile Asn His Thr Gly Glu Lys Glu Val LeuLeu Ser Lys Met Ala Ile Asn His Thr Gly Glu Lys Glu Val Leu 1655 1660 1665 1655 1660 1665 Glu Ala Val Gly Ser Cys Leu Gly Glu Val Gly Pro Ile Asp PheGlu Ala Val Gly Ser Cys Leu Gly Glu Val Gly Pro Ile Asp Phe 1670 1675 1680 1670 1675 1680 Ser Thr Ile Ala Ile Gln His Ser Lys Asp Ala Ser Tyr Thr LysSer Thr Ile Ala Ile Gln His Ser Lys Asp Ala Ser Tyr Thr Lys 1685 1690 1695 1685 1690 1695 Ala Leu Lys Leu Phe Glu Asp Lys Glu Leu Gln Trp Thr Phe IleAla Leu Lys Leu Phe Glu Asp Lys Glu Leu Gln Trp Thr Phe Ile 1700 1705 1710 1700 1705 1710 Met Leu Thr Tyr Leu Asn Asn Thr Leu Val Glu Asp Cys Val LysMet Leu Thr Tyr Leu Asn Asn Thr Leu Val Glu Asp Cys Val Lys 1715 1720 1725 1715 1720 1725 Val Arg Ser Ala Ala Val Thr Cys Leu Lys Asn Ile Leu Ala ThrVal Arg Ser Ala Ala Val Thr Cys Leu Lys Asn Ile Leu Ala Thr 1730 1735 1740 1730 1735 1740 Lys Thr Gly His Ser Phe Trp Glu Ile Tyr Lys Met Thr Thr AspLys Thr Gly His Ser Phe Trp Glu Ile Tyr Lys Met Thr Thr Asp 1745 1750 1755 1745 1750 1755 Pro Met Leu Ala Tyr Leu Gln Pro Phe Arg Thr Ser Arg Lys LysPro Met Leu Ala Tyr Leu Gln Pro Phe Arg Thr Ser Arg Lys Lys 1760 1765 1770 1760 1765 1770 Phe Leu Glu Val Pro Arg Phe Asp Lys Glu Asn Pro Phe Glu GlyPhe Leu Glu Val Pro Arg Phe Asp Lys Glu Asn Pro Phe Glu Gly 1775 1780 1785 1775 1780 1785 Leu Asp Asp Ile Asn Leu Trp Ile Pro Leu Ser Glu Asn His AspLeu Asp Asp Ile Asn Leu Trp Ile Pro Leu Ser Glu Asn His Asp 1790 1795 1800 1790 1795 1800 Ile Trp Ile Lys Thr Leu Thr Cys Ala Phe Leu Asp Ser Gly GlyIle Trp Ile Lys Thr Leu Thr Cys Ala Phe Leu Asp Ser Gly Gly 1805 1810 1815 1805 1810 1815 Thr Lys Cys Glu Ile Leu Gln Leu Leu Lys Pro Met Cys Glu ValThr Lys Cys Glu Ile Leu Gln Leu Leu Lys Pro Met Cys Glu Val 1820 1825 1830 1820 1825 1830 Lys Thr Asp Phe Cys Gln Thr Val Leu Pro Tyr Leu Ile His AspLys Thr Asp Phe Cys Gln Thr Val Leu Pro Tyr Leu Ile His Asp 1835 1840 1845 1835 1840 1845 Ile Leu Leu Gln Asp Thr Asn Glu Ser Trp Arg Asn Leu Leu SerIle Leu Leu Gln Asp Thr Asn Glu Ser Trp Arg Asn Leu Leu Ser 1850 1855 1860 1850 1855 1860 Thr His Val Gln Gly Phe Phe Thr Ser Cys Leu Arg His Phe SerThr His Val Gln Gly Phe Phe Thr Ser Cys Leu Arg His Phe Ser 1865 1870 1875 1865 1870 1875 Gln Thr Ser Arg Ser Thr Thr Pro Ala Asn Leu Asp Ser Glu SerGln Thr Ser Arg Ser Thr Thr Pro Ala Asn Leu Asp Ser Glu Ser 1880 1885 1890 1880 1885 1890 Glu His Phe Phe Arg Cys Cys Leu Asp Lys Lys Ser Gln Arg ThrGlu His Phe Phe Arg Cys Cys Leu Asp Lys Lys Ser Gln Arg Thr 1895 1900 1905 1895 1900 1905 Met Leu Ala Val Val Asp Tyr Met Arg Arg Gln Lys Arg Pro SerMet Leu Ala Val Val Asp Tyr Met Arg Arg Gln Lys Arg Pro Ser 1910 1915 1920 1910 1915 1920 Ser Gly Thr Ile Phe Asn Asp Ala Phe Trp Leu Asp Leu Asn TyrSer Gly Thr Ile Phe Asn Asp Ala Phe Trp Leu Asp Leu Asn Tyr 1925 1930 1935 1925 1930 1935 Leu Glu Val Ala Lys Val Ala Gln Ser Cys Ala Ala His Phe ThrLeu Glu Val Ala Lys Val Ala Gln Ser Cys Ala Ala His Phe Thr 1940 1945 1950 1940 1945 1950 Ala Leu Leu Tyr Ala Glu Ile Tyr Ala Asp Lys Lys Ser Met AspAla Leu Leu Tyr Ala Glu Ile Tyr Ala Asp Lys Lys Ser Met Asp 1955 1960 1965 1955 1960 1965 Asp Gln Glu Lys Arg Ser Leu Ala Phe Glu Glu Gly Ser Gln AsnAsp Gln Glu Lys Arg Ser Leu Ala Phe Glu Glu Gly Ser Gln Asn 1970 1975 1980 1970 1975 1980 Thr Thr Ile Ser Ser Leu Ser Glu Lys Ser Lys Glu Glu Thr GlyThr Thr Ile Ser Ser Leu Ser Glu Lys Ser Lys Glu Glu Thr Gly 1985 1990 1995 1985 1990 1995 Ile Ser Leu Gln Asp Leu Leu Leu Glu Ile Tyr Arg Ser Ile GlyIle Ser Leu Gln Asp Leu Leu Leu Glu Ile Tyr Arg Ser Ile Gly 2000 2005 2010 2000 2005 2010 Glu Pro Asp Ser Leu Tyr Gly Cys Gly Gly Gly Lys Met Leu GlnGlu Pro Asp Ser Leu Tyr Gly Cys Gly Gly Gly Lys Met Leu Gln 2015 2020 2025 2015 2020 2025 Pro Ile Thr Arg Leu Arg Thr Tyr Glu His Glu Ala Met Trp GlyPro Ile Thr Arg Leu Arg Thr Tyr Glu His Glu Ala Met Trp Gly 2030 2035 2040 2030 2035 2040 Lys Ala Leu Val Thr Tyr Asp Leu Glu Thr Ala Ile Pro Ser SerLys Ala Leu Val Thr Tyr Asp Leu Glu Thr Ala Ile Pro Ser Ser 2045 2050 2055 2045 2050 2055 Thr Arg Gln Ala Gly Ile Ile Gln Ala Leu Gln Asn Leu Gly LeuThr Arg Gln Ala Gly Ile Ile Gln Ala Leu Gln Asn Leu Gly Leu 2060 2065 2070 2060 2065 2070 Cys His Ile Leu Ser Val Tyr Leu Lys Gly Leu Asp Tyr Glu AsnCys His Ile Leu Ser Val Tyr Leu Lys Gly Leu Asp Tyr Glu Asn 2075 2080 2085 2075 2080 2085 Lys Asp Trp Cys Pro Glu Leu Glu Glu Leu His Tyr Gln Ala AlaLys Asp Trp Cys Pro Glu Leu Glu Glu Leu His Tyr Gln Ala Ala 2090 2095 2100 2090 2095 2100 Trp Arg Asn Met Gln Trp Asp His Cys Thr Ser Val Ser Lys GluTrp Arg Asn Met Gln Trp Asp His Cys Thr Ser Val Ser Lys Glu 2105 2110 2115 2105 2110 2115 Val Glu Gly Thr Ser Tyr His Glu Ser Leu Tyr Asn Ala Leu GlnVal Glu Gly Thr Ser Tyr His Glu Ser Leu Tyr Asn Ala Leu Gln 2120 2125 2130 2120 2125 2130 Ser Leu Arg Asp Arg Glu Phe Ser Thr Phe Tyr Glu Ser Leu LysSer Leu Arg Asp Arg Glu Phe Ser Thr Phe Tyr Glu Ser Leu Lys 2135 2140 2145 2135 2140 2145 Tyr Ala Arg Val Lys Glu Val Glu Glu Met Cys Lys Arg Ser LeuTyr Ala Arg Val Lys Glu Val Glu Glu Met Cys Lys Arg Ser Leu 2150 2155 2160 2150 2155 2160 Glu Ser Val Tyr Ser Leu Tyr Pro Thr Leu Ser Arg Leu Gln AlaGlu Ser Val Tyr Ser Leu Tyr Pro Thr Leu Ser Arg Leu Gln Ala 2165 2170 2175 2165 2170 2175 Ile Gly Glu Leu Glu Ser Ile Gly Glu Leu Phe Ser Arg Ser ValIle Gly Glu Leu Glu Ser Ile Gly Glu Leu Phe Ser Arg Ser Val 2180 2185 2190 2180 2185 2190 Thr His Arg Gln Leu Ser Glu Val Tyr Ile Lys Trp Gln Lys HisThr His Arg Gln Leu Ser Glu Val Tyr Ile Lys Trp Gln Lys His 2195 2200 2205 2195 2200 2205 Ser Gln Leu Leu Lys Asp Ser Asp Phe Ser Phe Gln Glu Pro IleSer Gln Leu Leu Lys Asp Ser Asp Phe Ser Phe Gln Glu Pro Ile 2210 2215 2220 2210 2215 2220 Met Ala Leu Arg Thr Val Ile Leu Glu Ile Leu Met Glu Lys GluMet Ala Leu Arg Thr Val Ile Leu Glu Ile Leu Met Glu Lys Glu 2225 2230 2235 2225 2230 2235 Met Asp Asn Ser Gln Arg Glu Cys Ile Lys Asp Ile Leu Thr LysMet Asp Asn Ser Gln Arg Glu Cys Ile Lys Asp Ile Leu Thr Lys 2240 2245 2250 2240 2245 2250 His Leu Val Glu Leu Ser Ile Leu Ala Arg Thr Phe Lys Asn ThrHis Leu Val Glu Leu Ser Ile Leu Ala Arg Thr Phe Lys Asn Thr 2255 2260 2265 2255 2260 2265 Gln Leu Pro Glu Arg Ala Ile Phe Gln Ile Lys Gln Tyr Asn SerGln Leu Pro Glu Arg Ala Ile Phe Gln Ile Lys Gln Tyr Asn Ser 2270 2275 2280 2270 2275 2280 Val Ser Cys Gly Val Ser Glu Trp Gln Leu Glu Glu Ala Gln ValVal Ser Cys Gly Val Ser Glu Trp Gln Leu Glu Glu Ala Gln Val 2285 2290 2295 2285 2290 2295 Phe Trp Ala Lys Lys Glu Gln Ser Leu Ala Leu Ser Ile Leu LysPhe Trp Ala Lys Lys Glu Gln Ser Leu Ala Leu Ser Ile Leu Lys 2300 2305 2310 2300 2305 2310 Gln Met Ile Lys Lys Leu Asp Ala Ser Cys Ala Ala Asn Asn ProGln Met Ile Lys Lys Leu Asp Ala Ser Cys Ala Ala Asn Asn Pro 2315 2320 2325 2315 2320 2325 Ser Leu Lys Leu Thr Tyr Thr Glu Cys Leu Arg Val Cys Gly AsnSer Leu Lys Leu Thr Tyr Thr Glu Cys Leu Arg Val Cys Gly Asn 2330 2335 2340 2330 2335 2340 Trp Leu Ala Glu Thr Cys Leu Glu Asn Pro Ala Val Ile Met GlnTrp Leu Ala Glu Thr Cys Leu Glu Asn Pro Ala Val Ile Met Gln 2345 2350 2355 2345 2350 2355 Thr Tyr Leu Glu Lys Ala Val Glu Val Ala Gly Asn Tyr Asp GlyThr Tyr Leu Glu Lys Ala Val Glu Val Ala Gly Asn Tyr Asp Gly 2360 2365 2370 2360 2365 2370 Glu Ser Ser Asp Glu Leu Arg Asn Gly Lys Met Lys Ala Phe LeuGlu Ser Ser Asp Glu Leu Arg Asn Gly Lys Met Lys Ala Phe Leu 2375 2380 2385 2375 2380 2385 Ser Leu Ala Arg Phe Ser Asp Thr Gln Tyr Gln Arg Ile Glu AsnSer Leu Ala Arg Phe Ser Asp Thr Gln Tyr Gln Arg Ile Glu Asn 2390 2395 2400 2390 2395 2400 Tyr Met Lys Ser Ser Glu Phe Glu Asn Lys Gln Ala Leu Leu LysTyr Met Lys Ser Ser Glu Phe Glu Asn Lys Gln Ala Leu Leu Lys 2405 2410 2415 2405 2410 2415 Arg Ala Lys Glu Glu Val Gly Leu Leu Arg Glu His Lys Ile GlnArg Ala Lys Glu Glu Val Gly Leu Leu Arg Glu His Lys Ile Gln 2420 2425 2430 2420 2425 2430 Thr Asn Arg Tyr Thr Val Lys Val Gln Arg Glu Leu Glu Leu AspThr Asn Arg Tyr Thr Val Lys Val Gln Arg Glu Leu Glu Leu Asp 2435 2440 2445 2435 2440 2445 Glu Leu Ala Leu Arg Ala Leu Lys Glu Asp Arg Lys Arg Phe LeuGlu Leu Ala Leu Arg Ala Leu Lys Glu Asp Arg Lys Arg Phe Leu 2450 2455 2460 2450 2455 2460 Cys Lys Ala Val Glu Asn Tyr Ile Asn Cys Leu Leu Ser Gly GluCys Lys Ala Val Glu Asn Tyr Ile Asn Cys Leu Leu Ser Gly Glu 2465 2470 2475 2465 2470 2475 Glu His Asp Met Trp Val Phe Arg Leu Cys Ser Leu Trp Leu GluGlu His Asp Met Trp Val Phe Arg Leu Cys Ser Leu Trp Leu Glu 2480 2485 2490 2480 2485 2490 Asn Ser Gly Val Ser Glu Val Asn Gly Met Met Lys Arg Asp GlyAsn Ser Gly Val Ser Glu Val Asn Gly Met Met Lys Arg Asp Gly 2495 2500 2505 2495 2500 2505 Met Lys Ile Pro Thr Tyr Lys Phe Leu Pro Leu Met Tyr Gln LeuMet Lys Ile Pro Thr Tyr Lys Phe Leu Pro Leu Met Tyr Gln Leu 2510 2515 2520 2510 2515 2520 Ala Ala Arg Met Gly Thr Lys Met Met Gly Gly Leu Gly Phe HisAla Ala Arg Met Gly Thr Lys Met Met Gly Gly Leu Gly Phe His 2525 2530 2535 2525 2530 2535 Glu Val Leu Asn Asn Leu Ile Ser Arg Ile Ser Met Asp His ProGlu Val Leu Asn Asn Leu Ile Ser Arg Ile Ser Met Asp His Pro 2540 2545 2550 2540 2545 2550 His His Thr Leu Phe Ile Ile Leu Ala Leu Ala Asn Ala Asn ArgHis His Thr Leu Phe Ile Ile Leu Ala Leu Ala Asn Ala Asn Arg 2555 2560 2565 2555 2560 2565 Asp Glu Phe Leu Thr Lys Pro Glu Val Ala Arg Arg Ser Arg IleAsp Glu Phe Leu Thr Lys Pro Glu Val Ala Arg Arg Ser Arg Ile 2570 2575 2580 2570 2575 2580 Thr Lys Asn Val Pro Lys Gln Ser Ser Gln Leu Asp Glu Asp ArgThr Lys Asn Val Pro Lys Gln Ser Ser Gln Leu Asp Glu Asp Arg 2585 2590 2595 2585 2590 2595 Thr Glu Ala Ala Asn Arg Ile Ile Cys Thr Ile Arg Ser Arg ArgThr Glu Ala Ala Asn Arg Ile Ile Cys Thr Ile Arg Ser Arg Arg 2600 2605 2610 2600 2605 2610 Pro Gln Met Val Arg Ser Val Glu Ala Leu Cys Asp Ala Tyr IlePro Gln Met Val Arg Ser Val Glu Ala Leu Cys Asp Ala Tyr Ile 2615 2620 2625 2615 2620 2625 Ile Leu Ala Asn Leu Asp Ala Thr Gln Trp Lys Thr Gln Arg LysIle Leu Ala Asn Leu Asp Ala Thr Gln Trp Lys Thr Gln Arg Lys 2630 2635 2640 2630 2635 2640 Gly Ile Asn Ile Pro Ala Asp Gln Pro Ile Thr Lys Leu Lys AsnGly Ile Asn Ile Pro Ala Asp Gln Pro Ile Thr Lys Leu Lys Asn 2645 2650 2655 2645 2650 2655 Leu Glu Asp Val Val Val Pro Thr Met Glu Ile Lys Val Asp HisLeu Glu Asp Val Val Val Pro Thr Met Glu Ile Lys Val Asp His 2660 2665 2670 2660 2665 2670 Thr Gly Glu Tyr Gly Asn Leu Val Thr Ile Gln Ser Phe Lys AlaThr Gly Glu Tyr Gly Asn Leu Val Thr Ile Gln Ser Phe Lys Ala 2675 2680 2685 2675 2680 2685 Glu Phe Arg Leu Ala Gly Gly Val Asn Leu Pro Lys Ile Ile AspGlu Phe Arg Leu Ala Gly Gly Val Asn Leu Pro Lys Ile Ile Asp 2690 2695 2700 2690 2695 2700 Cys Val Gly Ser Asp Gly Lys Glu Arg Arg Gln Leu Val Lys GlyCys Val Gly Ser Asp Gly Lys Glu Arg Arg Gln Leu Val Lys Gly 2705 2710 2715 2705 2710 2715 Arg Asp Asp Leu Arg Gln Asp Ala Val Met Gln Gln Val Phe GlnArg Asp Asp Leu Arg Gln Asp Ala Val Met Gln Gln Val Phe Gln 2720 2725 2730 2720 2725 2730 Met Cys Asn Thr Leu Leu Gln Arg Asn Thr Glu Thr Arg Lys ArgMet Cys Asn Thr Leu Leu Gln Arg Asn Thr Glu Thr Arg Lys Arg 2735 2740 2745 2735 2740 2745 Lys Leu Thr Ile Cys Thr Tyr Lys Val Val Pro Leu Ser Gln ArgLys Leu Thr Ile Cys Thr Tyr Lys Val Val Pro Leu Ser Gln Arg 2750 2755 2760 2750 2755 2760 Ser Gly Val Leu Glu Trp Cys Thr Gly Thr Val Pro Ile Gly GluSer Gly Val Leu Glu Trp Cys Thr Gly Thr Val Pro Ile Gly Glu 2765 2770 2775 2765 2770 2775 Phe Leu Val Asn Asn Glu Asp Gly Ala His Lys Arg Tyr Arg ProPhe Leu Val Asn Asn Glu Asp Gly Ala His Lys Arg Tyr Arg Pro 2780 2785 2790 2780 2785 2790 Asn Asp Phe Ser Ala Phe Gln Cys Gln Lys Lys Met Met Glu ValAsn Asp Phe Ser Ala Phe Gln Cys Gln Lys Lys Met Met Glu Val 2795 2800 2805 2795 2800 2805 Gln Lys Lys Ser Phe Glu Glu Lys Tyr Glu Val Phe Met Asp ValGln Lys Lys Ser Phe Glu Glu Lys Tyr Glu Val Phe Met Asp Val 2810 2815 2820 2810 2815 2820 Cys Gln Asn Phe Gln Pro Val Phe Arg Tyr Phe Cys Met Glu LysCys Gln Asn Phe Gln Pro Val Phe Arg Tyr Phe Cys Met Glu Lys 2825 2830 2835 2825 2830 2835 Phe Leu Asp Pro Ala Ile Trp Phe Glu Lys Arg Leu Ala Tyr ThrPhe Leu Asp Pro Ala Ile Trp Phe Glu Lys Arg Leu Ala Tyr Thr 2840 2845 2850 2840 2845 2850 Arg Ser Val Ala Thr Ser Ser Ile Val Gly Tyr Ile Leu Gly LeuArg Ser Val Ala Thr Ser Ser Ile Val Gly Tyr Ile Leu Gly Leu 2855 2860 2865 2855 2860 2865 Gly Asp Arg His Val Gln Asn Ile Leu Ile Asn Glu Gln Ser AlaGly Asp Arg His Val Gln Asn Ile Leu Ile Asn Glu Gln Ser Ala 2870 2875 2880 2870 2875 2880 Glu Leu Val His Ile Asp Leu Gly Val Ala Phe Glu Gln Gly LysGlu Leu Val His Ile Asp Leu Gly Val Ala Phe Glu Gln Gly Lys 2885 2890 2895 2885 2890 2895 Ile Leu Pro Thr Pro Glu Thr Val Pro Phe Arg Leu Thr Arg AspIle Leu Pro Thr Pro Glu Thr Val Pro Phe Arg Leu Thr Arg Asp 2900 2905 2910 2900 2905 2910 Ile Val Asp Gly Met Gly Ile Thr Gly Val Glu Gly Val Phe ArgIle Val Asp Gly Met Gly Ile Thr Gly Val Glu Gly Val Phe Arg 2915 2920 2925 2915 2920 2925 Arg Cys Cys Glu Lys Thr Met Glu Val Met Arg Asn Ser Gln GluArg Cys Cys Glu Lys Thr Met Glu Val Met Arg Asn Ser Gln Glu 2930 2935 2940 2930 2935 2940 Thr Leu Leu Thr Ile Val Glu Val Leu Leu Tyr Asp Pro Leu PheThr Leu Leu Thr Ile Val Glu Val Leu Leu Tyr Asp Pro Leu Phe 2945 2950 2955 2945 2950 2955 Asp Trp Thr Met Asn Pro Leu Lys Ala Leu Tyr Leu Gln Gln ArgAsp Trp Thr Met Asn Pro Leu Lys Ala Leu Tyr Leu Gln Gln Arg 2960 2965 2970 2960 2965 2970 Pro Glu Asp Glu Thr Glu Leu His Pro Thr Leu Asn Ala Asp AspPro Glu Asp Glu Thr Glu Leu His Pro Thr Leu Asn Ala Asp Asp 2975 2980 2985 2975 2980 2985 Gln Glu Cys Lys Arg Asn Leu Ser Asp Ile Asp Gln Ser Phe AsnGln Glu Cys Lys Arg Asn Leu Ser Asp Ile Asp Gln Ser Phe Asn 2990 2995 3000 2990 2995 3000 Lys Val Ala Glu Arg Val Leu Met Arg Leu Gln Glu Lys Leu LysLys Val Ala Glu Arg Val Leu Met Arg Leu Gln Glu Lys Leu Lys 3005 3010 3015 3005 3010 3015 Gly Val Glu Glu Gly Thr Val Leu Ser Val Gly Gly Gln Val AsnGly Val Glu Glu Gly Thr Val Leu Ser Val Gly Gly Gly Gln Val Asn 3020 3025 3030 3020 3025 3030 Leu Leu Ile Gln Gln Ala Ile Asp Pro Lys Asn Leu Ser Arg LeuLeu Leu Ile Gln Gln Ala Ile Asp Pro Lys Asn Leu Ser Arg Leu 3035 3040 3045 3035 3040 3045 Phe Pro Gly Trp Lys Ala Trp ValPhe Pro Gly Trp Lys Ala Trp Val 3050 3055 3050 3055 <210> 3<210> 3 <211> 543<211> 543 <212> DNA<212> DNA <213> Homo sapiens<213> Homo sapiens <400> 3<400> 3 atgagtctag tacttaatga tctgcttatc tgctgccgtc aactagaaca tgatagagct 60atgagtctag tacttaatga tctgcttatc tgctgccgtc aactagaaca tgatagagct 60 acagaacgaa agaaagaagt tgagaaattt aagcgcctga ttcgagatcc tgaaacaatt 120acagaacgaa agaaagaagt tgagaaattt aagcgcctga ttcgagatcc tgaaacaatt 120 aaacatctag atcggcattc agattccaaa caaggaaaat atttgaattg ggatgctgtt 180aaacatctag atcggcattc agattccaaa caaggaaaat atttgaattg ggatgctgtt 180 tttagatttt tacagaaata tattcagaaa gaaacagaat gtctgagaat agcaaaacca 240tttagatttt tacagaaata tattcagaaa gaaacagaat gtctgagaat agcaaaacca 240 aatgtatcag cctcaacaca agcctccagg cagaaaaaga tgcaggaaat cagtagtttg 300aatgtatcag cctcaacaca agcctccagg cagaaaaaga tgcaggaaat cagtagtttg 300 gtcaaatact tcatcaaatg tgcaaacaga agagcaccta ggctaaaatg tcaagaactc 360gtcaaatact tcatcaaatg tgcaaacaga agagcaccta ggctaaaatg tcaagaactc 360 ttaaattata tcatggatac agtgaaagat tcatctaatg gtgctattta cggagctgat 420ttaaattata tcatggatac agtgaaagat tcatctaatg gtgctattta cggagctgat 420 tgtagcaaca tactactcaa agacattctt tctgtgagaa aatactggtg tgaaatagca 480tgtagcaaca tactactcaa agacattctt tctgtgagaa aatactggtg tgaaatagca 480 acagtggtta gaattgttct ctgtgtactt caggctctat ctgaaacctt cacaagatgt 540acagtggtta gaattgttct ctgtgtactt caggctctat ctgaaacctt cacaagatgt 540 tca 543tca 543 <210> 4<210> 4 <211> 181<211> 181 <212> PRT<212> PRT <213> Homo sapiens<213> Homo sapiens <400> 4<400> 4 Met Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu GluMet Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu Glu 1 5 10 151 5 10 15 His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys ArgHis Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys Arg 20 25 30 20 25 30 Leu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser AspLeu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser Asp 35 40 45 35 40 45 Ser Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe LeuSer Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu 50 55 60 50 55 60 Gln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys ProGln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys Pro 65 70 75 8065 70 75 80 Asn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln GluAsn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln Glu 85 90 95 85 90 95 Ile Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg AlaIle Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg Ala 100 105 110 100 105 110 Pro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr ValPro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr Val 115 120 125 115 120 125 Lys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn IleLys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn Ile 130 135 140 130 135 140 Leu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile AlaLeu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile Ala 145 150 155 160145 150 155 160 Thr Val Val Arg Ile Val Leu Cys Val Leu Gln Ala Leu Ser Glu ThrThr Val Val Arg Ile Val Leu Cys Val Leu Gln Ala Leu Ser Glu Thr 165 170 175 165 170 175 Phe Thr Arg Cys SerPhe Thr Arg Cys Ser 180 180 <210> 5<210> 5 <211> 4785<211> 4785 <212> DNA<212> DNA <213> Homo sapiens<213> Homo sapiens <400> 5<400> 5 atgagtctag tacttaatga tctgcttatc tgctgccgtc aactagaaca tgatagagct 60atgagtctag tacttaatga tctgcttatc tgctgccgtc aactagaaca tgatagagct 60 acagaacgaa agaaagaagt tgagaaattt aagcgcctga ttcgagatcc tgaaacaatt 120acagaacgaa agaaagaagt tgagaaattt aagcgcctga ttcgagatcc tgaaacaatt 120 aaacatctag atcggcattc agattccaaa caaggaaaat atttgaattg ggatgctgtt 180aaacatctag atcggcattc agattccaaa caaggaaaat atttgaattg ggatgctgtt 180 tttagatttt tacagaaata tattcagaaa gaaacagaat gtctgagaat agcaaaacca 240tttagatttt tacagaaata tattcagaaa gaaacagaat gtctgagaat agcaaaacca 240 aatgtatcag cctcaacaca agcctccagg cagaaaaaga tgcaggaaat cagtagtttg 300aatgtatcag cctcaacaca agcctccagg cagaaaaaga tgcaggaaat cagtagtttg 300 gtcaaatact tcatcaaatg tgcaaacaga agagcaccta ggctaaaatg tcaagaactc 360gtcaaatact tcatcaaatg tgcaaacaga agagcaccta ggctaaaatg tcaagaactc 360 ttaaattata tcatggatac agtgaaagat tcatctaatg gtgctattta cggagctgat 420ttaaattata tcatggatac agtgaaagat tcatctaatg gtgctattta cggagctgat 420 tgtagcaaca tactactcaa agacattctt tctgtgagaa aatactggtg tgaaatatct 480tgtagcaaca tactactcaa agacattctt tctgtgagaa aatactggtg tgaaatatct 480 cagcaacagt ggttagaatt gttctctgtg tacttcaggc tctatctgaa accttcacaa 540cagcaacagt ggttagaatt gttctctgtg tacttcaggc tctatctgaa accttcacaa 540 gatgttcata gagttttagt ggctagaata attcatgctg ttaccaaagg atgctgttct 600gatgttcata gagttttagt ggctagaata attcatgctg ttaccaaagg atgctgttct 600 cagactgacg gattaaattc caaatttttg gacttttttt ccaaggctat tcagtgtgcg 660cagactgacg gattaaattc caaatttttg gacttttttt ccaaggctat tcagtgtgcg 660 agacaagaaa agagctcttc aggtctaaat catatcttag cagctcttac tatcttcctc 720agacaagaaa agagctcttc aggtctaaat catatcttag cagctcttac tatcttcctc 720 aagactttgg ctgtcaactt tcgaattcga gtgtgtgaat taggagatga aattcttccc 780aagactttgg ctgtcaactt tcgaattcga gtgtgtgaat taggagatga aattcttccc 780 actttgcttt atatttggac tcaacatagg cttaatgatt ctttaaaaga agtcattatt 840actttgcttt atatttggac tcaacatagg cttaatgatt ctttaaaaga agtcattatt 840 gaattatttc aactgcaaat ttatatccat catccgaaag gagccaaaac ccaagaaaaa 900gaattatttc aactgcaaat ttatatccat catccgaaag gagccaaaac ccaagaaaaa 900 ggtgcttatg aatcaacaaa atggagaagt attttataca acttatatga tctgctagtg 960ggtgcttatg aatcaacaaa atggagaagt attttataca acttatatga tctgctagtg 960 aatgagataa gtcatatagg aagtagagga aagtattctt caggatttcg taatattgcc 1020aatgagataa gtcatatagg aagtagagga aagtattctt caggatttcg taatattgcc 1020 gtcaaagaaa atttgattga attgatggca gatatctgtc accaggtttt taatgaagat 1080gtcaaagaaa atttgattga attgatggca gatatctgtc accaggtttt taatgaagat 1080 accagatcct tggagatttc tcaatcttac actactacac aaagagaatc tagtgattac 1140accagatcct tggagatttc tcaatcttac actactacac aaagagaatc tagtgattac 1140 agtgtccctt gcaaaaggaa gaaaatagaa ctaggctggg aagtaataaa agatcacctt 1200agtgtccctt gcaaaaggaa gaaaatagaa ctaggctggg aagtaataaa agatcacctt 1200 cagaagtcac agaatgattt tgatcttgtg ccttggctac agattgcaac ccaattaata 1260cagaagtcac agaatgattt tgatcttgtg ccttggctac agattgcaac ccaattaata 1260 tcaaagtatc ctgcaagttt acctaactgt gagctgtctc cattactgat gatactatct 1320tcaaagtatc ctgcaagttt acctaactgt gagctgtctc cattactgat gatactatct 1320 cagcttctac cccaacagcg acatggggaa cgtacaccat atgtgttacg atgccttacg 1380cagcttctac cccaacagcg acatggggaa cgtacaccat atgtgttacg atgccttacg 1380 gaagttgcat tgtgtcaaga caagaggtca aacctagaaa gctcacaaaa gtcagattta 1440gaagttgcat tgtgtcaaga caagaggtca aacctagaaa gctcacaaaa gtcagattta 1440 ttaaaactct ggaataaaat ttggtgtatt acctttcgtg gtataagttc tgagcaaata 1500ttaaaactct ggaataaaat ttggtgtatt acctttcgtg gtataagttc tgagcaaata 1500 caagctgaaa actttggctt acttggagcc ataattcagg gtagtttagt tgaggttgac 1560caagctgaaa actttggctt acttggagcc ataattcagg gtagtttagt tgaggttgac 1560 agagaattct ggaagttatt tactgggtca gcctgcagac cttcatgtcc tgcagtatgc 1620agagaattct ggaagttatt tactgggtca gcctgcagac cttcatgtcc tgcagtatgc 1620 tgtttgactt tggcactgac caccagtata gttccaggaa cggtaaaaat gggaatagag 1680tgtttgactt tggcactgac caccagtata gttccaggaa cggtaaaaat gggaatagag 1680 caaaatatgt gtgaagtaaa tagaagcttt tctttaaagg aatcaataat gaaatggctc 1740caaaatatgt gtgaagtaaa tagaagcttt tctttaaagg aatcaataat gaaatggctc 1740 ttattctatc agttagaggg tgacttagaa aatagcacag aagtgcctcc aattcttcac 1800ttattctatc agttagaggg tgacttagaa aatagcacag aagtgcctcc aattcttcac 1800 agtaattttc ctcatcttgt actggagaaa attcttgtga gtctcactat gaaaaactgt 1860agtaattttc ctcatcttgt actggagaaa attcttgtga gtctcactat gaaaaactgt 1860 aaagctgcaa tgaatttttt ccaaagcgtg ccagaatgtg aacaccacca aaaagataaa 1920aaagctgcaa tgaatttttt ccaaagcgtg ccagaatgtg aacaccacca aaaagataaa 1920 gaagaacttt cattctcaga agtagaagaa ctatttcttc agacaacttt tgacaagatg 1980gaagaacttt cattctcaga agtagaagaa ctatttcttc agacaacttt tgacaagatg 1980 gactttttaa ccattgtgag agaatgtggt atagaaaagc accagtccag tattggcttc 2040gactttttaa ccattgtgag agaatgtggt atagaaaagc accagtccag tattggcttc 2040 tctgtccacc agaatctcaa ggaatcactg gatcgctgtc ttctgggatt atcagaacag 2100tctgtccacc agaatctcaa ggaatcactg gatcgctgtc ttctgggatt atcagaacag 2100 cttctgaata attactcatc tgagattaca aattcagaaa ctcttgtccg gtgttcacgt 2160cttctgaata attactcatc tgagattaca aattcagaaa ctcttgtccg gtgttcacgt 2160 cttttggtgg gtgtccttgg ctgctactgt tacatgggtg taatagctga agaggaagca 2220cttttggtgg gtgtccttgg ctgctactgt tacatgggtg taatagctga agaggaagca 2220 tataagtcag aattattcca gaaagccaag tctctaatgc aatgtgcagg agaaagtatc 2280tataagtcag aattattcca gaaagccaag tctctaatgc aatgtgcagg agaaagtatc 2280 actctgttta aaaataagac aaatgaggaa ttcagaattg gttccttgag aaatatgatg 2340actctgttta aaaataagac aaatgaggaa ttcagaattg gttccttgag aaatatgatg 2340 cagctatgta cacgttgctt gagcaactgt accaagaaga gtccaaataa gattgcatct 2400cagctatgta cacgttgctt gagcaactgt accaagaaga gtccaaataa gattgcatct 2400 ggctttttcc tgcgattgtt aacatcaaag ctaatgaatg acattgcaga tatttgtaaa 2460ggctttttcc tgcgattgtt aacatcaaag ctaatgaatg acattgcaga tatttgtaaa 2460 agtttagcat ccttcatcaa aaagccattt gaccgtggag aagtagaatc aatggaagat 2520agtttagcat ccttcatcaa aaagccattt gaccgtggag aagtagaatc aatggaagat 2520 gatactaatg gaaatctaat ggaggtggag gatcagtcat ccatgaatct atttaacgat 2580gatactaatg gaaatctaat ggaggtggag gatcagtcat ccatgaatct atttaacgat 2580 taccctgata gtagtgttag tgatgcaaac gaacctggag agagccaaag taccataggt 2640taccctgata gtagtgttag tgatgcaaac gaacctggag agagccaaag taccataggt 2640 gccattaatc ctttagctga agaatatctg tcaaagcaag atctactttt cttagacatg 2700gccattaatc ctttagctga agaatatctg tcaaagcaag atctactttt cttagacatg 2700 ctcaagttct tgtgtttgtg tgtaactact gctcagacca atactgtgtc ctttagggca 2760ctcaagttct tgtgtttgtg tgtaactact gctcagacca atactgtgtc ctttagggca 2760 gctgatattc ggaggaaatt gttaatgtta attgattcta gcacgctaga acctaccaaa 2820gctgatattc ggaggaaatt gttaatgtta attgattcta gcacgctaga acctaccaaa 2820 tccctccacc tgcatatgta tctaatgctt ttaaaggagc ttcctggaga agagtacccc 2880tccctccacc tgcatatgta tctaatgctt ttaaaggagc ttcctggaga agagtacccc 2880 ttgccaatgg aagatgttct tgaacttctg aaaccactat ccaatgtgtg ttctttgtat 2940ttgccaatgg aagatgttct tgaacttctg aaaccactat ccaatgtgtg ttctttgtat 2940 cgtcgtgacc aagatgtttg taaaactatt ttaaaccatg tccttcatgt agtgaaaaac 3000cgtcgtgacc aagatgtttg taaaactatt ttaaaccatg tccttcatgt agtgaaaaac 3000 ctaggtcaaa gcaatatgga ctctgagaac acaagggatg ctcaaggaca gtttcttaca 3060ctaggtcaaa gcaatatgga ctctgagaac acaagggatg ctcaaggaca gtttcttaca 3060 gtaattggag cattttggca tctaacaaag gagaggaaat atatattctc tgtaagaatg 3120gtaattggag cattttggca tctaacaaag gagaggaaat atatattctc tgtaagaatg 3120 gccctagtaa attgccttaa aactttgctt gaggctgatc cttattcaaa atgggccatt 3180gccctagtaa attgccttaa aactttgctt gaggctgatc cttattcaaa atgggccatt 3180 cttaatgtaa tgggaaaaga ctttcctgta aatgaagtat ttacacaatt tcttgctgac 3240cttaatgtaa tgggaaaaga ctttcctgta aatgaagtat ttacacaatt tcttgctgac 3240 aatcatcacc aagttcgcat gttggctgca gagtcaatca atagattgtt ccaggacacg 3300aatcatcacc aagttcgcat gttggctgca gagtcaatca atagattgtt ccaggacacg 3300 aagggagatt cttccaggtt actgaaagca cttcctttga agcttcagca aacagctttt 3360aagggagatt cttccaggtt actgaaagca cttcctttga agcttcagca aacagctttt 3360 gaaaatgcat acttgaaagc tcaggaagga atgagagaaa tgtcccatag tgctgagaac 3420gaaaatgcat acttgaaagc tcaggaagga atgagagaaa tgtcccatag tgctgagaac 3420 cctgaaactt tggatgaaat ttataataga aaatctgttt tactgacgtt gatagctgtg 3480cctgaaactt tggatgaaat ttataataga aaatctgttt tactgacgtt gatagctgtg 3480 gttttatcct gtagccctat ctgcgaaaaa caggctttgt ttgccctgtg taaatctgtg 3540gttttatcct gtagccctat ctgcgaaaaa caggctttgt ttgccctgtg taaatctgtg 3540 aaagagaatg gattagaacc tcaccttgtg aaaaaggttt tagagaaagt ttctgaaact 3600aaagagaatg gattagaacc tcaccttgtg aaaaaggttt tagagaaagt ttctgaaact 3600 tttggatata gacgtttaga agactttatg gcatctcatt tagattatct ggttttggaa 3660tttggatata gacgtttaga agactttatg gcatctcatt tagattatct ggttttggaa 3660 tggctaaatc ttcaagatac tgaatacaac ttatcttctt ttccttttat tttattaaac 3720tggctaaatc ttcaagatac tgaatacaac ttatcttctt ttccttttat tttattaaac 3720 tacacaaata ttgaggattt ctatagatct tgttataagg ttttgattcc acatctggtg 3780tacacaaata ttgaggattt ctatagatct tgttataagg ttttgattcc acatctggtg 3780 attagaagtc attttgatga ggtgaagtcc attgctaatc agattcaaga ggactggaaa 3840attagaagtc attttgatga ggtgaagtcc attgctaatc agattcaaga ggactggaaa 3840 agtcttctaa cagactgctt tccaaagatt cttgtaaata ttcttcctta ttttgcctat 3900agtcttctaa cagactgctt tccaaagatt cttgtaaata ttcttcctta ttttgcctat 3900 gagggtacca gagacagtgg gatggcacag caaagagaga ctgctaccaa ggtctatgat 3960gagggtacca gagacagtgg gatggcacag caaagagaga ctgctaccaa ggtctatgat 3960 atgcttaaaa gtgaaaactt attgggaaaa cagattgatc acttattcat tagtaattta 4020atgcttaaaa gtgaaaactt attgggaaaa cagattgatc acttattcat tagtaattta 4020 ccagagattg tggtggagtt attgatgacg ttacatgagc cagcaaattc tagtgccagt 4080ccagagattg tggtggagtt attgatgacg ttacatgagc cagcaaattc tagtgccagt 4080 cagagcactg acctctgtga cttttcaggg gatttggatc ctgctcctaa tccacctcat 4140cagagcactg acctctgtga cttttcaggg gatttggatc ctgctcctaa tccacctcat 4140 tttccatcgc atgtgattaa agcaacattt gcctatatca gcaattgtca taaaaccaag 4200tttccatcgc atgtgattaa agcaacattt gcctatatca gcaattgtca taaaaccaag 4200 ttaaaaagca ttttagaaat tctttccaaa agccctgatt cctatcagaa aattcttctt 4260ttaaaaagca ttttagaaat tctttccaaa agccctgatt cctatcagaa aattcttctt 4260 gccatatgtg agcaagcagc tgaaacaaat aatgtttata agaagcacag aattcttaaa 4320gccatatgtg agcaagcagc tgaaacaaat aatgtttata agaagcacag aattcttaaa 4320 atatatcacc tgtttgttag tttattactg aaagatataa aaagtggctt aggaggagct 4380atatatcacc tgtttgttag tttattactg aaagatataa aaagtggctt aggaggagct 4380 tgggcctttg ttcttcgaga cgttatttat actttgattc actatatcaa ccaaaggcct 4440tgggcctttg ttcttcgaga cgttatttat actttgattc actatatcaa ccaaaggcct 4440 tcttgtatca tggatgtgtc attacgtagc ttctcccttt gttgtgactt attaagtcag 4500tcttgtatca tggatgtgtc attacgtagc ttctcccttt gttgtgactt attaagtcag 4500 gtttgccaga cagccgtgac ttactgtaag gatgctctag aaaaccatct tcatgttatt 4560gtttgccaga cagccgtgac ttactgtaag gatgctctag aaaaccatct tcatgttatt 4560 gttggtacac ttatacccct tgtgtatgag caggtggagg ttcagaaaca ggtattggac 4620gttggtacac ttatacccct tgtgtatgag caggtggagg ttcagaaaca ggtattggac 4620 ttgttgaaat acttagtgat agataacaag gataatgaaa acctctatat cacgattaag 4680ttgttgaaat acttagtgat agataacaag gataatgaaa acctctatat cacgattaag 4680 cttttagatc cttttcctga ccatgttgtt tttaaggatt tgcgtattac tcagcaaaaa 4740cttttagatc cttttcctga ccatgttgtt tttaaggatt tgcgtattac tcagcaaaaa 4740 atcaaataca gtagaggacc cttttcactc ttggagttct cagga 4785atcaaataca gtagaggacc cttttcactc ttggagttct cagga 4785 <210> 6<210> 6 <211> 1595<211> 1595 <212> PRT<212> PRT <213> Homo sapiens<213> Homo sapiens <400> 6<400> 6 Met Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu GluMet Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu Glu 1 5 10 151 5 10 15 His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys ArgHis Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys Arg 20 25 30 20 25 30 Leu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser AspLeu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser Asp 35 40 45 35 40 45 Ser Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe LeuSer Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu 50 55 60 50 55 60 Gln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys ProGln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys Pro 65 70 75 8065 70 75 80 Asn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln GluAsn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln Glu 85 90 95 85 90 95 Ile Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg AlaIle Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg Ala 100 105 110 100 105 110 Pro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr ValPro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr Val 115 120 125 115 120 125 Lys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn IleLys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn Ile 130 135 140 130 135 140 Leu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile SerLeu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile Ser 145 150 155 160145 150 155 160 Gln Gln Gln Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr LeuGln Gln Gln Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr Leu 165 170 175 165 170 175 Lys Pro Ser Gln Asp Val His Arg Val Leu Val Ala Arg Ile Ile HisLys Pro Ser Gln Asp Val His Arg Val Leu Val Ala Arg Ile Ile His 180 185 190 180 185 190 Ala Val Thr Lys Gly Cys Cys Ser Gln Thr Asp Gly Leu Asn Ser LysAla Val Thr Lys Gly Cys Cys Ser Gln Thr Asp Gly Leu Asn Ser Lys 195 200 205 195 200 205 Phe Leu Asp Phe Phe Ser Lys Ala Ile Gln Cys Ala Arg Gln Glu LysPhe Leu Asp Phe Phe Ser Lys Ala Ile Gln Cys Ala Arg Gln Glu Lys 210 215 220 210 215 220 Ser Ser Ser Gly Leu Asn His Ile Leu Ala Ala Leu Thr Ile Phe LeuSer Ser Ser Gly Leu Asn His Ile Leu Ala Ala Leu Thr Ile Phe Leu 225 230 235 240225 230 235 240 Lys Thr Leu Ala Val Asn Phe Arg Ile Arg Val Cys Glu Leu Gly AspLys Thr Leu Ala Val Asn Phe Arg Ile Arg Val Cys Glu Leu Gly Asp 245 250 255 245 250 255 Glu Ile Leu Pro Thr Leu Leu Tyr Ile Trp Thr Gln His Arg Leu AsnGlu Ile Leu Pro Thr Leu Leu Tyr Ile Trp Thr Gln His Arg Leu Asn 260 265 270 260 265 270 Asp Ser Leu Lys Glu Val Ile Ile Glu Leu Phe Gln Leu Gln Ile TyrAsp Ser Leu Lys Glu Val Ile Ile Glu Leu Phe Gln Leu Gln Ile Tyr 275 280 285 275 280 285 Ile His His Pro Lys Gly Ala Lys Thr Gln Glu Lys Gly Ala Tyr GluIle His His Pro Lys Gly Ala Lys Thr Gln Glu Lys Gly Ala Tyr Glu 290 295 300 290 295 300 Ser Thr Lys Trp Arg Ser Ile Leu Tyr Asn Leu Tyr Asp Leu Leu ValSer Thr Lys Trp Arg Ser Ile Leu Tyr Asn Leu Tyr Asp Leu Leu Val 305 310 315 320305 310 315 320 Asn Glu Ile Ser His Ile Gly Ser Arg Gly Lys Tyr Ser Ser Gly PheAsn Glu Ile Ser His Ile Gly Ser Arg Gly Lys Tyr Ser Ser Gly Phe 325 330 335 325 330 335 Arg Asn Ile Ala Val Lys Glu Asn Leu Ile Glu Leu Met Ala Asp IleArg Asn Ile Ala Val Lys Glu Asn Leu Ile Glu Leu Met Ala Asp Ile 340 345 350 340 345 350 Cys His Gln Val Phe Asn Glu Asp Thr Arg Ser Leu Glu Ile Ser GlnCys His Gln Val Phe Asn Glu Asp Thr Arg Ser Leu Glu Ile Ser Gln 355 360 365 355 360 365 Ser Tyr Thr Thr Thr Gln Arg Glu Ser Ser Asp Tyr Ser Val Pro CysSer Tyr Thr Thr Thr Gln Arg Glu Ser Ser Asp Tyr Ser Val Pro Cys 370 375 380 370 375 380 Lys Arg Lys Lys Ile Glu Leu Gly Trp Glu Val Ile Lys Asp His LeuLys Arg Lys Lys Ile Glu Leu Gly Trp Glu Val Ile Lys Asp His Leu 385 390 395 400385 390 395 400 Gln Lys Ser Gln Asn Asp Phe Asp Leu Val Pro Trp Leu Gln Ile AlaGln Lys Ser Gln Asn Asp Phe Asp Leu Val Pro Trp Leu Gln Ile Ala 405 410 415 405 410 415 Thr Gln Leu Ile Ser Lys Tyr Pro Ala Ser Leu Pro Asn Cys Glu LeuThr Gln Leu Ile Ser Lys Tyr Pro Ala Ser Leu Pro Asn Cys Glu Leu 420 425 430 420 425 430 Ser Pro Leu Leu Met Ile Leu Ser Gln Leu Leu Pro Gln Gln Arg HisSer Pro Leu Leu Met Ile Leu Ser Gln Leu Leu Pro Gln Gln Arg His 435 440 445 435 440 445 Gly Glu Arg Thr Pro Tyr Val Leu Arg Cys Leu Thr Glu Val Ala LeuGly Glu Arg Thr Pro Tyr Val Leu Arg Cys Leu Thr Glu Val Ala Leu 450 455 460 450 455 460 Cys Gln Asp Lys Arg Ser Asn Leu Glu Ser Ser Gln Lys Ser Asp LeuCys Gln Asp Lys Arg Ser Asn Leu Glu Ser Ser Gln Lys Ser Asp Leu 465 470 475 480465 470 475 480 Leu Lys Leu Trp Asn Lys Ile Trp Cys Ile Thr Phe Arg Gly Ile SerLeu Lys Leu Trp Asn Lys Ile Trp Cys Ile Thr Phe Arg Gly Ile Ser 485 490 495 485 490 495 Ser Glu Gln Ile Gln Ala Glu Asn Phe Gly Leu Leu Gly Ala Ile IleSer Glu Gln Ile Gln Ala Glu Asn Phe Gly Leu Leu Gly Ala Ile Ile 500 505 510 500 505 510 Gln Gly Ser Leu Val Glu Val Asp Arg Glu Phe Trp Lys Leu Phe ThrGln Gly Ser Leu Val Glu Val Asp Arg Glu Phe Trp Lys Leu Phe Thr 515 520 525 515 520 525 Gly Ser Ala Cys Arg Pro Ser Cys Pro Ala Val Cys Cys Leu Thr LeuGly Ser Ala Cys Arg Pro Ser Cys Pro Ala Val Cys Cys Leu Thr Leu 530 535 540 530 535 540 Ala Leu Thr Thr Ser Ile Val Pro Gly Thr Val Lys Met Gly Ile GluAla Leu Thr Thr Ser Ile Val Pro Gly Thr Val Lys Met Gly Ile Glu 545 550 555 560545 550 555 560 Gln Asn Met Cys Glu Val Asn Arg Ser Phe Ser Leu Lys Glu Ser IleGln Asn Met Cys Glu Val Asn Arg Ser Phe Ser Leu Lys Glu Ser Ile 565 570 575 565 570 575 Met Lys Trp Leu Leu Phe Tyr Gln Leu Glu Gly Asp Leu Glu Asn SerMet Lys Trp Leu Leu Phe Tyr Gln Leu Glu Gly Asp Leu Glu Asn Ser 580 585 590 580 585 590 Thr Glu Val Pro Pro Ile Leu His Ser Asn Phe Pro His Leu Val LeuThr Glu Val Pro Pro Ile Leu His Ser Asn Phe Pro His Leu Val Leu 595 600 605 595 600 605 Glu Lys Ile Leu Val Ser Leu Thr Met Lys Asn Cys Lys Ala Ala MetGlu Lys Ile Leu Val Ser Leu Thr Met Lys Asn Cys Lys Ala Ala Met 610 615 620 610 615 620 Asn Phe Phe Gln Ser Val Pro Glu Cys Glu His His Gln Lys Asp LysAsn Phe Phe Gln Ser Val Pro Glu Cys Glu His His Gln Lys Asp Lys 625 630 635 640625 630 635 640 Glu Glu Leu Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gln Thr ThrGlu Glu Leu Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gln Thr Thr 645 650 655 645 650 655 Phe Asp Lys Met Asp Phe Leu Thr Ile Val Arg Glu Cys Gly Ile GluPhe Asp Lys Met Asp Phe Leu Thr Ile Val Arg Glu Cys Gly Ile Glu 660 665 670 660 665 670 Lys His Gln Ser Ser Ile Gly Phe Ser Val His Gln Asn Leu Lys GluLys His Gln Ser Ser Ile Gly Phe Ser Val His Gln Asn Leu Lys Glu 675 680 685 675 680 685 Ser Leu Asp Arg Cys Leu Leu Gly Leu Ser Glu Gln Leu Leu Asn AsnSer Leu Asp Arg Cys Leu Leu Gly Leu Ser Glu Gln Leu Leu Asn Asn 690 695 700 690 695 700 Tyr Ser Ser Glu Ile Thr Asn Ser Glu Thr Leu Val Arg Cys Ser ArgTyr Ser Ser Glu Ile Thr Asn Ser Glu Thr Leu Val Arg Cys Ser Arg 705 710 715 720705 710 715 720 Leu Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly Val Ile AlaLeu Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly Val Ile Ala 725 730 735 725 730 735 Glu Glu Glu Ala Tyr Lys Ser Glu Leu Phe Gln Lys Ala Lys Ser LeuGlu Glu Glu Ala Tyr Lys Ser Glu Leu Phe Gln Lys Ala Lys Ser Leu 740 745 750 740 745 750 Met Gln Cys Ala Gly Glu Ser Ile Thr Leu Phe Lys Asn Lys Thr AsnMet Gln Cys Ala Gly Glu Ser Ile Thr Leu Phe Lys Asn Lys Thr Asn 755 760 765 755 760 765 Glu Glu Phe Arg Ile Gly Ser Leu Arg Asn Met Met Gln Leu Cys ThrGlu Glu Phe Arg Ile Gly Ser Leu Arg Asn Met Met Gln Leu Cys Thr 770 775 780 770 775 780 Arg Cys Leu Ser Asn Cys Thr Lys Lys Ser Pro Asn Lys Ile Ala SerArg Cys Leu Ser Asn Cys Thr Lys Lys Ser Pro Asn Lys Ile Ala Ser 785 790 795 800785 790 795 800 Gly Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp Ile AlaGly Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp Ile Ala 805 810 815 805 810 815 Asp Ile Cys Lys Ser Leu Ala Ser Phe Ile Lys Lys Pro Phe Asp ArgAsp Ile Cys Lys Ser Leu Ala Ser Phe Ile Lys Lys Pro Phe Asp Arg 820 825 830 820 825 830 Gly Glu Val Glu Ser Met Glu Asp Asp Thr Asn Gly Asn Leu Met GluGly Glu Val Glu Ser Met Glu Asp Asp Thr Asn Gly Asn Leu Met Glu 835 840 845 835 840 845 Val Glu Asp Gln Ser Ser Met Asn Leu Phe Asn Asp Tyr Pro Asp SerVal Glu Asp Gln Ser Ser Met Asn Leu Phe Asn Asp Tyr Pro Asp Ser 850 855 860 850 855 860 Ser Val Ser Asp Ala Asn Glu Pro Gly Glu Ser Gln Ser Thr Ile GlySer Val Ser Asp Ala Asn Glu Pro Gly Glu Ser Gln Ser Thr Ile Gly 865 870 875 880865 870 875 880 Ala Ile Asn Pro Leu Ala Glu Glu Tyr Leu Ser Lys Gln Asp Leu LeuAla Ile Asn Pro Leu Ala Glu Glu Tyr Leu Ser Lys Gln Asp Leu Leu 885 890 895 885 890 895 Phe Leu Asp Met Leu Lys Phe Leu Cys Leu Cys Val Thr Thr Ala GlnPhe Leu Asp Met Leu Lys Phe Leu Cys Leu Cys Val Thr Thr Ala Gln 900 905 910 900 905 910 Thr Asn Thr Val Ser Phe Arg Ala Ala Asp Ile Arg Arg Lys Leu LeuThr Asn Thr Val Ser Phe Arg Ala Ala Asp Ile Arg Arg Lys Leu Leu 915 920 925 915 920 925 Met Leu Ile Asp Ser Ser Thr Leu Glu Pro Thr Lys Ser Leu His LeuMet Leu Ile Asp Ser Ser Thr Leu Glu Pro Thr Lys Ser Leu His Leu 930 935 940 930 935 940 His Met Tyr Leu Met Leu Leu Lys Glu Leu Pro Gly Glu Glu Tyr ProHis Met Tyr Leu Met Leu Leu Lys Glu Leu Pro Gly Glu Glu Tyr Pro 945 950 955 960945 950 955 960 Leu Pro Met Glu Asp Val Leu Glu Leu Leu Lys Pro Leu Ser Asn ValLeu Pro Met Glu Asp Val Leu Glu Leu Leu Lys Pro Leu Ser Asn Val 965 970 975 965 970 975 Cys Ser Leu Tyr Arg Arg Asp Gln Asp Val Cys Lys Thr Ile Leu AsnCys Ser Leu Tyr Arg Arg Asp Gln Asp Val Cys Lys Thr Ile Leu Asn 980 985 990 980 985 990 His Val Leu His Val Val Lys Asn Leu Gly Gln Ser Asn Met Asp SerHis Val Leu His Val Val Lys Asn Leu Gly Gln Ser Asn Met Asp Ser 995 1000 1005 995 1000 1005 Glu Asn Thr Arg Asp Ala Gln Gly Gln Phe Leu Thr Val Ile GlyGlu Asn Thr Arg Asp Ala Gln Gly Gln Phe Leu Thr Val Ile Gly 1010 1015 1020 1010 1015 1020 Ala Phe Trp His Leu Thr Lys Glu Arg Lys Tyr Ile Phe Ser ValAla Phe Trp His Leu Thr Lys Glu Arg Lys Tyr Ile Phe Ser Val 1025 1030 1035 1025 1030 1035 Arg Met Ala Leu Val Asn Cys Leu Lys Thr Leu Leu Glu Ala AspArg Met Ala Leu Val Asn Cys Leu Lys Thr Leu Leu Glu Ala Asp 1040 1045 1050 1040 1045 1050 Pro Tyr Ser Lys Trp Ala Ile Leu Asn Val Met Gly Lys Asp PhePro Tyr Ser Lys Trp Ala Ile Leu Asn Val Met Gly Lys Asp Phe 1055 1060 1065 1055 1060 1065 Pro Val Asn Glu Val Phe Thr Gln Phe Leu Ala Asp Asn His HisPro Val Asn Glu Val Phe Thr Gln Phe Leu Ala Asp Asn His His 1070 1075 1080 1070 1075 1080 Gln Val Arg Met Leu Ala Ala Glu Ser Ile Asn Arg Leu Phe GlnGln Val Arg Met Leu Ala Ala Glu Ser Ile Asn Arg Leu Phe Gln 1085 1090 1095 1085 1090 1095 Asp Thr Lys Gly Asp Ser Ser Arg Leu Leu Lys Ala Leu Pro LeuAsp Thr Lys Gly Asp Ser Ser Arg Leu Leu Lys Ala Leu Pro Leu 1100 1105 1110 1100 1105 1110 Lys Leu Gln Gln Thr Ala Phe Glu Asn Ala Tyr Leu Lys Ala GlnLys Leu Gln Gln Thr Ala Phe Glu Asn Ala Tyr Leu Lys Ala Gln 1115 1120 1125 1115 1120 1125 Glu Gly Met Arg Glu Met Ser His Ser Ala Glu Asn Pro Glu ThrGlu Gly Met Arg Glu Met Ser His Ser Ala Glu Asn Pro Glu Thr 1130 1135 1140 1130 1135 1140 Leu Asp Glu Ile Tyr Asn Arg Lys Ser Val Leu Leu Thr Leu IleLeu Asp Glu Ile Tyr Asn Arg Lys Ser Val Leu Leu Thr Leu Ile 1145 1150 1155 1145 1150 1155 Ala Val Val Leu Ser Cys Ser Pro Ile Cys Glu Lys Gln Ala LeuAla Val Val Leu Ser Cys Ser Pro Ile Cys Glu Lys Gln Ala Leu 1160 1165 1170 1160 1165 1170 Phe Ala Leu Cys Lys Ser Val Lys Glu Asn Gly Leu Glu Pro HisPhe Ala Leu Cys Lys Ser Val Lys Glu Asn Gly Leu Glu Pro His 1175 1180 1185 1175 1180 1185 Leu Val Lys Lys Val Leu Glu Lys Val Ser Glu Thr Phe Gly TyrLeu Val Lys Lys Val Leu Glu Lys Val Ser Glu Thr Phe Gly Tyr 1190 1195 1200 1190 1195 1200 Arg Arg Leu Glu Asp Phe Met Ala Ser His Leu Asp Tyr Leu ValArg Arg Leu Glu Asp Phe Met Ala Ser His Leu Asp Tyr Leu Val 1205 1210 1215 1205 1210 1215 Leu Glu Trp Leu Asn Leu Gln Asp Thr Glu Tyr Asn Leu Ser SerLeu Glu Trp Leu Asn Leu Gln Asp Thr Glu Tyr Asn Leu Ser Ser 1220 1225 1230 1220 1225 1230 Phe Pro Phe Ile Leu Leu Asn Tyr Thr Asn Ile Glu Asp Phe TyrPhe Pro Phe Ile Leu Leu Asn Tyr Thr Asn Ile Glu Asp Phe Tyr 1235 1240 1245 1235 1240 1245 Arg Ser Cys Tyr Lys Val Leu Ile Pro His Leu Val Ile Arg SerArg Ser Cys Tyr Lys Val Leu Ile Pro His Leu Val Ile Arg Ser 1250 1255 1260 1250 1255 1260 His Phe Asp Glu Val Lys Ser Ile Ala Asn Gln Ile Gln Glu AspHis Phe Asp Glu Val Lys Ser Ile Ala Asn Gln Ile Gln Glu Asp 1265 1270 1275 1265 1270 1275 Trp Lys Ser Leu Leu Thr Asp Cys Phe Pro Lys Ile Leu Val AsnTrp Lys Ser Leu Leu Thr Asp Cys Phe Pro Lys Ile Leu Val Asn 1280 1285 1290 1280 1285 1290 Ile Leu Pro Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Gly MetIle Leu Pro Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Gly Met 1295 1300 1305 1295 1300 1305 Ala Gln Gln Arg Glu Thr Ala Thr Lys Val Tyr Asp Met Leu LysAla Gln Gln Arg Glu Thr Ala Thr Lys Val Tyr Asp Met Leu Lys 1310 1315 1320 1310 1315 1320 Ser Glu Asn Leu Leu Gly Lys Gln Ile Asp His Leu Phe Ile SerSer Glu Asn Leu Leu Gly Lys Gln Ile Asp His Leu Phe Ile Ser 1325 1330 1335 1325 1330 1335 Asn Leu Pro Glu Ile Val Val Glu Leu Leu Met Thr Leu His GluAsn Leu Pro Glu Ile Val Val Glu Leu Leu Met Thr Leu His Glu 1340 1345 1350 1340 1345 1350 Pro Ala Asn Ser Ser Ala Ser Gln Ser Thr Asp Leu Cys Asp PhePro Ala Asn Ser Ser Ala Ser Gln Ser Thr Asp Leu Cys Asp Phe 1355 1360 1365 1355 1360 1365 Ser Gly Asp Leu Asp Pro Ala Pro Asn Pro Pro His Phe Pro SerSer Gly Asp Leu Asp Pro Ala Pro Asn Pro Pro His Phe Pro Ser 1370 1375 1380 1370 1375 1380 His Val Ile Lys Ala Thr Phe Ala Tyr Ile Ser Asn Cys His LysHis Val Ile Lys Ala Thr Phe Ala Tyr Ile Ser Asn Cys His Lys 1385 1390 1395 1385 1390 1395 Thr Lys Leu Lys Ser Ile Leu Glu Ile Leu Ser Lys Ser Pro AspThr Lys Leu Lys Ser Ile Leu Glu Ile Leu Ser Lys Ser Pro Asp 1400 1405 1410 1400 1405 1410 Ser Tyr Gln Lys Ile Leu Leu Ala Ile Cys Glu Gln Ala Ala GluSer Tyr Gln Lys Ile Leu Leu Ala Ile Cys Glu Gln Ala Ala Glu 1415 1420 1425 1415 1420 1425 Thr Asn Asn Val Tyr Lys Lys His Arg Ile Leu Lys Ile Tyr HisThr Asn Asn Val Tyr Lys Lys His Arg Ile Leu Lys Ile Tyr His 1430 1435 1440 1430 1435 1440 Leu Phe Val Ser Leu Leu Leu Lys Asp Ile Lys Ser Gly Leu GlyLeu Phe Val Ser Leu Leu Leu Lys Asp Ile Lys Ser Gly Leu Gly 1445 1450 1455 1445 1450 1455 Gly Ala Trp Ala Phe Val Leu Arg Asp Val Ile Tyr Thr Leu IleGly Ala Trp Ala Phe Val Leu Arg Asp Val Ile Tyr Thr Leu Ile 1460 1465 1470 1460 1465 1470 His Tyr Ile Asn Gln Arg Pro Ser Cys Ile Met Asp Val Ser LeuHis Tyr Ile Asn Gln Arg Pro Ser Cys Ile Met Asp Val Ser Leu 1475 1480 1485 1475 1480 1485 Arg Ser Phe Ser Leu Cys Cys Asp Leu Leu Ser Gln Val Cys GlnArg Ser Phe Ser Leu Cys Cys Asp Leu Leu Ser Gln Val Cys Gln 1490 1495 1500 1490 1495 1500 Thr Ala Val Thr Tyr Cys Lys Asp Ala Leu Glu Asn His Leu HisThr Ala Val Thr Tyr Cys Lys Asp Ala Leu Glu Asn His Leu His 1505 1510 1515 1505 1510 1515 Val Ile Val Gly Thr Leu Ile Pro Leu Val Tyr Glu Gln Val GluVal Ile Val Gly Thr Leu Ile Pro Leu Val Tyr Glu Gln Val Glu 1520 1525 1530 1520 1525 1530 Val Gln Lys Gln Val Leu Asp Leu Leu Lys Tyr Leu Val Ile AspVal Gln Lys Gln Val Leu Asp Leu Leu Lys Tyr Leu Val Ile Asp 1535 1540 1545 1535 1540 1545 Asn Lys Asp Asn Glu Asn Leu Tyr Ile Thr Ile Lys Leu Leu AspAsn Lys Asp Asn Glu Asn Leu Tyr Ile Thr Ile Lys Leu Leu Asp 1550 1555 1560 1550 1555 1560 Pro Phe Pro Asp His Val Val Phe Lys Asp Leu Arg Ile Thr GlnPro Phe Pro Asp His Val Val Phe Lys Asp Leu Arg Ile Thr Gln 1565 1570 1575 1565 1570 1575 Gln Lys Ile Lys Tyr Ser Arg Gly Pro Phe Ser Leu Leu Glu PheGln Lys Ile Lys Tyr Ser Arg Gly Pro Phe Ser Leu Leu Glu Phe 1580 1585 1590 1580 1585 1590 Ser GlySer Gly 1595 1595 <210> 7<210> 7 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 7<400> 7 gtactgccca ccagaacctt 20gtactgccca ccagaacctt 20 <210> 8<210> 8 <211> 23<211> 23 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 8<400> 8 ccaaactgct atcctgaata tgg 23ccaaactgct atcctgaata tgg 23 <210> 9<210> 9 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 9<400> 9 attttgcttg gggccataat 20attttgcttg gggccataat 20 <210> 10<210> 10 <211> 21<211> 21 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 10<400> 10 cagacagagt gctttctttg g 21cagacagagt gctttctttg g 21 <210> 11<210> 11 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 11<400> 11 agggtttgca gtggaagaaa 20agggtttgca gtggaagaaa 20 <210> 12<210> 12 <211> 21<211> 21 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 12<400> 12 tgacaatgaa accaagagca a 21tgacaatgaa accaagagca a 21 <210> 13<210> 13 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 13<400> 13 tggcaaggtg agtatgttgg 20tggcaaggtg agtatgttgg 20 <210> 14<210> 14 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 14<400> 14 acatgcgaac ttggtgatga 20acatgcgaac ttggtgatga 20 <210> 15<210> 15 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 15<400> 15 tgcttgacct tcaatgctgt 20tgcttgacct tcaatgctgt 20 <210> 16<210> 16 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 16<400> 16 ggcaatggaa aagaaagcag 20ggcaatggaa aagaaagcag 20 <210> 17<210> 17 <211> 25<211> 25 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> QPCR引物<223> QPCR primers <400> 17<400> 17 tgatccactc tttgactgga ccatg 25tgatccactc tttgactgga ccatg 25 <210> 18<210> 18 <211> 25<211> 25 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> QPCR引物<223> QPCR primers <400> 18<400> 18 gcattcagag tagggtgaag ctcag 25gcattcagag tagggtgaag ctcag 25 <210> 19<210> 19 <211> 24<211> 24 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> QPCR引物<223> QPCR primers <400> 19<400> 19 gccagtatgg tgaaaccctg tctc 24gccagtatgg tgaaaccctg tctc 24 <210> 20<210> 20 <211> 23<211> 23 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> QPCR引物<223> QPCR primers <400> 20<400> 20 agattctcct gcctcagcct ctc 23agattctcct gcctcagcct ctc 23 <210> 21<210> 21 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 21<400> 21 ccccttgtgt atgagcaggt 20ccccttgtgt atgagcaggt 20 <210> 22<210> 22 <211> 20<211> 20 <212> DNA<212> DNA <213> Artificial<213> Artificial <220><220> <223> 引物<223> primers <400> 22<400> 22 acttctccca agcagcttcc 20acttctccca agcagcttcc 20

### Claims

Claims (7) Translated from Chinese 1.一种分离的编码ATM基因突变体的核酸，其特征在于，与SEQ ID NO：1相比，所述核酸具有选自下列的至少一种突变：c.4777-2A>T、c.3078G>T、c.7983_7985delTGT和c.477_481delATCTC。1. An isolated nucleic acid encoding an ATM gene mutant, characterized in that, compared with SEQ ID NO: 1, the nucleic acid has at least one mutation selected from the group consisting of: c.4777-2A>T, c. 3078G>T, c.7983_7985delTGT and c.477_481delATCTC. 2.一种分离的多肽，其特征在于，与SEQ ID NO：2相比，所述分离的多肽具有选自下列的至少一种突变：p.Glu2950fs、p.Trp1026Cys、p.Val2662del和p.Ile159fs。2. An isolated polypeptide, characterized in that, compared with SEQ ID NO: 2, the isolated polypeptide has at least one mutation selected from the group consisting of: p.Glu2950fs, p.Trp1026Cys, p.Val2662del and p. Ile159fs. 3.根据权利要求2所述的分离的多肽，所述多肽是由权利要求1所述的核酸编码的。3. The isolated polypeptide of claim 2 encoded by the nucleic acid of claim 1. 4.一种用于筛选易患共济失调毛细血管扩张症的生物样品的试剂盒，其特征在于，含有：4. A test kit for screening a biological sample susceptible to ataxia telangiectasia, comprising: 适于检测ATM基因突变体的试剂，其中与SEQ ID NO：1相比，所述ATM基因突变体具有选自下列的至少一种突变：c.4777-2A>T、c.3078G>T、c.7983_7985delTGT和c.477_481delATCTC，A reagent suitable for detecting an ATM gene mutant, wherein the ATM gene mutant has at least one mutation selected from the group consisting of: c.4777-2A>T, c.3078G>T, c.7983_7985delTGT and c.477_481delATCTC, 所述试剂为核酸探针或引物，The reagent is a nucleic acid probe or primer, 所述核酸探针或引物具有如SEQ ID NO：7-16所示的核苷酸序列。The nucleic acid probes or primers have nucleotide sequences as shown in SEQ ID NOs: 7-16. 5.根据权利要求4所述的试剂盒，其特征在于，所述共济失调毛细血管扩张症为常染色体隐性遗传疾病。5. The kit according to claim 4, wherein the ataxia telangiectasia is an autosomal recessive genetic disease. 6.一种构建体，其特征在于，包含权利要求1所述的分离的编码ATM基因突变体的核酸。6. A construct comprising the isolated nucleic acid of claim 1 encoding an ATM gene mutant. 7.一种重组细胞，其特征在于，所述重组细胞是通过权利要求6所述的构建体转化受体细胞而获得的。7. A recombinant cell, characterized in that the recombinant cell is obtained by transforming a recipient cell with the construct of claim 6.
